Antibody-drug conjugates
By introducing lactone modification into antibody-drug conjugates, the problem of deterioration of kinetics and decreased stability of ADC in vivo is solved, improving its stability and anti-tumor effect in the blood, and extending the survival time of the drug and lethality.
Patent Information
- Application Number
- CN202380036370.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-30
- Filing Date
- 2023-02-28
- Publication Date
- 2024-12-06
AI Technical Summary
The kinetics of existing antibody-drug conjugates (ADCs) deteriorate in vivo, resulting in a weakening of drug efficacy. Especially when the drug/antibody ratio (DAR) exceeds 3 to 4, the stability of ADC decreases, affecting the therapeutic effect.
An anti-tumor drug or linker with an ADC with more than one lactone group as a substituent was designed. Through lactone group modification, the stability of ADC in blood was improved, and its anti-tumor was verified in in vitro and in vivo tests. effect.
Through lactone modification, the stability and anti-tumor effect of ADC in the blood are improved, the survival time of drugs in the body is extended, and the killing ability of targeted tumor cells is enhanced.
Smart Images

Figure CN119095625A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel antibody-drug conjugate (ADC) useful as an antitumor drug, which is formed by combining an antibody capable of targeting tumor cells with an antitumor drug via a linker. Background Art
[0002] Antibody Drug Conjugates (ADCs) in which a cytotoxic drug (payload) is bound to an antibody that binds to an antigen that can be expressed on the surface of tumor cells and internalized in the cells can be expected to "selectively deliver the drug to tumor cells, release / accumulate the drug in the tumor cells, and kill the tumor cells" (Non-Patent Documents 1 to 2). As ADCs, for example, Adcetris (vebrituximab), which is an anti-CD30 antibody bound to monomethyl auristatin E (Patent Document 1), is approved as a treatment for Hodgkin's lymphoma and undifferentiated large cell lymphoma, Kadcyla (enmetazuzumab), which is an anti-HER2 antibody bound to emtansine, is approved as a treatment for HER2-positive metastatic breast cancer, Enhertu (derutuzumab), which is an anti-HER2 antibody bound to drugliase, is approved as a treatment for HER2-positive metastatic breast cancer (Patent Document 2), and drugliase (drugliase) is approved as a treatment for HER2-positive metastatic breast cancer (Patent Document 2). Trodelvy (gosartumomab), an SN-38-based drug, is approved as a treatment for TROP-2-positive metastatic breast cancer. Blenrep (mabetuzumab), an anti-CD269 (BCMA) antibody conjugated to MMAF, is approved as a treatment for multiple myeloma. Tivdak (tisomab), an anti-CD142 antibody conjugated to monomethyl auristatin E, is approved as a treatment for metastatic cervical cancer. Zynlonta (lantuximab), an anti-CD19 antibody conjugated to a pyrrolobenzodiazepine dimer, is approved as a treatment for B-cell lymphoma (Non-Patent Documents 3-10). Furthermore, many new ADCs are under clinical development as anti-tumor drugs (Non-Patent Documents 11-14).
[0003] In order for ADCs to exert their superior anti-tumor effects, they must be stable in vivo (in the blood) after administration. However, as the DAR (average number of drug bound per antibody, or drug / antibody ratio) increases, the in vivo kinetics deteriorate and the efficacy decreases, due to factors such as increased hydrophobicity of the ADC, which tends to cause aggregation. For example, ADCs using MMAE (monomethyl auristatin E) as a payload are reported to be most stable and have the highest in vivo efficacy when the DAR is around 3 to 4, while DARs above this value lead to instability and decreased efficacy (Non-Patent Document 15). To address this issue, research to increase the hydrophilicity of ADCs has been actively conducted (Patent Document 3, Non-Patent Documents 16 to 19).
[0004] Prior art literature
[0005] Patent Literature
[0006] Patent Document 1: WO2003043583
[0007] Patent Document 2: Japanese Patent Application Laid-Open No. 2016-196484
[0008] Patent Document 3: WO2016001485
[0009] Non-patent literature
[0010] Non-patent document 1: Current Opin. Chem. Biol., 2010, 14, 529-537
[0011] Non-patent document 2: Expert Opin. Biol. Ther., 2004, 4, 1445-1452
[0012] Non-patent document 3: Biotechnol Lett., 2016, 38, 1655-1664.
[0013] Non-patent literature 4: Chem Pharm Bull., 2019, 67, 173-185.
[0014] Non-patent document 5: N Engl J Med., 2012, 367, 1783-1791
[0015] Non-patent literature 6: N Engl J Med., 2018, 378, 331-344.
[0016] Non-patent literature 7: Expert Opin. Biol. Ther., 2020, 8, 871-875
[0017] Non-patent literature 8: Drugs Today, 2021, 57, 653-663
[0018] Non-patent literature 9: Drugs, 2021, 81, 2141-2147
[0019] Non-patent literature 10: Drugs, 2021, 81, 1229-1233
[0020] Non-patent literature 11: Clin Cancer Res., 2019, 25, 5441-5448.
[0021] Non-Patent Literature 12: Molecules.2020,25,4764
[0022] Non-patent literature 13: Methods Mol Biol., 2020, 2078, 1-22
[0023] Non-patent document 14: Nat. Rev. Drug Discov., 2017, 16, 315
[0024] Non-patent document 15: Clin Cancer Res., 2004, 10, 7063-7070
[0025] Non-patent literature 16: Mol Cancer Ther., 2017, 16, 116-123
[0026] Non-Patent Literature 17: Antibodies (Basel)., 2018, July 15
[0027] Non-patent literature 18: Nat. Biotech., 2015, 33, 733-735
[0028] Non-patent literature 19: Separations 2019, 6(1), 1 Summary of the Invention
[0029] Problems to be solved by the invention
[0030] The present invention provides a novel linker, a linker payload, an ADC, and an anti-tumor drug.
[0031] Solutions for solving problems
[0032] The present inventors designed and successfully synthesized ADCs in which the anti-tumor drug or linker has one or more lactone groups as substituents or protecting groups. The inventors discovered that modification of the ADC with the lactone group stabilizes the ADC in the blood after administration. The inventors also confirmed that the resulting ADC exhibits anti-tumor effects in in vitro and in vivo studies.
[0033] The present invention provides the following [1] to
[26] . [1]
[0035] An antibody-drug conjugate (hereinafter also referred to as antibody-drug conjugate (I) or the conjugate of the present invention), a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the antibody-drug conjugate is represented by the following general formula (I):
[0036] A-(BLD) a (I)
[0037] [Where,
[0038] A represents an antibody residue obtained by removing functional groups in the antibody that are involved in binding to the linker from an antibody capable of targeting tumor cells.
[0039] B is a divalent group derived from a functional group in the antibody,
[0040] a is an integer from 1 to 10,
[0041] D is an antitumor drug residue obtained by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug molecule, an analog thereof, or a derivative thereof,
[0042] L is a linker connecting B and D,
[0043] At least one of D and L has one or more lactone groups as substituents or protecting groups at any position]. [2]
[0045] The antibody-drug conjugate (I) according to [1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is an antibody residue obtained by removing a functional group in the antibody that participates in binding to a linker from an antibody having any one or more of the properties of being able to recognize target cells, being able to bind to target cells, being able to be internalized in target cells, and being able to damage target cells. [3]
[0047] The antibody-drug conjugate (I) according to [1] or [2], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein:
[0048] A represents an antibody residue obtained by removing a thiol, hydroxyl, amino, azide, alkynyl, cycloalkynyl, or azacycloalkynyl functional group from an antibody capable of targeting tumor cells. [4]
[0050] The antibody-drug conjugate (I) according to any one of [1] to [3], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EP HA2 antibody, anti-EPHA3 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo antibodyH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF-1R Antibodies, anti-KDR antibodies, anti-CEACAM8 antibodies, anti-IL5R antibodies, anti-CD205 (Ly75) antibodies, anti-MSR1 antibodies, anti-KREMEN2 antibodies, anti-SSEA-4 antibodies, anti-CD228 antibodies, anti-CD5 antibodies, anti-DLL4 antibodies, anti-FAP antibodies, anti-Notch3 antibodies, anti-AG7 antibodies, anti-guanylate cyclase antibodies, anti-adhesion protein-4 antibodies, anti-CD226 (DNAM-1) antibodies, anti-FcRL5 antibodies, anti-HLA-DR antibodies, anti-ITGB3 antibodies, anti-DLK1 antibodies, anti-CD157 (BST1) antibodies, anti-CD56 (NCAM1) antibodies, anti-MICA (MHC Class I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin Antibodies to αvβ3, anti-AGS-5, anti-CA19-9, anti-PSA, anti-MAGE3, anti-transferrin receptor 1 (CD71), anti-CEACAM1, anti-SLC3A2 (CD98), anti-ACVR1, anti-AG-7, anti-AMHR2, anti-ABCB1, anti-C16orf54, anti-cathepsin D, anti-CCR7, anti-SLC44A4, anti-CD300LF, anti-DPEP3, anti-FucGM1, anti-GPR20, anti-ITGB6, anti-Lewis-A-like carbohydrate antibodies, anti-prolactin receptor antibodies, and anti-SialylAntibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from a Tn antibody, an anti-SLAMF6 antibody, an anti-SLAMF7 antibody, an anti-TRA-1-60 antibody, an anti-proteinase antibody, an anti-B7-H4 antibody, an anti-Cripto antibody, an anti-CD99 antibody, an anti-CanAg antibody, an anti-A33 antibody, an anti-α10β1 integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody. [5]
[0052] The antibody-drug conjugate (I) according to any one of [1] to [4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD14 2 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-mucin-16 (CA125) antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-EGFR variant III antibody, anti-PTK7 antibody, anti-GPC1 antibody, anti-CD38 antibody, anti-DDL3 antibody, anti-SEZ6 antibody, anti-CD166 (ALCAM) antibody, anti-CDH3 antibody, anti-FGFR3 antibody, anti-Globo H antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CD46 antibody, anti-FLT3 antibody, CD138 antibody, anti-TM4SF1 antibody, anti-IGF-1R antibody, anti-CEACAM8 antibody, anti-CD205 (Ly75) antibody, anti-CD228 antibody, anti-FAP antibody, anti-AG7 antibody, anti-fibronectin-4 antibody, anti-CD226 (DNAM-1) antibody, anti-HLA-DR antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-CCR5 antibody, anti-ROR2 antibody, anti-LIV -1 antibody, anti-TIM-1 antibody, anti-CA19-9 antibody, anti-CEACAM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-cathepsin D antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carbohydrate antibody, anti-prolactin receptor antibody, anti-SialylAntibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from a Tn antibody, an anti-SLAMF6 antibody, an anti-SLAMF7 antibody, an anti-TRA-1-60 antibody, an anti-matrix antibody, an anti-B7-H4 antibody, an anti-Cripto antibody, an anti-CD99 antibody, an anti-CanAg antibody, an anti-α10β1 integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody. [6]
[0054] The antibody-drug conjugate (I) according to any one of [1] to [5], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD123 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-mucin Antibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from an anti-CA125 antibody, an anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, an anti-CD25 antibody, an anti-CEACAM5 antibody, an anti-CD79b antibody, an anti-HER3 antibody, an anti-PTK7 antibody, an anti-CD38 antibody, an anti-CDH3 antibody, an anti-CD37 antibody, an anti-FLT3 antibody, an anti-IGF-1R antibody, an anti-FAP antibody, an anti-fibronectin-4 antibody, an anti-CD56 (NCAM1) antibody, an anti-AG-7 antibody, an anti-CCR7 antibody, an anti-DPEP3 antibody, an anti-ITGB6 antibody, an anti-matrix antibody, an anti-Cripto antibody, an anti-ALPP antibody, or an anti-GPRC5D antibody. [7]
[0056] The antibody-drug conjugate (I) according to [1], its pharmacologically acceptable salt, or hydrate thereof, wherein:
[0057] A represents an antibody residue obtained by removing functional groups in the anti-HER2 antibody that participate in binding to the linker. [8]
[0059] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to [7], wherein
[0060] B is an -S- group, an -O- group, an -NH- group, or a 1,2,3-triazolylene group. [9]
[0062] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to [8], wherein
[0063] B is a -S- group or a -NH- group.
[10]
[0065] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to [9], wherein
[0066] B is a -S- group.
[11]
[0068] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to
[10] , wherein a is an integer of 1 to 8.
[12]
[0070] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to
[11] , wherein a is an integer of 2 to 8.
[13]
[0072] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to
[12] , wherein a is an integer of 4 to 8.
[14]
[0074] The antibody-drug conjugate (I) according to any one of [1] to
[13] , its pharmacologically acceptable salt, or hydrate thereof, wherein D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; duocarmycin; urospermia 10; superdox; ciprofloxacin; caderfloxacin (CS-940); or an analogue of these antitumor drugs; or a derivative of the antitumor drug molecule or their analogues.
[15]
[0076] The antibody-drug conjugate (I) according to any one of [1] to
[14] , its pharmacologically acceptable salt, or hydrate thereof, wherein D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; duocarmycin; dolastatin 10; superdox; or an analogue of these antitumor drugs; or a derivative of the above antitumor drug molecule or its analogue.
[16]
[0078] The antibody-drug conjugate (I) according to any one of [1] to
[15] , its pharmacologically acceptable salt, or hydrate thereof, wherein D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; or analogs of these antitumor drugs; or derivatives of the antitumor drug molecule or their analogs.
[17]
[0080] The antibody-drug conjugate (I) according to any one of [1] to
[16] , its pharmacologically acceptable salt, or hydrate thereof, wherein D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug or an analogue of such antitumor drug that has been phosphated at least one of the hydroxyl groups present in the molecule; or a derivative of the above-mentioned antitumor drug molecule or its analogue.
[18]
[0082] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to
[17] , wherein L is an optionally substituted alkylene group;
[0083] One or more methylene groups in the alkylene chain are optionally independently selected from
[0084] -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5)-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-OP(=S)(OR 13 )-O-;-OP(=O)(OR 13 )-S-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -; optionally substituted alkenylene; optionally substituted alkynylene; optionally substituted cycloalkylene; optionally substituted cycloalkenylene; optionally substituted cycloalkynylene; optionally substituted azaheterocycloalkynyl; optionally substituted arylene; optionally substituted heteroarylene; and optionally substituted heterocyclylene,
[0085] R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、R 9 、R 10 、R 11 、R 12 、R 13 , and R 14are each independently a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted cycloalkynyl group; an optionally substituted azacycloalkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclic group, R 3 When it is an alkyl group, the alkyl group may form a ring structure together with the alkyl group in the adjacent methylene group.
[0086] m and n are each independently an integer of 0-2.
[19]
[0088] The antibody-drug conjugate (I) according to
[18] , its pharmacologically acceptable salt, or hydrate thereof, wherein:
[0089] L is an optionally substituted alkylene group;
[0090] One or more methylene groups in the alkylene chain are replaced with one or more divalent groups independently selected from the following chemical formulae.
[0091] Chemical formula group:
[0092] -OC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0093] -SC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0094] -N(H or C1-C4 alkyl)-;
[0095] -N(H or C1-C4 alkyl)-OC(H or C1-C4 alkyl)(C(H or C1-C4 alkyl)-;
[0096] -C(H or C1-C4 alkyl)-SO 0-2 -C(H or C1-C4 alkyl)-;
[0097] -C(H or C1-C4 alkyl)-SSC(H or C1-C4 alkyl)-;
[0098] -C(H or C1-C4 alkyl)=C(H or C1-C4 alkyl)-;
[0099] -C(H or C1-C4 alkyl)=N-;
[0100] -C(H or C1-C4 alkyl)=NO-;
[0101] -C(H or C1-C4 alkyl)=NN(H or C1-C4 alkyl)-;
[0102] -C(=C(H or C1-C4 alkyl)(H or C1-C4 alkyl))-;
[0103] -C(=NO(H or C1-C4 alkyl))-;
[0104] -C(=NN(H or C1-C4 alkyl)(H or C1-C4 alkyl))-;
[0105] -O-Si(C1-C4 alkylCH3)(C1-C4 alkyl)-O-;
[0106] -C(H or C1-C4 alkyl)-N(C1-C4 alkyl)-CH2-;
[0107] -C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-C(═O)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0108] -C(=O)-O-;
[0109] -C(=O)-S-;
[0110] -C(=O)-N(H or C1-C4 alkyl)-;
[0111] -OC(=O)-O-;
[0112] -N(H or C1-C4 alkyl)-C(=O)-N(H or C1-C4 alkyl)-;
[0113] -C(=O)-N(H or C1-C4 alkyl)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0114] -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -C(=O)-;
[0115] -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-;
[0116] -NH-CH2-(CH2) 1-10 (O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-;
[0117] -C(=O)-N(C1-C4 alkyl)-CH2CH2-N(C1-C4 alkyl)-C(=O)-;
[0118]
[0119] [Wherein, * is the bonding point with the adjacent group];
[0120] -P(=O)(OH)-O-;
[0121] -OP(=O)(OH)-O-;
[0122] -OP(=S)(OH)-O-;
[0123] -OP(=O)(OH)-S-;
[0124] -OP(=O)(OH)-OP(=O)(OH)-O-;
[0125] -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-;
[0126] -CH(CH2-NH2)-;
[0127] -CH(CH2-NH(C1-C4 alkyl))-;
[0128] -CH(CH2-N(C1-C4alkyl)2)-;
[0129] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 0-20 -C1-C4 alkyl)-;
[0130] -CH(CH2-NH-C(=O)-(CH2) 0-20 -lactone)-;
[0131] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-lactone)-;
[0132] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-lactone)-;
[0133] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-C(=O)-lactonyl)-;
[0134] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-lactonyl)-;
[0135] -CH(CH2-NH-(CH2) 1-20 -(O) 0-1 -(P(=O)(OH)2)-;
[0136] -CH(CH2-NH-C(=O)-(CH2) 1-20 -(P(=O)(OH)2)-;
[0137] -CH(CH2-NH-C(=O)-(CH2) 1-20 -C(=O)-NH-(CH2) 1-10 -(P(=O)(OH)2)-;
[0138] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-(P(=O)(OH)2)-;
[0139] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -(P(=O)(OH)2)-;
[0140] -CH(CH2-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0141] -CH(CH2-NH-C(=O)-(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0142] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0143] -(cis)-CH=CH-P(=O)(O-CH2CH3)-NH-(phenylene)-C(=O)-;
[0144] -C(=O)-(cyclohexylene)-;
[0145] -(succinimidyl)-;
[0146] -Ser-;
[0147] -Cys-;
[0148] -Ama-:
[0149] -Asp-;
[0150] -Glu-;
[0151] -Orn-;
[0152] -Lys-;
[0153] -ValLys-;
[0154] -ValCit-;
[0155] -ValAla-;
[0156] -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0157] -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0158] -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0159] -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0160] -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0161] -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0162] -LysAspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0163] -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0164] -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0165] -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0166] -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0167] -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0168] -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0169] -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0170] -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0171] -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0172] -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0173] -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0174] -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0175] -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0176] -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0177] -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0178] -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0179] -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0180] -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0181] -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0182] -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0183] -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0184] -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0185] -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0186] -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0187] -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0188] -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0189] -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0190] -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0191] -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0192] -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0193] -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0194] -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0195] -GlyGlyPheGly-C(=O)-NH-CH2-;
[0196] -AspGlyGlyPheGly-C(=O)-NH-CH2-;
[0197] (Among the above amino acid residues, and amino acid residues in peptides,
[0198] The carboxyl groups of the side chains of Ama, Asp, and Glu may form (alkyl)esters, (aminoalkyl)esters, ((N-alkylamino)alkyl)esters, ((N,N-dialkylamino)alkyl)esters, ((trialkylammonium)alkyl)esters, (lactonyl)esters, ((lactonyl)alkyl)esters, ((phosphoryl)alkyl)esters, or ((bisphosphoryl)alkyl)esters, and may also form unsubstituted amides, alkylamides, dialkylamides, ((N-alkylamino)alkyl)amides, ((N,N-dialkylamino)alkyl)amides, ((trialkylammonium)alkyl)amides, (lactonyl)amides, ((lactonyl)alkyl)amides, (phosphoryl)amides, ((phosphoryl)alkyl)amides, or ((bisphosphoryl)alkyl)amides.
[0199] The amino group in the side chain of Lys and Orn may have one or two alkyl groups, alkylcarbonyl groups, (aminoalkyl)carbonyl groups, ((N-alkylamino)alkyl)carbonyl groups, ((N,N-dialkylamino)alkyl)carbonyl groups, ((trialkylammonium)alkyl)carbonyl groups, lactone groups, (lactonyl)alkyl groups, (lactonyl)carbonyl groups, ((lactonyl)alkyl)carbonyl groups, phosphoryl groups, (phosphoryl)alkyl groups, ((phosphoryl)alkyl)carbonyl groups, (bisphosphoryl)alkyl groups, or ((bisphosphoryl)alkyl)carbonyl groups as substituents.
[0200] The hydroxyl group of the side chain of Ser and the thiol group of the side chain of Cys may have an alkyl group, an alkylcarbonyl group, an aminoalkyl group, an (aminoalkyl)carbonyl group, an (N-alkylamino)alkyl group, a ((N-alkylamino)alkyl)carbonyl group, an (N,N-dialkylamino)alkyl group, a ((N,N-dialkylamino)alkyl)carbonyl group, a (trialkylammonium)alkyl group, a (trialkylammonium)alkyl)carbonyl group, a lactone group, a (lacone group)alkyl group, a (lacone group)carbonyl group, a ((lacone group)alkyl)carbonyl group, a phosphoryl group, a (phosphoryl)alkyl group, a ((phosphoryl)alkyl)carbonyl group, a (bisphosphoryl)alkyl group, or a ((bisphosphoryl)alkyl)carbonyl group as a substituent.
[0201] and a 1,2,3-triazolylene group of the following formula.
[0202]
[0203]
[0204] [Wherein, * is the bonding point to the adjacent group.]
[20]
[0206] The antibody-drug conjugate (I) according to
[18] , its pharmacologically acceptable salt, or hydrate thereof, wherein:
[0207] L is any one divalent group selected from the following chemical formulae.
[0208] Chemical formula group:
[0209]
[0210]
[0211]
[0212]
[0213]
[0214] [Where, * 1 is the bonding point to antibody residue AS-, 2 is the bonding point with the antibody residue A-NH-, # is the bonding point with the anti-tumor drug residue D-] [twenty one]
[0216] The antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [1] to
[20] , wherein
[0217] At least one of D and L has one or more lactone groups as substituents or protecting groups at any position, and, independently of this,
[0218] At least either D or L has at any position one or more groups selected from phosphoryl (-P(=O)(OH)2); phosphorylalkylcarbonyl (-C(=O)-alkylene-P(=O)(OH)2); bisphosphorylmethyl (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); amino; monoalkylamino; dialkylamino; a cyclic amino group in which the two alkyl groups of the dialkylamino group form a ring together with the nitrogen atom to which they are bonded; and trialkylammonium group as a substituent or protecting group, and when the total number of such groups is multiple, they may be the same or different. [twenty two]
[0220] The antibody-drug conjugate (I) according to any one of [1] to
[21] , a pharmacologically acceptable salt thereof, or a hydrate thereof, which is selected from the group consisting of the following chemical formulas:
[0221] Example 1
[0222]
[0223] Example 2
[0224]
[0225] Example 3
[0226]
[0227] Example 3b
[0228]
[0229] Example 3c
[0230]
[0231] Example 4
[0232]
[0233] Example 5
[0234]
[0235] Example 6
[0236]
[0237] Example 7
[0238]
[0239] Example 8
[0240]
[0241] Example 9
[0242]
[0243] Example 10
[0244]
[0245] Example 11
[0246]
[0247] Example 12
[0248]
[0249] Example 13
[0250]
[0251] Example 14
[0252]
[0253] Example 15
[0254]
[0255] Example 16
[0256]
[0257] Example 17
[0258]
[0259] Example 18
[0260]
[0261] Example 19
[0262]
[0263] Example 20
[0264]
[0265] Example 21
[0266]
[0267] Example 22
[0268]
[0269] Example 23
[0270]
[0271] and
[0272] Example 24
[0273]
[0274] [Where A HER2
[0065] It is an antibody residue obtained by removing a thiol group present in an anti-HER2 antibody from the antibody, and a has the same meaning as above.] [twenty three]
[0276] A pharmaceutical composition comprising the antibody-drug conjugate (I) according to any one of [1] to
[22] , a pharmacologically acceptable salt thereof, or a hydrate thereof. [twenty four]
[0278] An antitumor drug comprising the antibody-drug conjugate (I) according to any one of [1] to
[22] , a pharmacologically acceptable salt thereof, or a hydrate thereof.
[25]
[0280] A pharmaceutical composition comprising the antibody-drug conjugate (I) according to any one of [1] to
[22] , a pharmacologically acceptable salt thereof, or a hydrate thereof as an active ingredient, and further comprising a pharmacologically acceptable formulation component.
[26]
[0282] A method for treating tumors, characterized by administering the antibody-drug conjugate (I) according to any one of [1] to
[22] , a pharmacologically acceptable salt thereof, or a hydrate thereof.
[0283] The following describes embodiments of the present invention. It should be noted that embodiments obtained by arbitrarily selecting and combining the following embodiments, and embodiments obtained by arbitrarily combining the following embodiments with any embodiment or implementation example described in this specification are also included in the present invention.
[0284] [Method A1]
[0285] An antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is an antibody residue obtained by removing a functional group in the antibody that participates in binding to a linker from an antibody capable of targeting tumor cells.
[0286] [Method A2]
[0287] The antibody-drug conjugate (I) according to [Embodiment A1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is an antibody residue obtained by removing a functional group within the antibody that participates in binding to a linker from an antibody having any one or more of the properties of being able to recognize target cells, being able to bind to target cells, being able to be internalized into target cells, and being able to damage target cells.
[0288] [Method A3]
[0289] The antibody-drug conjugate (I) according to [Embodiment A1] or [Embodiment A2], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is an antibody residue obtained by removing a thiol group, hydroxyl group, amino group, azide group, alkynyl group, cycloalkynyl group, or azacycloalkynyl group that is a functional group in the antibody from an antibody capable of targeting tumor cells.
[0290] [Mode A4]
[0291] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A3], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, Anti-EPHA2 antibody, anti-EPHA3 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo antibodyH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF-1R Antibodies, anti-KDR antibodies, anti-CEACAM8 antibodies, anti-IL5R antibodies, anti-CD205 (Ly75) antibodies, anti-MSR1 antibodies, anti-KREMEN2 antibodies, anti-SSEA-4 antibodies, anti-CD228 antibodies, anti-CD5 antibodies, anti-DLL4 antibodies, anti-FAP antibodies, anti-Notch3 antibodies, anti-AG7 antibodies, anti-guanylate cyclase antibodies, anti-adhesion protein-4 antibodies, anti-CD226 (DNAM-1) antibodies, anti-FcRL5 antibodies, anti-HLA-DR antibodies, anti-ITGB3 antibodies, anti-DLK1 antibodies, anti-CD157 (BST1) antibodies, anti-CD56 (NCAM1) antibodies, anti-MICA (MHC Class I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin Antibodies to αvβ3, anti-AGS-5, anti-CA19-9, anti-PSA, anti-MAGE3, anti-transferrin receptor 1 (CD71), anti-CEACAM1, anti-SLC3A2 (CD98), anti-ACVR1, anti-AG-7, anti-AMHR2, anti-ABCB1, anti-C16orf54, anti-cathepsin D, anti-CCR7, anti-SLC44A4, anti-CD300LF, anti-DPEP3, anti-FucGM1, anti-GPR20, anti-ITGB6, anti-Lewis-A-like carbohydrate antibodies, anti-prolactin receptor antibodies, and anti-SialylAntibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from a Tn antibody, an anti-SLAMF6 antibody, an anti-SLAMF7 antibody, an anti-TRA-1-60 antibody, an anti-proteinase antibody, an anti-B7-H4 antibody, an anti-Cripto antibody, an anti-CD99 antibody, an anti-CanAg antibody, an anti-A33 antibody, an anti-α10β1 integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody.
[0292] [Mode A5]
[0293] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-C D142 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-mucin-16 (CA125) antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-EGFR variant III antibody, anti-PTK7 antibody, anti-GPC1 antibody, anti-CD38 antibody, anti-DDL3 antibody, anti-SEZ6 antibody, anti-CD166 (ALCAM) antibody, anti-CDH3 antibody, anti-FGFR3 antibody, anti-Globo H antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CD46 antibody, anti-FLT3 antibody, CD138 antibody, anti-TM4SF1 antibody, anti-IGF-1R antibody, anti-CEACAM8 antibody, anti-CD205 (Ly75) antibody, anti-CD228 antibody, anti-FAP antibody, anti-AG7 antibody, anti-fibronectin-4 antibody, anti-CD226 (DNAM-1) antibody, anti-HLA-DR antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-CCR5 antibody, anti-ROR2 antibody, anti-LIV -1 antibody, anti-TIM-1 antibody, anti-CA19-9 antibody, anti-CEACAM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-cathepsin D antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carbohydrate antibody, anti-prolactin receptor antibody, anti-SialylAntibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from a Tn antibody, an anti-SLAMF6 antibody, an anti-SLAMF7 antibody, an anti-TRA-1-60 antibody, an anti-matrix antibody, an anti-B7-H4 antibody, an anti-Cripto antibody, an anti-CD99 antibody, an anti-CanAg antibody, an anti-α10β1 integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody.
[0294] [Mode A6]
[0295] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A5], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD123 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti- Antibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from a mucin-16 (CA125) antibody, an anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, an anti-CD25 antibody, an anti-CEACAM5 antibody, an anti-CD79b antibody, an anti-HER3 antibody, an anti-PTK7 antibody, an anti-CD38 antibody, an anti-CDH3 antibody, an anti-CD37 antibody, an anti-FLT3 antibody, an anti-IGF-1R antibody, an anti-FAP antibody, an anti-nectin-4 antibody, an anti-CD56 (NCAM1) antibody, an anti-AG-7 antibody, an anti-CCR7 antibody, an anti-DPEP3 antibody, an anti-ITGB6 antibody, an anti-matrix antibody, an anti-Cripto antibody, an anti-ALPP antibody, or an anti-GPRC5D antibody.
[0296] [Mode A7]
[0297] An antibody-drug conjugate (I), a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein A is an antibody residue obtained by removing a functional group in the antibody that participates in binding to a linker from an anti-HER2 antibody.
[0298] [Method B1]
[0299] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein B is a -S- group, a -NH- group, or a 1,2,3-triazolylene group.
[0300] [Method B2]
[0301] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7] and [Embodiment B1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein B is a -S- group or a -NH- group.
[0302] [Method B3]
[0303] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1], and [Embodiment B2], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein B is a -S- group.
[0304] [Method C1]
[0305] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7] and [Embodiment B1] to [Embodiment B3], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein a is an integer of 1 to 10.
[0306] [Method C2]
[0307] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7] and [Embodiment B1] to [Embodiment B3], a pharmaceutically acceptable salt thereof, or a hydrate thereof, wherein a is an integer of 1 to 8.
[0308] [Method C3]
[0309] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7] and [Embodiment B1] to [Embodiment B3], a pharmaceutically acceptable salt thereof, or a hydrate thereof, wherein a is an integer of 2 to 8.
[0310] [Method C4]
[0311] The antibody-drug conjugate (I) according to any one of [Embodiment C1] to [Embodiment C3], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein a is an integer of 4 to 8.
[0312] [Method D1]
[0313] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], and [Embodiment C1] to [Embodiment C4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug molecule, an analog thereof, or a derivative thereof.
[0314] [Method D2]
[0315] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], and [Embodiment C1] to [Embodiment C4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein D is: camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026 ; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; duocarmycin; Aplysia 10; superdox; ciprofloxacin; caderfloxacin (CS-940); or analogs of these antitumor drugs; or residues formed by removing one hydrogen atom or one hydroxyl group from any position of the derivatives of the antitumor drug molecules or their analogs.
[0316] [Mode D3]
[0317] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], and [Embodiment C1] to [Embodiment C4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein D is selected from camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; duocarmycin; Aplysia 10; superdox; or analogs of these anti-tumor drugs; or residues formed by removing one hydrogen atom or one hydroxyl group from any position of derivatives of the above-mentioned anti-tumor drug molecules or their analogs.
[0318] [Method D4]
[0319] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], and [Embodiment C1] to [Embodiment C4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein D is a residue obtained by removing one hydrogen atom or one hydroxyl group from any position of camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; or an analog of these anti-tumor drugs; or a derivative of the anti-tumor drug molecule or an analog thereof.
[0320] [Mode D5]
[0321] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], and [Embodiment C1] to [Embodiment C4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein D is a residue obtained by removing one hydrogen atom or one hydroxyl group from any position of camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); eribulin; or an analog of these anti-tumor drugs; or a derivative of the anti-tumor drug molecule or its analog.
[0322] [Mode D6]
[0323] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], and [Embodiment D1] to [Embodiment D5], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein D is an anti-tumor drug or an analog thereof whose at least one hydroxyl group present in the molecule is phosphated; or a derivative of the anti-tumor drug molecule or its analogue is removed from any position.
[0324] [Method E1]
[0325] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], and [Embodiment D1] to [Embodiment D6], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is a linker connecting B and D.
[0326] [Method E2]
[0327] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is an optionally substituted alkylene group;
[0328] One or more methylene groups in the alkylene chain are optionally independently selected from
[0329] -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3)-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-OP(=S)(OR 13 )-O-;-OP(=O)(OR 13 )-S-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -; optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted cycloalkylene; optionally substituted cycloalkenylene; optionally substituted cycloalkynylene; optionally substituted azacycloalkynylene; optionally substituted arylene; optionally substituted heteroarylene; and optionally substituted heterocyclylene,
[0330] R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、R 9 、R 10 、R 11 、R 12 、R 13 , and R14 are each independently a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted cycloalkynyl group, an optionally substituted azacycloalkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclic group, and R 3 When it is an alkyl group, the alkyl group may form a ring structure together with the alkyl group in the adjacent methylene group.
[0331] m and n are each independently an integer of 0-2.
[0332] [Method E3]
[0333] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is an optionally substituted alkylene group;
[0334] One or more methylene groups in the alkylene chain are replaced with one or more divalent groups independently selected from the following chemical formulae.
[0335] Chemical formula group:
[0336] -OC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0337] -SC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0338] -N(H or C1-C4 alkyl)-;
[0339] -N(H or C1-C4 alkyl)-OC(H or C1-C4 alkyl)(C(H or C1-C4 alkyl)-;
[0340] -C(H or C1-C4 alkyl)-SO 0-2 -C(H or C1-C4 alkyl)-;
[0341] -C(H or C1-C4 alkyl)-SSC(H or C1-C4 alkyl)-;
[0342] -C(H or C1-C4 alkyl)=C(H or C1-C4 alkyl)-;
[0343] -C(H or C1-C4 alkyl)=N-;
[0344] -C(H or C1-C4 alkyl)=NO-;
[0345] -C(H or C1-C4 alkyl)=NN(H or C1-C4 alkyl)-;
[0346] -C(=C(H or C1-C4 alkyl)(H or C1-C4 alkyl))-;
[0347] -C(=NO(H or C1-C4 alkyl))-;
[0348] -C(=NN(H or C1-C4 alkyl)(H or C1-C4 alkyl))-;
[0349] -O-Si(C1-C4 alkylCH3)(C1-C4 alkyl)-O-;
[0350] -C(H or C1-C4 alkyl)-N(C1-C4 alkyl)-CH2-;
[0351] -C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-C(═O)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0352] -C(=O)-O-;
[0353] -C(=O)-S-;
[0354] -C(=O)-N(H or C1-C4 alkyl)-;
[0355] -OC(=O)-O-;
[0356] -N(H or C1-C4 alkyl)-C(=O)-N(H or C1-C4 alkyl)-;
[0357] -C(=O)-N(H or C1-C4 alkyl)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0358] -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -C(=O)-;
[0359] -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-;
[0360] -NH-CH2-(CH2) 1-10 (O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-;
[0361] -C(=O)-N(C1-C4 alkyl)-CH2CH2-N(C1-C4 alkyl)-C(=O)-;
[0362]
[0363] [Wherein, * is the bonding point with the adjacent group];
[0364] -P(=O)(OH)-O-;
[0365] -OP(=O)(OH)-O-;
[0366] -OP(=S)(OH)-O-;
[0367] -OP(=O)(OH)-S-;
[0368] -OP(=O)(OH)-OP(=O)(OH)-O-;
[0369] -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-;
[0370] -CH(CH2-NH2)-;
[0371] -CH(CH2-NH(C1-C4 alkyl))-;
[0372] -CH(CH2-N(C1-C4alkyl)2)-;
[0373] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 0-20 -C1-C4 alkyl)-;
[0374] -CH(CH2-NH-C(=O)-(CH2) 0-20 -lactone)-;
[0375] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-lactone)-;
[0376] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-lactone)-;
[0377] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10-CH2-NH-C(=O)-lactonyl)-;
[0378] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-lactone)-;
[0379] -CH(CH2-NH-(CH2) 1-20 -(O) 0-1 -(P(=O)(OH)2)-;
[0380] -CH(CH2-NH-C(=O)-(CH2) 1-20 -(P(=O)(OH)2)-;
[0381] -CH(CH2-NH-C(=O)-(CH2) 1-20 -C(=O)-NH-(CH2) 1-10 -(P(=O)(OH)2)-;
[0382] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-(P(=O)(OH)2)-;
[0383] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -(P(=O)(OH)2)-;
[0384] -CH(CH2-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0385] -CH(CH2-NH-C(=O)-(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0386] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0387] -(cis)-CH=CH-P(=O)(O-CH2CH3)-NH-(phenylene)-C(=O)-;
[0388] -C(=O)-(cyclohexylene)-;
[0389] -(succinimidyl)-;
[0390] -Ser-;
[0391] -Cys-;
[0392] -Ama-:
[0393] -Asp-;
[0394] -Glu-;
[0395] -Orn-;
[0396] -Lys-;
[0397] -ValLys-;
[0398] -ValCit-;
[0399] -ValAla-;
[0400] -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0401] -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0402] -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0403] -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0404] -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0405] -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0406] -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0407] -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0408] -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0409] -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0410] -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0411] -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0412] -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0413] -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0414] -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0415] -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0416] -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0417] -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0418] -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0419] -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0420] -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0421] -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0422] -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0423] -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0424] -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0425] -LysAspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0426] -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0427] -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0428] -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0429] -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0430] -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0431] -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0432] -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0433] -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0434] -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0435] -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0436] -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0437] -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0438] -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-;
[0439] -GlyGlyPheGly-C(=O)-NH-CH2-;
[0440] -AspGlyGlyPheGly-C(=O)-NH-CH2-;
[0441] (Among the above amino acid residues, and amino acid residues in peptides,
[0442] The carboxyl groups of the side chains of Ama, Asp, and Glu may form (alkyl)esters, (aminoalkyl)esters, ((N-alkylamino)alkyl)esters, ((N,N-dialkylamino)alkyl)esters, ((trialkylammonium)alkyl)esters, (lactonyl)esters, ((lactonyl)alkyl)esters, ((phosphoryl)alkyl)esters, or ((bisphosphoryl)alkyl)esters, and may also form unsubstituted amides, alkylamides, dialkylamides, ((N-alkylamino)alkyl)amides, ((N,N-dialkylamino)alkyl)amides, ((trialkylammonium)alkyl)amides, (lactonyl)amides, ((lactonyl)alkyl)amides, (phosphoryl)amides, ((phosphoryl)alkyl)amides, or ((bisphosphoryl)alkyl)amides.
[0443] phosphoryl)alkyl)amide,
[0444] The amino group in the side chain of Lys and Orn may have one or two alkyl groups, alkylcarbonyl groups, (aminoalkyl)carbonyl groups, ((N-alkylamino)alkyl)carbonyl groups, ((N,N-dialkylamino)alkyl)carbonyl groups, ((trialkylammonium)alkyl)carbonyl groups, lactone groups, (lactonyl)alkyl groups, (lactonyl)carbonyl groups, ((lactonyl)alkyl)carbonyl groups, phosphoryl groups, (phosphoryl)alkyl groups, ((phosphoryl)alkyl)carbonyl groups, (bisphosphoryl)alkyl groups, or ((bisphosphoryl)alkyl)carbonyl groups as substituents.
[0445] The hydroxyl group of the side chain of Ser and the thiol group of the side chain of Cys may have an alkyl group, an alkylcarbonyl group, an aminoalkyl group, an (aminoalkyl)carbonyl group, an (N-alkylamino)alkyl group, a ((N-alkylamino)alkyl)carbonyl group, an (N,N-dialkylamino)alkyl group, a ((N,N-dialkylamino)alkyl)carbonyl group, a (trialkylammonium)alkyl group, a (trialkylammonium)alkyl)carbonyl group, a lactone group, a (lacone group)alkyl group, a (lacone group)carbonyl group, a ((lacone group)alkyl)carbonyl group, a phosphoryl group, a (phosphoryl)alkyl group, a ((phosphoryl)alkyl)carbonyl group, a (bisphosphoryl)alkyl group, or a ((bisphosphoryl)alkyl)carbonyl group as a substituent.
[0446] and a 1,2,3-triazolylene group of the following formula.
[0447]
[0448]
[0449] [Wherein, * is the bonding point to the adjacent group.]
[0450] [Method E4]
[0451] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is an optionally substituted alkylene group;
[0452] One or more methylene groups in the alkylene chain are replaced with one or more divalent groups independently selected from the following chemical formulae.
[0453] Chemical formula group:
[0454] -O-;
[0455] -C(=O)-;
[0456] -N(H or C1-C4 alkyl)-;
[0457] -OC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0458] optionally substituted phenylene;
[0459] -C(H or C1-C4 alkyl)-N(C1-C4 alkyl)-CH2-;
[0460] -C(=O)-O-;
[0461] -OC(=O)-O-;
[0462] -C(=O)-N(H or C1-C4 alkyl)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-;
[0463] -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -C(=O)-;
[0464] -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-;
[0465] -NH-CH2-(CH2) 1-10 (O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-;
[0466] -C(=O)-N(C1-C4 alkyl)-CH2CH2-N(C1-C4 alkyl)-C(=O)-;
[0467]
[0468] [Wherein, * is the bonding point with the adjacent group];
[0469] -OP(=O)(OH);
[0470] -OP(=O)(OH)-O-;
[0471] -OP(=O)(OH)-OP(=O)(OH)-O-;
[0472] -CH(CH2-NH-C(=O)-(CH2) 0-20 -lactone)-;
[0473] -CH(CH2-NH-(CH2) 1-20 -(O) 0-1 -(P(=O)(OH)2)-;
[0474] -CH(CH2-NH-C(=O)-(CH2) 1-20 -(P(=O)(OH)2)-;
[0475] -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10-C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-;
[0476] -(succinimidyl)-;
[0477] -Asp-;
[0478] -Lys-;
[0479] -Phe-;
[0480] -Val-;
[0481] -Cit-;
[0482] -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0483] -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0484] -LysAspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-;
[0485] -GlyGlyPheGly-C(=O)-NH-CH2-;
[0486] -AspGlyGlyPheGly-C(=O)-NH-CH2-;
[0487] (Among the above amino acid residues, and amino acid residues in peptides,
[0488] The carboxyl group of the Asp side chain can form (lactone) amides,
[0489] The amino group of the Lys side chain may have two alkyl groups as substituents.)
[0490] [Method E5]
[0491] The antibody-drug conjugate (I) according to any one of [Embodiment E2] to [Embodiment E4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is an optionally substituted C 10 -C 50 Alkylene.
[0492] [Method E6]
[0493] The antibody-drug conjugate (I) according to any one of [Embodiment E2] to [Embodiment E4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is an optionally substituted C 15 -C 40 Alkylene.
[0494] [Method E7]
[0495] The antibody-drug conjugate (I) according to any one of [Embodiment E2] to [Embodiment E4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is an optionally substituted C 20 -C 35 Alkylene.
[0496] [Method E8]
[0497] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L comprises one or more structures selected from the following.
[0498]
[0499] [Wherein, * is the bonding point to the adjacent group.]
[0500] [Method E9]
[0501] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L comprises one or more structures selected from the following.
[0502]
[0503] [Wherein, * is the bonding point to the adjacent group.]
[0504] [Method E10]
[0505] The antibody-drug conjugate (I) according to [Embodiment E8] or [Embodiment E9], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L further comprises one or more structures selected from the following.
[0506]
[0507] [Wherein, * is the bonding point to the adjacent group.]
[0508] [Method E11]
[0509] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein L is any divalent group selected from the following chemical formulae.
[0510] Chemical formula group:
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517] [Where, * 1 is the bonding point to antibody residue AS-, 2 is the bonding point with the antibody residue A-NH-, # is the bonding point with the anti-tumor drug residue D-]
[0518] [Method E12]
[0519] The antibody-drug conjugate (I) according to any one of [Embodiment A1] to [Embodiment A7], [Embodiment B1] to [Embodiment B3], [Embodiment C1] to [Embodiment C4], [Embodiment D1] to [Embodiment D6], and [Embodiment E1] to [Embodiment E11], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein at least one of D and L has one or more lactone groups as substituents or protecting groups at any position, and independently of these,
[0520] At least either D or L has one or more groups selected from phosphoryl (-P(=O)(OH)2); phosphorylalkylcarbonyl (-C(=O)-alkylene-P(=O)(OH)2); bisphosphorylmethyl (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); amino; monoalkylamino; dialkylamino; cyclic amino in which the dialkyl groups together form a ring; and trialkylammonium as a substituent or protecting group at any position, and when the total number of such groups is multiple, they may be the same or different.
[0521] [Mode F1]
[0522] An antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the antibody-drug conjugate is represented by the following general formula (I-1):
[0523]
[0524] [Where,
[0525] A, B, D, and a have the same meanings as above.
[0526] W is a divalent group selected from the following,
[0527]
[0528] [Where R X A hydrogen atom, -CH2-NH-C(=O)-(CH2) 0-4 -lactone group, -CH2-NH-C(=O)-(CH2) 1-4 -P(=O)(OH)2, -CH2-NH-C(=O)-(CH2) 1-4 -OP(=O)(OH)2, -CH2-NH-C(=O)-(CH2CH2-O-) 1-10 -(CH2) 1-4 -C(=O)-NH-(CH2) 1-4 -P(=O)(OH)2, or -CH2-NH-C(=O)-(CH2CH2-O-) 1-10 -(CH2) 1-4 -C(=O)-NH-(CH2) 1-4 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2;
[0529] * is the bonding point with the adjacent group.]
[0530] Y is a divalent group selected from the following.
[0531]
[0532] [Wherein, * is the bonding point to the adjacent group.]]
[0533] [Mode F2]
[0534] The antibody-drug conjugate according to [Embodiment F1], a pharmacologically acceptable salt thereof, or a hydrate thereof, which is represented by the following general formula (I-2) or general formula (I-3):
[0535]
[0536] [Where A, B, D, W, RX , and a have the same meanings as above, and p is an integer from 1 to 10.]
[0537] [Method G1]
[0538] A method for stabilizing an antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof in vivo, comprising substituting one or more lactone rings into a linker or an anti-tumor drug residue of the antibody-drug conjugate.
[0539] [Method G2]
[0540] The method according to embodiment G1, comprising further substituting one or more phosphate groups into a linker of the antibody-drug conjugate or an antitumor drug residue.
[0541] [Method G3]
[0542] A method for prolonging the survival time of an antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof after administration into a living body, comprising substituting one or more lactone rings into a linker or an antitumor drug residue of the antibody-drug conjugate.
[0543] [Method G4]
[0544] An antibody-drug conjugate with increased stability after in vivo administration, and a pharmacologically acceptable salt thereof, comprising a linker or an anti-tumor drug residue substituted with a lactone ring.
[0545] [Mode H1]
[0546] An antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the antibody-drug conjugate comprises an antibody and an anti-tumor drug molecule, the antibody and the anti-tumor drug molecule are covalently linked via a linker, and the linker is modified with a lactone group.
[0547] [Mode H2]
[0548] An antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the antibody-drug conjugate comprises an antibody and an anti-tumor drug molecule, the antibody and the anti-tumor drug molecule being covalently linked via a linker, and the linker being modified with a lactone group, thereby exhibiting higher blood stability compared to an antibody-drug conjugate not having a modification based on a lactone group.
[0549] [Mode H3]
[0550] The antibody-drug conjugate according to [Embodiment H1] or [Embodiment H2], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the lactone group comprises one or more lactone groups selected from the group consisting of an α-acetone lactone group, a β-propiolactone group, a γ-butyrolactone group, and a δ-valerolactone group.
[0551] [Mode H4]
[0552] The antibody-drug conjugate according to any one of [Embodiment H1] to [Embodiment H3], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the antibody is derived from an anti-HER2 antibody, an anti-EGFR antibody, an anti-lymphocyte antigen 6E (Ly-6E) antibody, an anti-hepatocyte growth factor receptor (HGFR) antibody, an anti-CD22 antibody, an anti-folate receptor α (FRα) antibody, an anti-PSMA (FOLH1) antibody, an anti-CD30 (TNFRSF8) antibody, an anti-TROP-2 antibody, an anti-CD19 antibody, an anti-5T4 antibody, an anti-mesothelin antibody, an anti-CD20 antibody, an anti-CD33 antibody, an anti-CDB7-H3 antibody, an anti-CD269 (BCMA) antibody, an anti-CD142 antibody, an anti-CD70 antibody, an anti-CD123 antibody, an anti-TAG-72 antibody, or an anti-TFRC antibody. , anti-EPHA2 antibody, anti-EPHA3 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo antibodyH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF-1R Antibodies, anti-KDR antibodies, anti-CEACAM8 antibodies, anti-IL5R antibodies, anti-CD205 (Ly75) antibodies, anti-MSR1 antibodies, anti-KREMEN2 antibodies, anti-SSEA-4 antibodies, anti-CD228 antibodies, anti-CD5 antibodies, anti-DLL4 antibodies, anti-FAP antibodies, anti-Notch3 antibodies, anti-AG7 antibodies, anti-guanylate cyclase antibodies, anti-adhesion protein-4 antibodies, anti-CD226 (DNAM-1) antibodies, anti-FcRL5 antibodies, anti-HLA-DR antibodies, anti-ITGB3 antibodies, anti-DLK1 antibodies, anti-CD157 (BST1) antibodies, anti-CD56 (NCAM1) antibodies, anti-MICA (MHC Class I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin Antibodies to αvβ3, anti-AGS-5, anti-CA19-9, anti-PSA, anti-MAGE3, anti-transferrin receptor 1 (CD71), anti-CEACAM1, anti-SLC3A2 (CD98), anti-ACVR1, anti-AG-7, anti-AMHR2, anti-ABCB1, anti-C16orf54, anti-cathepsin D, anti-CCR7, anti-SLC44A4, anti-CD300LF, anti-DPEP3, anti-FucGM1, anti-GPR20, anti-ITGB6, anti-Lewis-A-like carbohydrate antibodies, anti-prolactin receptor antibodies, and anti-SialylAntibody residues of Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matrix antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody.
[0553] [Mode H5]
[0554] The antibody-drug conjugate according to any one of [Embodiment H1] to [Embodiment H4], a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein the antibody has one or more properties selected from a property capable of being internalized into target cells (internalization activity) and a property of damaging target cells (e.g., antibody-dependent cellular cytotoxicity activity (ADCC) or complement-dependent cytotoxicity activity (CDC)).
[0555] [Mode H6]
[0556] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 1 to about 8.
[0557] [Mode H7]
[0558] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 4 to about 8.
[0559] [Mode H8]
[0560] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 6 to about 8.
[0561] [mode H9]
[0562] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 7 to about 8.
[0563] [mode H10]
[0564] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 8.
[0565] [mode H11]
[0566] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H10], wherein the antibody subclass is IgG.
[0567] [mode H12]
[0568] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H11], wherein the linker is cleavable (preferably cleavable in response to the internal environment of tumor tissue).
[0569] [mode H13]
[0570] The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of [Embodiment H1] to [Embodiment H11], wherein the linker is non-cleavable (preferably, cannot be cleaved in response to the internal environment of tumor tissue).
[0571] [mode H14]
[0572] A composition (preferably a pharmaceutical composition) comprising the antibody-drug conjugate according to any one of [Embodiment H1] to [Embodiment H13] above, a pharmacologically acceptable salt thereof, or a hydrate thereof.
[0573] [Method I1]
[0574] A composition for producing an antibody-drug conjugate comprising an antibody, a linker, and an anti-tumor drug molecule, wherein the linker comprises a linker having an antibody-reactive functional group and an anti-tumor drug molecule, and the linker is modified with a lactone group.
[0575] [Method I2]
[0576] The composition according to the above-mentioned [Embodiment I1], wherein the antibody-reactive functional group comprises a maleimide group.
[0577] [Method I3]
[0578] The composition according to [Aspect I1] or [Aspect I2], wherein the lactone group comprises one or more lactone groups selected from the group consisting of α-acetolactone, β-propiolactone, γ-butyrolactone, and δ-valerolactone.
[0579] [Method I4]
[0580] The composition according to any one of [Embodiment I1] to [Embodiment I3], wherein the antibody is derived from an anti-HER2 antibody, an anti-EGFR antibody, an anti-lymphocyte antigen 6E (Ly-6E) antibody, an anti-hepatocyte growth factor receptor (HGFR) antibody, an anti-CD22 antibody, an anti-folate receptor α (FRα) antibody, an anti-PSMA (FOLH1) antibody, an anti-CD30 (TNFRSF8) antibody, an anti-TROP-2 antibody, an anti-CD19 antibody, an anti-5T4 antibody, an anti-mesothelin antibody, an anti-CD20 antibody, an anti-CD33 antibody, an anti-CDB7-H3 antibody, an anti-CD269 (BCMA) antibody, an anti-CD142 antibody, an anti-CD70 antibody, an anti-CD123 antibody, an anti-TAG-72 antibody, an anti-TFRC antibody, an anti-EPHA2 antibody, or an anti-E PHA3 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo antibodyH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF-1R Antibodies, anti-KDR antibodies, anti-CEACAM8 antibodies, anti-IL5R antibodies, anti-CD205 (Ly75) antibodies, anti-MSR1 antibodies, anti-KREMEN2 antibodies, anti-SSEA-4 antibodies, anti-CD228 antibodies, anti-CD5 antibodies, anti-DLL4 antibodies, anti-FAP antibodies, anti-Notch3 antibodies, anti-AG7 antibodies, anti-guanylate cyclase antibodies, anti-adhesion protein-4 antibodies, anti-CD226 (DNAM-1) antibodies, anti-FcRL5 antibodies, anti-HLA-DR antibodies, anti-ITGB3 antibodies, anti-DLK1 antibodies, anti-CD157 (BST1) antibodies, anti-CD56 (NCAM1) antibodies, anti-MICA (MHC Class I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin Antibodies to αvβ3, anti-AGS-5, anti-CA19-9, anti-PSA, anti-MAGE3, anti-transferrin receptor 1 (CD71), anti-CEACAM1, anti-SLC3A2 (CD98), anti-ACVR1, anti-AG-7, anti-AMHR2, anti-ABCB1, anti-C16orf54, anti-cathepsin D, anti-CCR7, anti-SLC44A4, anti-CD300LF, anti-DPEP3, anti-FucGM1, anti-GPR20, anti-ITGB6, anti-Lewis-A-like carbohydrate antibodies, anti-prolactin receptor antibodies, and anti-SialylAntibody residues of Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matrix antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody.
[0581] [Method I5]
[0582] The composition according to any one of [Embodiment I1] to [Embodiment I4], wherein the antibody is an antibody having one or more properties selected from the group consisting of a property capable of being internalized into target cells (internalization activity) and a property of damaging target cells (e.g., antibody-dependent cellular cytotoxicity activity (ADCC) or complement-dependent cytotoxicity activity (CDC)).
[0583] [Method I6]
[0584] The composition according to any one of [Embodiment I1] to [Embodiment I5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 1 to about 8.
[0585] [Method I7]
[0586] The composition according to any one of [Embodiment I1] to [Embodiment I5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 4 to about 8.
[0587] [Method I8]
[0588] The composition according to any one of [Embodiment I1] to [Embodiment I5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 6 to about 8.
[0589] [Method I9]
[0590] The composition according to any one of [Embodiment I1] to [Embodiment I5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 7 to about 8.
[0591] [Method I10]
[0592] The composition according to any one of [Embodiment I1] to [Embodiment I5], wherein the ratio of the antibody to the anti-tumor drug molecule (drug molecule / antibody ratio, DAR) is about 8.
[0593] [Method I11]
[0594] The composition according to any one of [Embodiment I1] to [Embodiment I10], wherein the antibody subclass is IgG.
[0595] [Method I12]
[0596] The composition according to any one of [Embodiment I1] to [Embodiment I11], wherein the linker is cleavable.
[0597] [Method I13]
[0598] The composition according to any one of [Embodiment I1] to [Embodiment I11], wherein the linker is non-cleavable.
[0599] [Method I14]
[0600] The composition according to any one of [Embodiment I1] to [Embodiment I11], wherein the linker comprises a first spacer (preferably polyethylene glycol) and a dipeptide containing valine and citrulline.
[0601] [Method I15]
[0602] The composition according to any one of [Embodiment I1] to [Embodiment I11], wherein the linker comprises a first spacer (preferably polyethylene glycol), a dipeptide containing valine and citrulline, and a second spacer.
[0603] [Method I16]
[0604] The composition according to the above-mentioned [Embodiment I15], wherein the second spacer is p-aminobenzylcarbamic acid.
[0605] In the above-mentioned divalent groups, when a bilaterally asymmetric group or a group capable of becoming bilaterally asymmetric exists as a part of L in the general formula (I), the divalent group may be oriented in any direction, left, right, up, or down, on the paper. For example, -N(R 3 )-C(R 1 )(R 2 )-as L 1 When part of 3 )-on the B side, -C(R 1 )(R 2 )-In D 1 side, or can -C(R 1 )(R 2 )-on the B side, -N(R 3 )-In D 1 side.
[0606] It should be noted that "three-letter alphabets" are symbols for the following amino acids, and in particular, in this specification, they represent the divalent residues (-NH-CH(R 15 )-C(=O)-). wherein R 15 is a hydrogen atom (Gly), a methyl group (Ala), an isopropyl group (Val), an isobutyl group (Leu), a (butane-2-yl) group (Ile), a phenylmethyl group (Phe), a hydroxymethyl group (Ser), a mercaptomethyl group (Cys), a carboxyl group (Ama), a carboxylmethyl group (Asp), a 2-carboxyethyl group (Glu), a 3-aminopropyl group (Orn), a 4-aminobutyl group (Lys), a 3-(ureido)propyl group (Cit), a 3-guanidinopropyl group (Arg), or a (1H-imidazol-4-yl)methyl group (His) (the corresponding amino acids are shown in parentheses). In addition, the above formula (-NH-CH(R 15 )-C(=O)-), R 15 It is a propyl group. When the propyl group forms a 5-membered ring together with the nitrogen atom of "-NH-" in the formula, it becomes a cyclic amino acid (Pro; proline).
[0607] Gly; glycine
[0608] Ala; alanine
[0609] Val; valine
[0610] Leu; leucine
[0611] Ile; isoleucine
[0612] Phe; phenylalanine
[0613] Ser; serine
[0614] Cys; cysteine
[0615] Ama; 2-aminomalonic acid
[0616] Asp; Aspartic acid
[0617] Glu; glutamate
[0618] Orn; Ornithine
[0619] Lys; lysine
[0620] Citrulline
[0621] Arg; Arginine
[0622] His; histidine
[0623] Pro; Proline
[0624] It should be noted that when the "-LD" portion of the antibody-drug conjugate represented by the general formula (I) of the present invention contains an amino acid residue having an asymmetric center and optical isomerism may occur, both the D-type and the L-type optical isomers are included in the present invention.
[0625] Effects of the Invention
[0626] The antibody-drug conjugate represented by general formula (I) of the present invention, its pharmacologically acceptable salt, or hydrate thereof, after administration into a living body, is selectively delivered to target tumor cells, and the anti-tumor drug released within the cells exerts its function. Therefore, it is useful as a tumor therapeutic drug with excellent anti-tumor effect and safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0627] Figure 1 This is a graph showing the tumor volume inhibition rate of the compound of Example 2 (1 mg / kg) in Test Example 4.
[0628] Figure 2 This is a graph showing the tumor volume inhibition rate of the compound of Example 3 (1 mg / kg) in Test Example 4.
[0629] Figure 3 This is a graph showing the tumor volume inhibition rate of the compound of Example 15 (1 mg / kg) in Test Example 4.
[0630] Figure 4 This is a graph showing the tumor volume inhibition rate of the compound of Example 19 (1 mg / kg) in Test Example 4.
[0631] Figure 5 This is a chart showing the SEC analysis HPLC of Example 2 in Test Example 8. DETAILED DESCRIPTION
[0632] The following describes definitions of terms used in this specification, with specific examples provided for each, but the present invention is not limited thereto. Furthermore, the antibody-drug conjugates of the present invention, their pharmacologically acceptable salts, or hydrates thereof can be produced by arbitrarily selecting and combining the various antibodies, anti-tumor drug molecules, compounds, and substituents defined or exemplified below.
[0633] Unless otherwise specified, the following terms and expressions used in this specification have the meanings described below.
[0634] The term "tumor" as used herein refers to a "malignant tumor" including "cancer", "leukemia", "cancer", "sarcoma" and "brain tumor".
[0635] The "antibodies" described in this specification refer to complete monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (such as bispecific antibodies), heavy chain antibodies and antibody fragments. The above-mentioned "monoclonal antibodies" are antibodies obtained from a population of substantially uniform antibodies, and the individual antibodies contained in the population are identical except for the possibility of naturally occurring mutations that may exist very rarely. Monoclonal antibodies are highly specific and target a single antigenic site. The above-mentioned "polyclonal antibodies" refer to a heterogeneous population of antibody molecules from the serum of immunized animals. The above-mentioned "monospecific antibodies (monospecific antibody)" refer to antibodies that show binding specificity to a single antigen. The above-mentioned "multispecific antibodies (multispecific antibody)" refer to antibodies that show binding specificity to two or more different antigens (two in the case of bispecific antibodies (bispecific antibody)). Bispecific antibodies are produced by methods described in Journal of Hematology & Oncology 8, 130 (2015), Frontiers in Immunology 8, 38 (2017), BioDrugs 24 (2), 89-98 (2010), MAbs 1 (6), 539-547 (2009), Journal of Immunology 155 (1), 219-25 (1995), etc. The heavy chain antibody refers to an antibody composed of only two heavy chains without a light chain.
[0636] The "antibody fragment" includes the antigen-binding region or variable region and comprises a portion of an intact antibody. To be used in the present invention, the antibody fragment must have a functional group (e.g., a sulfhydryl group, an amino group, etc.) capable of binding to the drug moiety via a linker, or a disulfide bond capable of generating a sulfhydryl group upon reduction. The "antigen" mentioned above refers to the substance to which the antibody specifically binds.
[0637] The "antibodies" used in the present invention can be obtained by known methods, for example, by immunizing rats, mice, rabbits and other animals with various antigens, and screening and purifying the antibodies produced in vivo using various methods. Human monoclonal antibodies can be produced by known methods (e.g., Immunology Today, Vol. 4 72-79 (1983)). In the case of species other than humans, chimerization or humanization is preferably performed using known techniques.
[0638] The "antibodies" used in the present invention can be purchased as commercially available reagents, extracted from antibody pharmaceutical preparations, purified, or produced by known methods. The nucleotide sequence of the antibody required for production of the antibody can be obtained, for example, from databases such as the GenBank database or literature. Alternatively, the antibody can be obtained by cloning and sequencing using known methods.
[0639] As used in the present invention, an "antibody" is an immunoglobulin, a molecule containing an antigen-binding site that immunospecifically binds to an antigen. Such antibodies may be any of IgG, IgE, IgM, IgD, IgA, and IgY, with IgG being preferred. Furthermore, subclasses may be any of IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, with IgG1, IgG2, and IgG4 being preferred. These antibodies may be polyclonal or monoclonal, with monoclonal antibodies being preferred.
[0640] The antibodies used in the present invention can be any antibodies that can target tumor cells. In the antibody-drug conjugates of the present invention, the antibody is bound to the anti-tumor drug via a linker. Therefore, the antibody preferably has one or more of the following properties: the ability to recognize tumor cells, the ability to specifically bind to tumor cells, the ability to enter and internalize within tumor cells, and the ability to inhibit tumor cell activity. "Specific binding" means that the antibody or antibody derivative binds to the corresponding target antigen in a highly selective manner and does not bind to other antigens present in large quantities. This binding can be confirmed using flow cytometry. "Antibody internalization" refers to the binding of an antibody to an antigen on the cell membrane surface and its entry into the cell through endocytosis. This entry can be confirmed by using a secondary antibody (fluorescently labeled) that binds to the antibody and visualizing the antibody entering the cell under a fluorescence microscope (Cell Death and Differentiation 15, 751-761 (2008)), or measuring its fluorescence (Molecular Biology of the Cell 15, 5268-5282 (2004)), or using the Mab-ZAP method (BioTechniques 28, 162-165 (2000)) in which an immunotoxin that binds to the antibody is released upon entry into the cell, thereby inhibiting cell proliferation.
[0641] "Tumor cell damage" refers to cell killing by antibodies, and the cell-damaging activity thereof can be confirmed by measuring the inhibitory activity of cell proliferation in vitro.
[0642] The "antibody" recorded in this specification also includes modified forms of antibodies. Modified forms of antibodies refer to substances that have been chemically or biologically modified. Chemical modification includes chemical modification of the amino acid backbone of the antibody and chemical modification of N-bound or O-bound sugar chains. Biological modification includes post-translational modification (e.g., addition of sugar chains to oxygen atoms or N atoms, processing of the N-terminus or C-terminus, deamidation, isomerization of aspartic acid, oxidation of methionine), and addition of methionine residues to the N-terminus by expression in prokaryotic host cells.
[0643] The above-mentioned chemical or biological modifications also include substances that extend auxiliary linkers from functional groups (hydroxyl, thiol, amino, carboxyl, etc.) present in the original antibody, and add "thiol, hydroxyl, amino, maleimide (formula (ii) described later), α-halomethylcarbonyl, ethynylphosphonic acid amide ester (formula (iii) described later), carboxyl, active ester of carboxyl (for example, formula (iv) described later), azide (-N3 group), alkynyl, cycloalkynyl, azacycloalkynyl, etc." to the front end of the linker. It should be noted that in this specification, the "antibody" defined above and the "modified antibody" defined above are sometimes collectively referred to as "antibody". The above-mentioned "auxiliary linker" refers to a part of the linker "-L-" in the above-mentioned general formula (I).
[0644] The "functional groups within antibodies" as used herein refer to groups present in the "antibodies" and "modified antibodies" defined above. When producing the antibody-drug conjugates of the present invention, these functional groups react with the "reactive groups" present at the ends of the linkers to form antibody-drug conjugates. Specifically, examples of functional groups within antibodies include thiol, hydroxyl, amino, maleimide, α-halomethylcarbonyl, ethynylphosphonamide, carboxyl, active esters of carboxyl, azido (-N3), alkynyl, and cycloalkynyl groups. Furthermore, thiol, one of the functional groups within antibodies, also includes thiol groups generated by reduction of disulfide bonds (-SS-) present within the antibody.
[0645] In addition, as the "reactive group" described in this specification, specifically, for example, there can be mentioned: a maleimide group, an α-halomethylcarbonyl group or an ethynylphosphonic acid amide ester group that can react with a sulfhydryl group in an antibody; a carboxyl group or an active ester of a carboxyl group that can react with a hydroxyl group and an amino group; a sulfhydryl group that can react with a maleimide group, an α-halomethylcarbonyl group and an ethynylphosphonic acid amide ester group; an alkynyl group or a cycloalkynyl group that can react with an azide group (-N3); an azide group (-N3 group) that can react with an alkynyl group, a cycloalkynyl group and an azacycloalkynyl group, etc.
[0646] As used herein, "intracellular cleavage" refers to cleaving the covalent bond between the drug portion (D) and the linker (L) of the antibody-drug conjugate by intracellular metabolism or reaction, thereby generating a metabolic reaction product starting with the drug from the antibody-drug conjugate within the cell.
[0647] Specific examples of the antibodies used in the present invention are listed below, but the present invention is not limited to these.
[0648] A is anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-EPHA3 antibody, anti-c-KIT antibody, anti PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo antibodyH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CTLA4 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF -1R antibody, anti-KDR antibody, anti-CEACAM8 antibody, anti-IL5R antibody, anti-CD205 (Ly75) antibody, anti-MSR1 antibody, anti-KREMEN2 antibody, anti-SSEA-4 antibody, anti-CD228 antibody, anti-CD5 antibody, anti-DLL4 antibody, anti-FAP antibody, anti-Notch3 antibody, anti-AG7 antibody, anti-guanylate cyclase antibody, anti-fibronectin-4 antibody, anti-CD226 (DNAM-1) antibody, anti-FcRL5 antibody, anti-HLA-DR antibody, anti-ITGB3 antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-MICA (MHC Class I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin Antibodies to αvβ3, anti-AGS-5, anti-CA19-9, anti-PSA, anti-MAGE3, anti-transferrin receptor 1 (CD71), anti-CEACAM1, anti-SLC3A2 (CD98), anti-ACVR1, anti-AG-7, anti-AMHR2, anti-ABCB1, anti-C16orf54, anti-cathepsin D, anti-CCR7, anti-SLC44A4, anti-CD300LF, anti-DPEP3, anti-FucGM1, anti-GPR20, anti-ITGB6, anti-Lewis-A-like carbohydrate antibodies, anti-prolactin receptor antibodies, and anti-SialylTn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matrix antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, and anti-GPRC5D antibody.
[0649] The "anti-tumor drug molecule" described in this specification is not particularly limited, regardless of its mechanism of action, as long as it exhibits an anti-tumor effect and has a substituent or partial structure capable of binding to the linker (L in the above-mentioned general formula (I)). Within tumor cells, the anti-tumor drug molecule exerts its anti-tumor effect after some or all of the linkers are cleaved and released.
[0650] Examples of antitumor drug molecules include camptothecins (SN-38, irinotecan, lertotecan, DB67, BMP1350, ST1481, CKD602, topotecan, and exitecan, and derivatives thereof); auristatins (auristatin E (AE), auristatin F phenylenediamine (AFP), monomethyl auristatin E (MMAE), monomethyl auristatin F, and derivatives thereof); maytansine; PBD (pyrrolebenzodiazepine) dimer; eribulin; 5-FU; and PD-318. 088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vinca alkaloids (vincristine, vinblastine, vindesine, and vinorelbine and their derivatives); daunomycin; doxorubicin; duocarmycin; Aplysia 10; superdox; ciprofloxacin; caderfloxacin (CS-940); or analogs of these anti-tumor drugs; or the anti-tumor drug molecules or their analogs, or their derivatives, etc.
[0651] The "analogs" of the "antitumor drug molecules or their analogs, or their derivatives" mentioned in this specification refer to compounds having a chemical structure and activity similar to those of the respective antitumor drug molecules. For example, "analogs of camptothecin" refer to compounds having a chemical structure similar to that of camptothecin and having the same type I topoisomerase inhibitory effect as camptothecin.
[0652] The term "derivative" in the context of "antitumor drug molecules or their analogs, or derivatives thereof" as used herein refers to derivatives in which functional groups such as hydroxyl, thiol (-SH), amino (-NH2, -NH- (including -NH- of amide groups and -NH- within heteroaryl or heterocyclic rings)), and carboxyl groups present in the antiitumor drug molecule are protected by "protecting groups," or glycoside derivatives produced by the reaction of such functional groups with sugars. The protecting groups of these derivatives may be deprotected in vivo through various chemical, biochemical, or metabolic reactions (e.g., pH fluctuations, hydrolysis, redox reactions, etc.), resulting in conversion to the parent compound (the original antiitumor drug molecule) and exhibiting antitumor activity. However, in other cases, the derivatives may not be deprotected and exhibit antitumor activity in their original form.
[0653] The "protecting group" can be arbitrarily selected from the protecting groups described in, for example, Greene's Protective Groups in Organic Synthesis, 5th edition, written by PGM Wuts, John Wiley & Sons Inc. (2014).
[0654] Examples of the protective group for the hydroxyl group as a functional group include: alkoxyalkyl groups such as methoxymethyl, methoxyethoxymethyl, and ethoxy-2-ethyl; arylalkyloxymethyl groups such as benzyloxymethyl; aryloxymethyl groups such as phenoxymethyl; alkylthiomethyl groups such as methylthiomethyl; arylalkylthiomethyl groups such as benzylthiomethyl; arylthiomethyl groups such as phenylthiomethyl; aminomethyl groups wherein the N atom is optionally protected by an alkyl group or an "amino-protecting group" described below; arylmethyl groups such as benzyl, 4-methoxybenzyl, and triphenylmethyl; alkylcarbonyl groups such as methylcarbonyl and ethylcarbonyl; alkenylcarbonyl groups such as allylcarbonyl; alkynylcarbonyl groups such as propargylcarbonyl; arylcarbonyl groups such as phenylcarbonyl; heteroarylcarbonyl groups such as pyridin-2, 3, or 4-ylcarbonyl; heterocyclylcarbonyl groups such as tetrahydrofuran-2 or 3-ylcarbonyl and 5-oxotetrahydrofuran-2-ylcarbonyl; tert-butoxycarbonyl, methoxycarbonyl, , alkoxycarbonyl such as ethoxycarbonyl; allyloxycarbonyl; aryloxycarbonyl such as phenoxycarbonyl, 4-nitrophenoxycarbonyl, 4-methoxyphenoxycarbonyl; arylmethoxycarbonyl such as 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4(or 2)-nitrobenzyloxycarbonyl, 4(or 2)-aminobenzyloxycarbonyl or its N-alkylcarbonyl or N-arylcarbonyl, 4(or 2)-hydroxybenzyloxycarbonyl or its O-alkylcarbonyl or O-arylcarbonyl; alkylaminocarbonyl such as tert-butylaminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl; silyl such as trimethylsilyl, trimethylsilylethoxymethyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl; tetrahydropyranyl such as tetrahydropyranyl and 2(or 4)-methoxytetrahydropyranyl, etc. Alternatively, the hydroxyl group may be protected in the form of an ester with formic acid, boric acid, phosphoric acid, phosphonic acid, phosphinic acid, sulfuric acid, sulfonic acid, sulfinic acid, sulfenic acid, amino acid or peptide.
[0655] In one embodiment, the protecting group for the hydroxyl group is an alkoxyalkyl group; an arylalkoxymethyl group; an aminomethyl group whose N atom is optionally protected by an alkyl group or an "amino protecting group" described later; an alkylcarbonyl group; an alkenylcarbonyl group; an alkynylcarbonyl group: an arylcarbonyl group; an alkoxycarbonyl group; an allyloxycarbonyl group; an aryloxycarbonyl group; an arylmethoxycarbonyl group; an alkylaminocarbonyl group; a tetrahydropyranyl group; a tetrahydrofuranyl group; a silyl group, a lactone group; a lactone alkyl group; a lactone carbonyl group; a lactone alkylcarbonyl group; a phosphoryl group; a phosphorylalkyl group; a phosphorylalkylcarbonyl group; a bisphosphorylmethyl group (-C(H, OH, NH2, Cl or alkyl) (P(=O)(OH)2)2); an aminoalkylcarbonyl group; an alkylaminoalkylcarbonyl group; a dialkylaminoalkylcarbonyl group; a cyclic aminoalkylcarbonyl group in which the dialkyl groups together form a ring; or a trialkylammoniumalkylcarbonyl group.
[0656] Examples of the protective group for the mercapto group as a functional group include the protective groups described above as the protective group for the hydroxyl group. In addition, a disulfide bond (-SS-) can also serve as a protective group.
[0657] Examples of the protective group for the carboxyl group as a functional group include alkyl groups such as methyl, ethyl, and tert-butyl; allyl; arylmethyl groups such as benzyl; lactone group; silyl groups such as trimethylsilyl, trimethylsilylethoxymethyl, tert-butyldimethylsilyl, and tert-butyldiphenylsilyl. In addition, the carboxyl group is sometimes protected in the form of an amide body (for example, an amide body with ammonia, an alkylamine, a dialkylamine, a lactone amine, an amino acid ester, an amino acid amide, etc.), and the N atom of the amide part may also have a lactone group; a lactone alkyl group; a lactone carbonyl group; a lactone alkylcarbonyl group; a phosphorylalkyl group; a phosphorylalkylcarbonyl group; a bisphosphorylmethyl group (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); an aminoalkyl group; an aminoalkylcarbonyl group, an alkylaminoalkyl group; an alkylaminoalkylcarbonyl group; a dialkylaminoalkyl group; a dialkylaminoalkylcarbonyl group; a cyclic aminoalkyl group in which the two alkyl groups together form a ring; a cyclic aminoalkylcarbonyl group in which the two alkyl groups together form a ring; a trialkylammoniumalkyl group, or a trialkylammoniumalkylcarbonyl group as a substituent.
[0658] In one embodiment, the protecting group of the carboxyl group is an alkyl group; an allyl group; an arylmethyl group; a lactone group; a lactone alkyl group; a phosphoalkyl group; a bisphosphomethyl group (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); an aminoalkyl group; an alkylaminoalkyl group; a dialkylaminoalkyl group; a cyclic aminoalkyl group in which the dialkyl groups together form a ring, or a trialkylammoniumalkyl group.
[0659] For the functional groups such as sulfenic acid group, sulfinic acid group, sulfonic acid group, phosphinic acid group, phosphonic acid group and boronic acid group, the same protective groups as those for the carboxyl group can be used.
[0660] Examples of the protecting group for the amino group as a functional group include alkoxycarbonyl groups such as tert-butoxycarbonyl, methoxycarbonyl, and ethoxycarbonyl; allyloxycarbonyl; aryloxycarbonyl groups such as phenoxycarbonyl, 4-nitrophenoxycarbonyl, and 4-methoxyphenoxycarbonyl; 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4(or 2)-nitrobenzyloxycarbonyl, 4(or 2)-aminobenzyloxycarbonyl or its N-alkylcarbonyl or N-arylcarbonyl form, 4(or 2)-hydroxybenzyloxycarbonyl or its O-alkylcarbonyl or O-arylcarbonyl form; arylmethyl groups such as benzyl and triphenylmethyl; alkoxyalkyl groups such as methoxymethyl, methoxyethoxymethyl, and ethoxy-2-ethyl; arylalkoxymethyl groups such as benzyloxymethyl; and aryloxy groups such as phenoxymethyl. Methyl; alkylthiomethyl such as methylthiomethyl; arylalkylthiomethyl such as benzylthiomethyl; arylthiomethyl such as phenoxymethyl; aminomethyl wherein the N atom is optionally protected by an alkyl or amino protecting group; alkylcarbonyl such as methylcarbonyl and ethylcarbonyl; alkenylcarbonyl such as allylcarbonyl; alkynylcarbonyl such as propargylcarbonyl; arylcarbonyl such as phenylcarbonyl; heteroarylcarbonyl such as pyridin-2,3 or 4-ylcarbonyl; heterocyclylcarbonyl such as tetrahydrofuran-2 or 3-ylcarbonyl and 5-oxotetrahydrofuran-2-ylcarbonyl; silyl such as trimethylsilyl, trimethylsilylethoxymethyl, triisopropylsilyl, tert-butyldimethylsilyl and tert-butyldiphenylsilyl; or amino protecting groups commonly used in peptide synthesis such as arylsulfonyl such as 2,4-dinitrobenzenesulfonyl and 4-nitrobenzenesulfonyl. Alternatively, the amino group may be protected in the form of an amide body of formic acid, phosphoric acid, phosphonic acid, phosphinic acid, sulfuric acid, sulfonic acid, sulfinic acid, sulfenic acid, amino acid or peptide.
[0661] In one embodiment, the protecting group of the amino group is an alkoxycarbonyl group; an allyloxycarbonyl group; an arylmethoxycarbonyl group; an alkylcarbonyl group; an alkenylcarbonyl group; an arylcarbonyl group; a silyl group, a lactone group; a lactone alkyl group; a lactone carbonyl group; a lactone alkylcarbonyl group; a phospho group; a phosphoalkyl group; a phosphoalkylcarbonyl group; a bisphosphomethyl group (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); an aminoalkylcarbonyl group; an alkylaminoalkylcarbonyl group; a dialkylaminoalkylcarbonyl group; a cyclic aminoalkylcarbonyl group in which the dialkyl groups together form a ring; or a trialkylammoniumalkylcarbonyl group.
[0662] The attachment and detachment of these protecting groups are performed according to commonly practiced methods (for example, refer to Greene's Protective Groups in Organic Synthesis, 5th edition, written by PGM Wuts, John Wiley & Sons Inc. (2014)).
[0663] The hydroxyl group, thiol group (-SH), amino group (-NH2, -NH- (including -NH- of amide group and -NH- in the ring of heteroaryl or heterocyclic group)) in the above functional groups can be protected in the form of ester, thioester, amide or imide with various sugar acids (gluconic acid, glucuronic acid, galacturonic acid, etc.).
[0664] The above describes the "protecting groups" of various functional groups in the "derivatives" of the "antitumor drug molecules or their analogs, or their derivatives" described in this specification. However, this can also be applied to the functional groups in the "antitumor drug molecules or their analogs", linkers, protecting groups, or substituents described in this specification.
[0665] In the "protecting group" of the present invention, in one embodiment, the protecting group is a polyetheralkylaminocarbonyl, a lactone group; a lactone alkyl group; a lactone carbonyl; a lactone alkylcarbonyl; a phospho group; a phosphoalkyl group; a phosphoalkylcarbonyl; a bisphosphomethyl group (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); an aminoalkyl group; an aminoalkylcarbonyl, an alkylaminoalkyl group; an alkylaminoalkylcarbonyl; a dialkylaminoalkyl group; a dialkylaminoalkylcarbonyl; a cyclic aminoalkyl group in which the dialkyl groups together form a ring; a cyclic aminoalkylcarbonyl group in which the dialkyl groups together form a ring; a trialkylammoniumalkyl group; or a trialkylammoniumalkylcarbonyl group.
[0666] It should be noted that the selection of the protecting group and the methods of attachment and detachment described above are also applicable to the preparation of the compound of the general formula (II) (conjugate precursor) described later.
[0667] Specific examples of the "anti-tumor drug molecules or analogs thereof, or derivatives thereof" described in this specification are shown in Example 1 below, specific examples of the structure of the general formula (II): linker-drug unit (LDU) are shown in Example 2 below, and specific examples of the precursor of the general formula (III): antibody-drug complex are shown in Example 3 below, but the present invention is not limited thereto.
[0668] Example 1. Examples of “anti-tumor drug molecules or analogs thereof, or derivatives thereof”
[0669]
[0670]
[0671]
[0672]
[0673]
[0674]
[0675]
[0676]
[0677]
[0678]
[0679]
[0680]
[0681]
[0682]
[0683]
[0684]
[0685]
[0686]
[0687]
[0688]
[0689]
[0690]
[0691]
[0692]
[0693]
[0694]
[0695]
[0696]
[0697]
[0698]
[0699]
[0700]
[0701]
[0702]
[0703]
[0704]
[0705]
[0706]
[0707]
[0708]
[0709] The "residue of an antitumor drug molecule" described in this specification refers to a residue formed by removing one hydrogen atom or one hydroxyl group from any position of the above-mentioned "antitumor drug molecule, its analogue, or its derivative".
[0710] The term "alkyl" as used herein refers to a group obtained by removing one hydrogen atom from a linear or branched saturated hydrocarbon (i.e., alkane) having 1 to 10 carbon atoms. Unless otherwise specified, the term "alkyl" includes "optionally substituted alkyl."
[0711] Examples of the substituent of the optionally substituted alkyl group include one or more substituents independently selected from the following Group A.
[0712] Group A:
[0713] a halogen atom (a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom);
[0714] alkoxy;
[0715] hydroxyl group;
[0716] thiol;
[0717] amino;
[0718] Alkylamino;
[0719] Dialkylamino (two alkyl groups may also form a heterocyclic group containing a nitrogen atom);
[0720] trialkylammonium groups;
[0721] carboxyl;
[0722] cyano group;
[0723] Nitro;
[0724] alkylcarbonyl;
[0725] alkenylcarbonyl;
[0726] Alkynylcarbonyl;
[0727] arylcarbonyl;
[0728] heteroarylcarbonyl;
[0729] heterocyclylcarbonyl;
[0730] lactone carbonyl;
[0731] Phosphorylalkylcarbonyl;
[0732] Alkoxycarbonyl;
[0733] Aryloxycarbonyl;
[0734] heteroaryloxycarbonyl;
[0735] aminocarbonyl;
[0736] The amino moiety is an aminocarbonyl group of any amino acid or peptide amino group;
[0737] N-alkylaminocarbonyl;
[0738] N,N-dialkylaminocarbonyl (two alkyl groups may also form a heterocyclic group containing a nitrogen atom);
[0739] aminocarbonyloxy;
[0740] N-alkylaminocarbonyloxy;
[0741] N,N-dialkylaminocarbonyloxy (two alkyl groups may form a heterocyclic group containing a nitrogen atom);
[0742] alkoxycarbonyloxy;
[0743] aryloxycarbonyloxy;
[0744] heteroaryloxycarbonyloxy;
[0745] urea group;
[0746] N-alkylurea group;
[0747] N,N-dialkylurea group (two alkyl groups may also form a heterocyclic group containing a nitrogen atom);
[0748] N,N,N'-trialkylurea group (two alkyl groups on the same N atom may together form a heterocyclic group containing the N atom);
[0749] Guanidine;
[0750] amidino group;
[0751] hydrazino;
[0752] Alkylhydrazine group;
[0753] N,N-dialkylhydrazine;
[0754] N,N'-dialkylhydrazine;
[0755] alkylthio;
[0756] alkylsulfinyl;
[0757] alkylsulfonyl;
[0758] arylthio;
[0759] arylsulfinyl;
[0760] arylsulfonyl;
[0761] heteroarylthio;
[0762] heteroarylsulfinyl;
[0763] heteroarylsulfonyl;
[0764] sulfenic acid group;
[0765] sulfinic acid group;
[0766] sulfonic acid group;
[0767] sulfate group;
[0768] sulfenamide group;
[0769] Sulfonamide group;
[0770] phosphine oxide group;
[0771] phosphinate group;
[0772] Phosphoryl (phosphonic acid -P(=O)(OH)2);
[0773] Bisphosphorylmethyl (-C(H, OH, NH2, Cl, or optionally substituted alkyl)(P(=O)(OH)2)2);
[0774] Phosphate group (phosphate ester -OP(=O)(OH)2);
[0775] Boronic acid group;
[0776] alkenyl;
[0777] Alkynyl;
[0778] Cycloalkyl;
[0779] cycloalkenyl;
[0780] aryl;
[0781] heteroaryl;
[0782] heterocyclic group;
[0783] lactone group;
[0784] and
[0785] -(OCH2CH2) x -Y group (x is an integer from 1 to 30,
[0786] Y is the reason
[0787] hydrogen atoms;
[0788] alkyl;
[0789] a halogen atom (a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom);
[0790] alkoxy;
[0791] alkylthio;
[0792] hydroxyl group;
[0793] thiol;
[0794] amino;
[0795] Alkylamino;
[0796] Dialkylamino (two alkyl groups may also form a heterocyclic group containing a nitrogen atom); trialkylammonium group;
[0797] carboxyl;
[0798] cyano group;
[0799] Nitro;
[0800] alkylcarbonyl;
[0801] alkenylcarbonyl;
[0802] Alkynylcarbonyl;
[0803] arylcarbonyl;
[0804] heteroarylcarbonyl;
[0805] heterocyclylcarbonyl;
[0806] lactone carbonyl;
[0807] Phosphorylalkylcarbonyl;
[0808] Alkoxycarbonyl;
[0809] Aryloxycarbonyl;
[0810] heteroaryloxycarbonyl;
[0811] aminocarbonyl;
[0812] The amino moiety is an aminocarbonyl group of any amino acid or peptide amino group;
[0813] N-alkylaminocarbonyl;
[0814] N,N-dialkylaminocarbonyl (two alkyl groups may also form a heterocyclic group containing a nitrogen atom);
[0815] aminocarbonyloxy;
[0816] N-alkylaminocarbonyloxy;
[0817] N,N-dialkylaminocarbonyloxy (two alkyl groups may form a heterocyclic group containing a nitrogen atom);
[0818] alkoxycarbonyloxy;
[0819] aryloxycarbonyloxy;
[0820] heteroaryloxycarbonyloxy;
[0821] urea group;
[0822] N-alkylurea group;
[0823] N,N-dialkylurea group (two alkyl groups may also form a heterocyclic group containing a nitrogen atom);
[0824] N,N,N'-trialkylurea group (two alkyl groups on the same N atom may together form a heterocyclic group containing the N atom);
[0825] Guanidine;
[0826] amidino group;
[0827] hydrazino;
[0828] Alkylhydrazine group;
[0829] N,N-dialkylhydrazine;
[0830] N,N'-dialkylhydrazine;
[0831] alkylthio;
[0832] alkylsulfinyl;
[0833] alkylsulfonyl;
[0834] arylthio;
[0835] arylsulfinyl;
[0836] arylsulfonyl;
[0837] heteroarylthio;
[0838] heteroarylsulfinyl;
[0839] heteroarylsulfonyl;
[0840] sulfenic acid group;
[0841] sulfinic acid group;
[0842] sulfonic acid group;
[0843] sulfate group;
[0844] sulfenamide group;
[0845] Sulfonamide group;
[0846] phosphine oxide group;
[0847] phosphinate group;
[0848] Phosphoryl (phosphonic acid -P(=O)(OH)2);
[0849] Bisphosphorylmethyl (-C(H, OH, NH2, Cl, or optionally substituted alkyl)(P(=O)(OH)2)2);
[0850] Phosphate group (phosphate ester -OP(=O)(OH)2);
[0851] Boronic acid group;
[0852] alkyl;
[0853] alkenyl;
[0854] Alkynyl;
[0855] Cycloalkyl;
[0856] cycloalkenyl;
[0857] aryl;
[0858] heteroaryl;
[0859] heterocyclic group;
[0860] lactone group); a group consisting of.
[0861] Specific examples of the alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
[0862] In addition, when the term "alkane" is used in this specification, the alkane refers to a "linear or branched saturated hydrocarbon having 1 to 10 carbon atoms" in which one hydrogen atom is added to the "alkyl group" defined above.
[0863] The "alkenyl group" described in this specification refers to a linear or branched unsaturated hydrocarbon group containing one or more double bonds (-C=C-) in the chain of the alkyl group defined above.
[0864] As the substituent of the optionally substituted alkenyl group, one or more substituents independently selected from Group A can be mentioned.
[0865] Specific examples of the alkenyl group include a methylene group (=CH2 group), a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1,3-butadienyl group, a 1-methyl-2-propenyl group, a 1,1-dimethyl-2-propenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, a 1-methyl-2-butenyl group, a 3-methyl-1-butenyl group, a 1-hexenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 1-methyl-2-pentenyl group, a 3-methyl-1-pentenyl group, a 2-heptenyl group, a 4-octenyl group, a 1-nonenyl group, and a 2-decenyl group.
[0866] The "alkynyl group" described in this specification refers to a linear or branched unsaturated hydrocarbon group containing one or more triple bonds (-C≡C-) in the chain of the above-defined alkyl group (wherein the number of carbon atoms is 2 to 10).
[0867] As the substituent of the optionally substituted alkynyl group, one or more substituents independently selected from Group A can be mentioned.
[0868] Specific examples of the alkynyl group include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1,1-dimethyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 3-methyl-1-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 3-methyl-1-pentynyl, 2-heptynyl, 4-octynyl, 1-nonynyl, and 2-decynyl.
[0869] The term "alkoxy" as used herein refers to a monovalent group (alkyl-O-group) formed by bonding an alkyl group having 1 to 10 carbon atoms as defined above to an oxy group. Specific examples of the alkoxy group include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexyloxy, n-heptyloxy, n-octyloxy, n-nonyloxy, and n-decyloxy.
[0870] The term "alkylthio" as used herein refers to a monovalent group (alkyl-S-group) formed by bonding an alkyl group having 1 to 10 carbon atoms as defined above to a thio group. Specific examples of the alkylthio group include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-pentylthio, n-hexylthio, n-heptylthio, n-octylthio, n-nonylthio, and n-decylthio.
[0871] As the substituent of the optionally substituted alkoxy group and the alkylthio group, one or more substituents independently selected from Group A can be mentioned.
[0872] The "cycloalkyl group" described in this specification refers to a group obtained by removing one hydrogen atom from a monocyclic cyclic hydrocarbon having 3 to 10 carbon atoms (i.e., cycloalkane), and a group obtained by removing one hydrogen atom from a bicyclic cyclic hydrocarbon having 4 to 10 carbon atoms (i.e., bicyclic cycloalkane).
[0873] As the substituent of the optionally substituted cycloalkyl group, there can be mentioned an oxo group (=O); a thioxo group (=S); an imino group (=N(R 8 )); Oximo group (=N-OR 9 ); hydrazine (=NN (R 10 )(R 11 )); alkyl; and one or more substituents independently selected from group A (hereinafter, oxo; thio; imino; oxime; hydrazine; alkyl; and group A consisting of group B) (in the above, R 8 、R 9 、R 10 and R 11 are each independently a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group or a heterocyclic group).
[0874] Specific examples of the cycloalkyl group include monocyclic cycloalkyl groups having 3 to 10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl; and bicyclic cycloalkyl groups having 4 to 10 carbon atoms, such as bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.3.0]octyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[6.1.0]nonyl, and bicyclo[4.4.0]decyl.
[0875] It should be noted that when the term "cycloalkane" is used in this specification, the cycloalkane refers to "monocyclic cyclic hydrocarbons having 3 to 10 carbon atoms and bicyclic cyclic hydrocarbons having 4 to 10 carbon atoms" in which one hydrogen atom is added to the "cycloalkyl group" defined above.
[0876] The "cycloalkenyl group" described in the present specification refers to a monocyclic or bicyclic cyclic unsaturated hydrocarbon group containing one or more double bonds (-C=C-) in the ring of the cycloalkyl group defined above.
[0877] As the substituent of the optionally substituted cycloalkenyl group, one or more substituents independently selected from Group B can be mentioned.
[0878] Specific examples of the cycloalkenyl group include monocyclic cycloalkenyl groups having 3 to 10 carbon atoms, such as 1-cyclopropenyl, 1-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1-cycloheptenyl, 2-cyclooctenyl, 3-cyclooctenyl, 4-cyclooctenyl, 1-cyclononenyl, and 1-cyclodecenyl; bicyclo[1.1.0]but-1-enyl, bicyclo[1.1.0]but-2-enyl, bicyclo[1.1.0]but-3-enyl, bicyclo[1.1.0]but-4-enyl, bicyclo[1.1.0]but-5-enyl, bicyclo[1.1.0]but-6-enyl, bicyclo[1.1.0]but-7-enyl, bicyclo[1.1.0]but-8-enyl, bicyclo[1.1.0]but-9-enyl, bicyclo[1.1.0]but-1 ... Bicyclic cycloalkenyl groups having 4 to 10 carbon atoms, such as cyclo[2.1.0]pent-2-enyl, bicyclo[3.1.0]hex-2-di-enyl, bicyclo[3.2.0]hept-3-enyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[3.3.0]oct-2-enyl, bicyclo[3.2.1]oct-2-enyl, bicyclo[2.2.2]oct-2-enyl, bicyclo[6.1.0]non-4-enyl and bicyclo[4.4.0]dec-3-enyl, etc.
[0879] The "cycloalkynyl group" described herein refers to a monocyclic, bicyclic, or tricyclic cyclic unsaturated hydrocarbon group containing one or more triple bonds (-C≡C-) in the ring of the above-defined cycloalkyl group (wherein the number of carbon atoms is 6 to 15).
[0880] As the substituent of the optionally substituted cycloalkynyl group, one or more substituents independently selected from Group B can be mentioned.
[0881] Specific examples of the cycloalkynyl group include cyclohexyn-(3 or 4)-yl, cycloheptyn-(3, 4 or 5)-yl, cyclooctyn-(3, 4, 5 or 6)-yl, cyclodecyn-(3, 4, 5 or 6)-yl, bicyclo[6.1.0]non-4-yn-9-yl, and dibenzocyclooctyn-(3, 4 or 5)-yl.
[0882] The "aryl group" described in this specification refers to a group obtained by removing one hydrogen atom from a monocyclic or bicyclic aromatic hydrocarbon (ie, arene) having 6 to 11 ring carbon atoms.
[0883] Examples of the substituent of the optionally substituted aryl group include one or more substituents independently selected from the alkyl group and group A (hereinafter, the group consisting of the alkyl group and group A is referred to as group C).
[0884] Specific examples of the aryl group include monocyclic aryl groups such as phenyl; optionally partially saturated aryl groups having 9 to 11 ring carbon atoms (C9 to C10); and aryl groups such as naphthyl, tetrahydronaphthyl, indenyl, and indanyl. 11 ) bicyclic aromatic group, etc.
[0885] It should be noted that when the term "aromatic hydrocarbon" is used in this specification, the aromatic hydrocarbon refers to a "monocyclic aromatic hydrocarbon having 6 to 11 ring carbon atoms or a bicyclic aromatic hydrocarbon having 9 to 11 ring carbon atoms" in which one hydrogen atom is added to the "aryl group" defined above.
[0886] The "heteroaryl group" described in this specification refers to a group obtained by removing one hydrogen atom from a 5- to 14-membered monocyclic, bicyclic, or tricyclic aromatic heterocycle (i.e., heteroarene) containing, in addition to carbon atoms, one to four heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms.
[0887] As the substituent of the optionally substituted heteroaryl group, one or more substituents independently selected from Group C can be mentioned.
[0888] Specific examples of the heteroaryl group include 5- to 6-membered monocyclic heteroaryl groups containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms, such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl; indolyl, isoindolyl, indazolyl, tetrahydroindazolyl, benzofuranyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzothienyl, dihydrobenzothienyl, dihydroisobenzothienyl, 8-11-membered bicyclic heteroaryl groups containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen atoms in addition to carbon atoms, such as benzoxazolyl, dihydrobenzoxazolyl, benzothiazolyl, dihydrobenzothiazolyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, naphthyridinyl, tetrahydronaphthyridinyl, quinoxalinyl, tetrahydroquinoxalinyl and quinazolinyl; 11-14-membered tricyclic heteroaryl groups containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen atoms in addition to carbon atoms, such as dibenzofuran, dibenzopyrrole, dibenzothiophene and dibenzopyridine.
[0889] It should be noted that when the term "heteroarene" is used in this specification, the heteroarene refers to a "5- to 14-membered monocyclic, bicyclic, or tricyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms" with one hydrogen atom added to the "heteroaryl" defined above.
[0890] The "heterocyclic group" described in this specification refers to a monovalent group obtained by removing one hydrogen atom from a 3- to 12-membered monocyclic non-aromatic heterocycle (i.e., a heterocyclic hydrocarbon) containing, in addition to carbon atoms, one to four heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms, and may contain a double bond or a triple bond in the ring.
[0891] Examples of the substituent of the optionally substituted heterocyclic group include oxo (=O); thio (=S); imino (=NR 9 ; R 9 Same as above); hydrazine (=NN(R 10 )(R 11 );R 10 and R 11 and one or more substituents independently selected from Group A (hereinafter, the group consisting of an oxo group; a thioxo group; an imino group; a hydrazono group; an alkyl group; and Group A is referred to as Group D).
[0892] Specific examples of the heterocyclic group include azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, piperidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, piperazinyl, morpholinyl, perhydroazepinyl, azocinyl, azocin-3-enyl, azocin-4-enyl, azononyl, azodecyl, 6- to 12-membered azabicycloalkyl groups (e.g., azabicyclohexyl, azabicycloheptyl, azabicyclooctyl, azabicyclo 1-aryl, azabicyclohexenyl, azabicycloheptenyl, azabicyclooctenyl, azabicyclononenyl, azabicyclodecenyl, azabicycloundecenyl or azabicyclododecyl), a 6-membered to 12-membered azabicycloalkyl group (e.g., azabicyclohexenyl, azabicycloheptenyl, azabicyclooctenyl, azabicyclononenyl, azabicyclodecenyl, azabicycloundecenyl or azabicyclododecenyl), a 6-membered to 12-membered azaspiroalkyl group (e.g., azaspirohexyl, azaspiroheptyl, azaspirooctyl, azaspirononyl, azaspirodecanyl, azaspiroundecyl, or azaspirododecyl), or a 5-azacyclooctyn-5-yl group.
[0893] It should be noted that when the term "heterocycle" is used in this specification, the heterocycle refers to a "4- to 12-membered monocyclic non-aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms" obtained by adding one hydrogen atom to the "heterocyclic group" defined above.
[0894] The cyclic compounds cycloalkanes, aromatic hydrocarbons, heteroaromatic hydrocarbons and heterocycles mentioned above can be condensed with any other cyclic compounds to form 2-4 ring cyclic compounds, and monovalent or divalent groups can be generated by removing one or two hydrogen atoms from these 2-4 ring compounds.
[0895] The "lactone group" described in this specification refers to one of the above-mentioned heterocyclic groups, and is a group in which the heterocyclic group has an oxygen atom as a heteroatom in the ring, and the carbon atom adjacent to the oxygen atom is substituted with an oxo group. Examples of the lactone group include α-acetone lactone, β-propiolactone, γ-butyrolactone, δ-valerolactone, ε-caprolactone, γ-nonalactone, γ-decalactone, γ-undecalactone, glucono-δ-lactone, and pantolactone (a monovalent residue of pantolactone). These lactone groups may be substituted in the same manner as the above-mentioned heterocyclic groups, and may also be condensed with any other cyclic compound to form a cyclic compound having two to four rings.
[0896] It should be noted that the lactone group in the antibody-drug conjugate of the present invention represented by general formula (I) can be a substituent bonded to a carbon atom or heteroatom (N, O, S, Ser, P, etc.) present in L or D.
[0897] Examples of lactone groups that substitute on heteroatoms present in L or D include, but are not limited to, α-acetone-3-yl, β-propiolactone-3-yl, β-propiolactone-4-yl, γ-butyrolactone-3-yl, γ-butyrolactone-4-yl, γ-butyrolactone-5-yl, δ-valerolactone-3-yl, δ-valerolactone-4-yl, δ-valerolactone-5-yl, δ-valerolactone-6-yl, ε-caprolactone-3-yl, ε-caprolactone-4-yl, ε-caprolactone-5-yl, ε-caprolactone-6-yl, ε-caprolactone-7-yl, ε-caprolactone-8-yl, ε-caprolactone-9-yl, ε-caprolactone-10-yl, ε-caprolactone-11-yl, ε-caprolactone-12-yl, ε-caprolactone-13-yl, ε-caprolactone-14-yl, ε-caprolactone-15-yl, ε-caprolactone-16-yl, ε-caprolactone-17-yl, ε-caprolactone-18-yl, ε-caprolactone-19-yl, ε-caprolactone-20-yl, ε-caprolactone-21-yl, ε-caprolactone-22-yl, ε-caprolactone-23-yl, ε-caprolactone-24-yl, ε-caprolactone-25-yl, ε-caprolactone-26-yl, ε-caprolactone-27-yl, ε-caprolactone-28-yl, ε-caprolactone-29-yl, ε-caprolactone-30-yl, ε-caprolactone-3 yl, (3-hydroxy-γ-butyrolactone-5-yl)methyl, 4-hydroxy-γ-butyrolactone-5-yl)methyl, gluconoyl-γ-lacton-3-yl, 2-(3,4-dihydroxy-γ-butyrolactone-5-yl)-1-hydroxyethyl, 4,4-dimethyl-β-propiolacton-3-yl, 4,5-dihydroxy-6-hydroxymethyl-δ-valerolacton-3-yl, 4,5-dihydroxy-δ-valerolacton-3-yl, and (3,4,5-trihydroxy-δ-valerolacton-3-yl)methyl.
[0898] As the lactone group, both (S) configuration and (R) configuration are encompassed by the present invention.
[0899] As used herein, "alkylene" refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "alkyl" group defined above. Furthermore, when the alkyl group has a substituent, the term "alkylene" refers to a divalent group obtained by removing another arbitrary hydrogen atom from a carbon atom constituting the alkyl chain that is not a substituent.
[0900] It should be noted that, in the general formula (I) of the present invention, L is an optionally substituted alkylene group, and one or more methylene groups in the chain of the alkylene group are optionally replaced with one or more divalent groups independently selected from the group consisting of the following groups:
[0901] -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-OP(=S)(OR 13 )-O-;-OP(=O)(OR 13 )-S-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -; optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted cycloalkylene; optionally substituted cycloalkenylene; optionally substituted cycloalkynylene; optionally substituted azaheterocycloalkynyl; optionally substituted arylene; optionally substituted heteroarylene; and optionally substituted heterocyclylene, the above R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、R 9 、R 10 、R 11 、R 12 、R 13 , and R 14 are each independently a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted cycloalkynyl group, an optionally substituted azacycloalkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclic group, and R 3 When it is an alkyl group, the alkyl group may form a cyclic structure together with the alkyl group in the adjacent methylene group, and m and n are each independently an integer of 0 to 2.
[0902] As the substituent of the optionally substituted alkylene group, one or more substituents independently selected from Group A can be mentioned.
[0903] Specific examples of the alkylene group include a methylene group, an ethylene group, a methylmethylene group, a trimethylene group, an ethylmethylene group, a dimethylmethylene group, an n-propylene group, an n-butylene group, an n-pentylene group, an n-hexylene group, an n-heptylene group, an n-octylene group, an n-nonylene group, an n-decylene group, an n-undecylene group, an n-dodecylene group, an n-tridecylene group, an n-tetradecylene group, an n-pentadecylene group, an n-hexadecylene group, an n-heptadecylene group, an n-octadecylene group, an n-nonadecylene group, an n-eicosylene group, an n-triacontylene group, an n-tetracontylene group, and an n-pentacontylene group.
[0904] The term "alkenylene" as used herein refers to a group constituting the linker chain represented by L in the general formula (I) above, and is a divalent group obtained by removing one arbitrary hydrogen atom from the "alkenyl" group defined above. Furthermore, when the alkenyl group has a substituent, the term refers to a divalent group obtained by removing another arbitrary hydrogen atom from a carbon atom constituting the alkenyl chain that is not a substituent.
[0905] As the substituent of the optionally substituted alkenylene group, one or more substituents independently selected from Group A can be mentioned.
[0906] Specific examples of the alkenylene group include vinylene, 1-propenylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene, 1,3-butadienylene, 1-methyl-2-propenylene, 1,1-dimethyl-2-propenylene, 1-pentenylene, 2-pentenylene, 3-pentenylene, 4-pentenylene, 1-methyl-2-butenylene, 3-methyl-1-butenylene, 1-hexenylene, 2-hexenylene, alkylene, 3-hexenylene, 4-hexenylene, 5-hexenylene, 1-methyl-2-pentenylene, 3-methyl-1-pentenylene, 2-heptenylene, 4-octenylene, 1-nonenylene, 2-decenylene, 1-undecenylene, 3-dodecenylene, 2-tridecenylene, 4-tetradecenylene, 1-pentadecenylene, 2-hexadecenylene, 3-heptadecenylene, 2-octadecenylene, 1-nonadecenylene, 1-eicosenylene and the like.
[0907] The "alkynylene group" described in this specification refers to a group constituting the linker chain represented by L in the general formula (I) above, and refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "alkynyl group" defined above. In addition, when the alkynyl group has a substituent, it refers to a divalent group obtained by further removing one arbitrary hydrogen atom from a carbon atom constituting the alkynyl chain that is not a substituent.
[0908] As the substituent of the optionally substituted alkynylene group, one or more substituents independently selected from Group A can be mentioned.
[0909] Specific examples of the alkynylene group include ethynylene, 1-propynylene, 2-propynylene, 1-butynylene, 2-butynylene, 3-butynylene, 1-methyl-2-propynylene, 1,1-dimethyl-2-propynylene, 1-pentynylene, 2-pentynylene, 3-pentynylene, 4-pentynylene, 1-methyl-2-butynylene, 3-methyl-1-butynylene, 1-hexynylene, 2-hexynylene, 3- hexynylene, 4-hexynylene, 5-hexynylene, 1-methyl-2-pentynylene, 3-methyl-1-pentynylene, 2-heptynylene, 4-octynylene, 1-nonynylene, 2-decynylene, 1-undecynylene, 3-dodecynylene, 2-tridecynylene, 4-tetradecynylene, 1-pentadeynylene, 2-hexadecynylene, 3-heptadecinylene, 2-octadecynylene, 1-nonadecinylene, 1-eicosynylene and the like.
[0910] The term "cycloalkylene" as used herein refers to a group constituting the linker chain represented by L in the general formula (I) above, and is a divalent group obtained by removing one arbitrary hydrogen atom from the "cycloalkyl" group defined above. Furthermore, when the cycloalkyl group has a substituent, the term refers to a divalent group obtained by removing another arbitrary hydrogen atom from a non-substituent ring-constituting carbon atom of the cycloalkyl group.
[0911] As the substituent of the optionally substituted cycloalkylene group, one or more substituents independently selected from Group B can be mentioned.
[0912] Specific examples of the cycloalkylene group include monocyclic cycloalkylene groups having 3 to 10 carbon atoms, such as cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, cyclooctylene, cyclononylene, and cyclodecylene; and bicyclic cycloalkylene groups having 4 to 10 carbon atoms, such as bicyclo[1.1.0]butylene, bicyclo[2.1.0]pentylene, bicyclo[3.1.0]hexylene, bicyclo[3.2.0]heptylene, bicyclo[2.2.1]heptylene, bicyclo[3.3.0]octylene, bicyclo[3.2.1]octylene, bicyclo[2.2.2]octylene, bicyclo[6.1.0]nonylene, and bicyclo[4.4.0]decylene.
[0913] The "cycloalkenylene group" described in this specification refers to a group constituting the linker chain represented by L in the general formula (I) above, and refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "cycloalkenyl group" defined above. Furthermore, when the cycloalkenyl group has a substituent, the group refers to a divalent group obtained by removing another arbitrary hydrogen atom from a non-substituent ring-constituting carbon atom of the cycloalkenyl group.
[0914] As the substituent of the optionally substituted cycloalkenylene group, one or more substituents independently selected from Group B can be mentioned.
[0915] Specific examples of the cycloalkenylene group include monocyclic cycloalkenylene groups having 3 to 10 carbon atoms, such as 1-cyclopropenylene, 1-cyclobutenylene, 1-cyclopentenylene, 2-cyclopentenylene, 1-cyclohexenylene, 2-cyclohexenylene, 3-cyclohexenylene, 1,3-cyclohexadienylene, 1,4-cyclohexadienylene, 1-cycloheptenylene, 2-cyclooctenylene, 3-cyclooctenylene, 4-cyclooctenylene, 1-cyclononenylene, and 1-cyclodecenylene; and bicyclo[1.1.0 ]but-1-enyl, bicyclo[2.1.0]pent-2-enyl, bicyclo[3.1.0]hex-2-enyl, bicyclo[3.2.0]hept-3-enyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[3.3.0]oct-2-enyl, bicyclo[3.2.1]oct-2-enyl, bicyclo[2.2.2]oct-2-enyl, bicyclo[6.1.0]non-4-enyl, bicyclo[4.4.0]dec-3-enyl, and the like.
[0916] The "cycloalkynylene group" described in this specification refers to a group constituting the linker chain represented by L in the general formula (I) above, and refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "cycloalkynyl group" defined above. In addition, when the cycloalkynyl group has a substituent, it refers to a divalent group obtained by removing another arbitrary hydrogen atom from a ring-constituting carbon atom of the cycloalkynyl group that is not a substituent.
[0917] As the substituent of the optionally substituted cycloalkynylene group, one or more substituents independently selected from Group B can be mentioned.
[0918] Specific examples of the cycloalkynylene group include cyclohexyne-(3,4)-diylide, cycloheptyne-(4,5)-diylide, cyclooctyne-(3,4)-diylide, cyclooctyne-(3,5)-diylide, cyclooctyne-(5,6)-diylide, and cyclooctyne-(3,8)-diylide.
[0919] The "arylene group" described herein refers to a group constituting the linker chain represented by L in the general formula (I) above, and refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "aryl group" defined above. Furthermore, when the aryl group has a substituent, the "arylene group" refers to a divalent group obtained by removing another arbitrary hydrogen atom from a non-substituent ring-forming carbon atom of the aryl group.
[0920] As the substituent of the optionally substituted arylene group, one or more substituents independently selected from Group C can be mentioned.
[0921] Specific examples of the arylene group include monocyclic arylene groups having 6 to 11 ring carbon atoms, such as phenylene; and optionally partially saturated bicyclic arylene groups having 9 to 11 ring carbon atoms, such as naphthylene, tetrahydronaphthylene, indenylene, and indanylene.
[0922] The "heteroarylene group" described herein refers to a group constituting the linker chain represented by L in the general formula (I) above, and refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "heteroaryl group" defined above. Furthermore, when the heteroarylene group has a substituent, it refers to a divalent group obtained by removing another arbitrary hydrogen atom from a ring-constituting atom of the heteroaryl group that is not a substituent.
[0923] As the substituent of the optionally substituted heteroarylene group, one or more substituents independently selected from Group C can be mentioned.
[0924] Specific examples of the heteroarylene group include 5- to 6-membered monocyclic heteroarylene groups containing 1 to 4 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to carbon atoms, such as pyrrolylene, furylene, thienylene, pyrazolylene, imidazolylene, oxazolylene, isoxazolylene, thiazolylene, isothiazolylene, thiadiazolylene, triazolylene, tetrazolylene, pyridylene, pyrazinylene, pyrimidylene, pyridazinylene and triazinylene; indolylene, isoindolylene, indazolylene, tetrahydroindazolylene, benzofuranylene, 8-11 membered bicyclic heteroarylene groups containing 1 to 4 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to carbon atoms, such as dihydrobenzofuranylene, dihydroisobenzofuranylene, benzothiophenylene, dihydrobenzothiophenylene, dihydroisobenzothiophenylene, benzoxazolylene, dihydrobenzoxazolylene, benzothiazolylene, dihydrobenzothiazolylene, quinolylene, tetrahydroquinolylene, isoquinolylene, tetrahydroisoquinolylene, naphthyridinylene, tetrahydronaphthyridinylene, quinoxalinylene, tetrahydroquinoxalinylene and quinazolinylene.
[0925] It should be noted that the 1,2,3-triazolylene group described above as the "divalent group derived from a functional group within an antibody" described in this specification refers to a divalent 1,2,3-triazole group generated by a click reaction between an azide group (-N3) as a functional group within the antibody of the modified antibody and an alkynyl, cycloalkynyl, or azacycloalkynyl group as a reactive group at the end of the linker. The 4- and 5-positions of the 1,2,3-triazole ring can be combined with a cycloalkane ring, a bicycloalkane ring, or a heterocyclic ring to form a bicyclic divalent group. The cycloalkane ring, bicycloalkane ring, or heterocyclic ring can be further fused with one or two other aliphatic or aromatic rings to form a tricyclic or tetracyclic divalent group.
[0926] The "heterocyclic group" described in this specification refers to a group constituting the linker chain represented by L in the above general formula (I), and refers to a divalent group obtained by removing one arbitrary hydrogen atom from the "heterocyclic group" defined above.
[0927] As the substituent of the optionally substituted heterocyclic group, one or more substituents independently selected from Group D can be mentioned.
[0928] Specific examples of the heterocyclic group include azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, piperidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, piperazinyl, morpholinyl, perhydroazepinyl, azacyclooctanyl, azacyclooctan-3-yl, azacyclooctan-4-yl, azacyclononyl, azacyclodecyl, 6- to 12-membered azabicycloalkyl (e.g., azabicyclohexyl, azabicycloheptyl, azabicyclooctyl, azabicyclononyl, azabicyclodecyl, azabicycloundecaryl, alkyl, or azabicyclododecyl), a 6-membered to 12-membered azabicycloalkenyl (for example, azabicyclohexenyl, azabicycloheptenyl, azabicyclooctenyl, azabicyclononenyl, azabicyclodecenyl, azabicycloundecenyl or azabicyclododecenyl), a 6-membered to 12-membered azabicycloalkyl (for example, azabicyclohexyl, azabicycloheptyl, azabicyclooctyl, azabicyclononyl, azabicyclodecyl, azabicycloundecyl or azabicyclododecyl), a 5-azacyclooctyne-3,5-diylidene, a 5-azacyclooctyne-4,5-diylidene, and the like.
[0929] The heterocyclic group may form a 2- to 4-cyclic heterocyclic group with one or more of the above-mentioned aryl rings and / or the above-mentioned heteroaryl rings.
[0930] It should be noted that when the above-mentioned alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, azacycloalkynyl, aryl, heteroaryl, heterocyclic, alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, cycloalkynylene, azacycloalkynylene, arylene, heteroarylene and heterocyclic groups have functional groups such as hydroxyl, thiol, amino (-NH2, -NH- (including -NH- in the ring of heteroaryl and heterocyclic groups)), carboxyl, sulfenic acid, sulfinic acid, sulfonic acid, phosphinic acid, phosphonic acid or boronic acid as substituents, these groups may be protected by the protecting groups described in the "anti-tumor drug molecules or analogs thereof, or derivatives thereof".
[0931] Examples of "pharmacologically acceptable salts" as used herein include alkali metal salts such as lithium, sodium, and potassium; salts of Group II metals such as magnesium and calcium; salts with aluminum or zinc; salts with amines such as ammonia, choline, diethanolamine, lysine, ethylenediamine, tert-butylamine, tert-octylamine, tris(hydroxymethyl)aminomethane, N-methyl-glucosamine, triethanolamine, and dehydroabietinamine; salts with inorganic acids such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, nitric acid, and phosphoric acid; salts with organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, and benzenesulfonic acid; and salts with acidic amino acids such as aspartic acid and glutamic acid. Furthermore, "pharmacologically acceptable salts" also include intramolecular salts.
[0932] It should be noted that any of the antibody-drug conjugates of the present invention and pharmacologically acceptable salts thereof may be obtained in the form of hydrates or solvates, and the present invention also includes any of them.
[0933] In the antibody-drug conjugate of the present invention (general formula (I)), the structure of the portion other than "AB-", i.e., the linker-drug unit (hereinafter sometimes referred to as LDU in this specification) is shown below as general formula (II), and the linker-drug unit (LDU) is composed of any combination of L and D as defined and exemplified above.
[0934] Linker-Drug Unit; Structure of LDU
[0935] General formula (II):
[0936] -LD (II)
[0937] In the above general formula (II), L and D have the same meanings as above.
[0938] Specific examples of the linker-drug unit (LDU) represented by the above general formula (II) are shown below, but the present invention is not limited thereto.
[0939] Example 2. Examples of Linker-Drug Units (LDU) Example 2-1
[0940]
[0941] Example 2-2
[0942]
[0943] Example 2-3
[0944]
[0945] Example 2-4
[0946]
[0947] Example 2-5
[0948]
[0949] Example 2-6
[0950]
[0951] Example 2-7
[0952]
[0953] Example 2-8
[0954]
[0955] Example 2-9
[0956]
[0957] Example 2-10
[0958]
[0959] Example 2-11
[0960]
[0961] Example 2-12
[0962]
[0963] Example 2-13
[0964]
[0965] Example 2-14
[0966]
[0967] Example 2-15
[0968]
[0969] Example 2-16
[0970]
[0971] Example 2-17
[0972]
[0973] Example 2-18
[0974]
[0975] Example 2-19
[0976]
[0977] Example 2-20
[0978]
[0979] Example 2-21
[0980]
[0981] Example 2-22
[0982]
[0983] Example 2-23
[0984]
[0985] Example 2-24
[0986]
[0987] Example 2-25
[0988]
[0989] Example 2-26
[0990]
[0991] Example 2-27
[0992]
[0993] Example 2-28
[0994]
[0995] Example 2-29
[0996]
[0997] Example 2-30
[0998]
[0999] Example 2-31
[1000]
[1001] Example 2-32
[1002]
[1003] Example 2-33
[1004]
[1005] Example 2-34
[1006]
[1007] Example 2-35
[1008]
[1009] Example 2-36
[1010]
[1011] Example 2-37
[1012]
[1013] Example 2-38
[1014]
[1015] Example 2-39
[1016]
[1017] Example 2-40
[1018]
[1019] Example 2-41
[1020]
[1021] Example 2-42
[1022]
[1023] Example 2-43
[1024]
[1025] Example 2-44
[1026]
[1027] Example 2-45
[1028]
[1029] Example 2-46
[1030]
[1031] Example 2-47
[1032]
[1033] Example 2-48
[1034]
[1035] Example 2-49
[1036]
[1037] Example 2-50
[1038]
[1039] Example 2-51
[1040]
[1041] Example 2-52
[1042]
[1043] Example 2-53
[1044]
[1045] Example 2-54
[1046]
[1047] Example 2-54b
[1048]
[1049] Example 2-55
[1050]
[1051] Example 2-55b
[1052]
[1053] Example 2-56
[1054]
[1055] Example 2-57
[1056]
[1057] Example 2-58
[1058]
[1059] Example 2-59
[1060]
[1061] Example 2-60
[1062]
[1063] Example 2-61
[1064]
[1065] Example 2-62
[1066]
[1067] Example 2-63
[1068]
[1069] Example 2-64
[1070]
[1071] Example 2-65
[1072]
[1073] Example 2-66
[1074]
[1075] Example 2-67
[1076]
[1077] Example 2-68
[1078]
[1079] Example 2-69
[1080]
[1081] Example 2-69b
[1082]
[1083] [In the above formula, * 1 is the bonding point to "antibody residue AS-", 2 is the bonding point to the "antibody residue A-NH-", * 3 is the bonding point to "antibody residue A-".]
[1084] [Manufacturing method]
[1085] Next, a general method for producing the antibody-drug conjugate of the present invention and its intermediates will be described.
[1086] The antibody-drug conjugate of the present invention is produced by reacting an antibody with a compound of the general formula (III) (hereinafter referred to as a reactive precursor).
[1087] General formula (III):
[1088] ZL 1 -D (III)
[1089] [Where,
[1090] Z represents a reactive group capable of reacting with a thiol group (—SH), an amino group (—NH 2 ), or an azide group (—N 3 ) present in the antibody to form a covalent bond, for example, a Hal—CH 2 —C(═O)— group (Hal is Cl, Br, or I), a maleimide group, an ethynylphosphonamide ester group (see Hackenberger CP et al., Angew. Chem. Int. Ed. 58, 11631-11636 (2019)), a carboxyl group, an N-hydroxysuccinimide ester group, an alkynyl group, or a cycloalkynyl group,
[1091] The maleimide group is represented by the following formula (i):
[1092] Formula (i)
[1093]
[1094] The ethynylphosphonamide group is represented by the following formula (ii):
[1095] Formula (ii)
[1096]
[1097] The N-hydroxysuccinimidyl ester group is represented by the following formula (iii):
[1098] Formula (iii)
[1099]
[1100] [In the above formula, R 16 is methyl, ethyl, or -CH2CH2OCH2CH2OH, etc., * is 1 bonding point]
[1101] L 1 is a linker constituting a part of the structure of L defined above, and D has the same meaning as above.]
[1102] Below is an example of the general formula (III).
[1103] Example 3. Examples of compounds of formula (III)
[1104] Example 3-1
[1105]
[1106] Example 3-2
[1107]
[1108] Example 3-3
[1109]
[1110] Example 3-4
[1111]
[1112] Example 3-5
[1113]
[1114] Example 3-6
[1115]
[1116] Example 3-7
[1117]
[1118] Example 3-8
[1119]
[1120] Example 3-9
[1121]
[1122] Example 3-10
[1123]
[1124] Example 3-11
[1125]
[1126] Example 3-12
[1127]
[1128] Example 3-13
[1129]
[1130] Example 3-14
[1131]
[1132] Example 3-15
[1133]
[1134] Example 3-16
[1135]
[1136] Example 3-17
[1137]
[1138] Example 3-18
[1139]
[1140] Example 3-19
[1141]
[1142] Example 3-20
[1143]
[1144] Example 3-21
[1145]
[1146] Example 3-22
[1147]
[1148] Example 3-23
[1149]
[1150] Example 3-24
[1151]
[1152] Example 3-25
[1153]
[1154] Example 3-26
[1155]
[1156] Example 3-27
[1157]
[1158] Example 3-28
[1159]
[1160] Example 3-29
[1161]
[1162] Example 3-30
[1163]
[1164] Example 3-31
[1165]
[1166] Example 3-32
[1167]
[1168] Example 3-33
[1169]
[1170] Example 3-34
[1171]
[1172] Example 3-35
[1173]
[1174] Example 3-36
[1175]
[1176] Example 3-37
[1177]
[1178] Example 3-38
[1179]
[1180] Example 3-39
[1181]
[1182] Example 3-40
[1183]
[1184] Example 3-41
[1185]
[1186] Example 3-42
[1187]
[1188] Example 3-43
[1189]
[1190] Example 3-44
[1191]
[1192] Example 3-45
[1193]
[1194] Example 3-46
[1195]
[1196] Example 3-47
[1197]
[1198] Example 3-48
[1199]
[1200] Example 3-49
[1201]
[1202] Example 3-50
[1203]
[1204] Example 3-51
[1205]
[1206] Example 3-52
[1207]
[1208] Example 3-53
[1209]
[1210] Example 3-54
[1211]
[1212] Example 3-55
[1213]
[1214] Example 3-56
[1215]
[1216] Example 3-57
[1217]
[1218] Example 3-58
[1219]
[1220] Example 3-59
[1221]
[1222] Example 3-60
[1223]
[1224] Example 3-61
[1225]
[1226] Example 3-62
[1227]
[1228] Example 3-63
[1229]
[1230] Example 3-64
[1231]
[1232] Example 3-65
[1233]
[1234] Example 3-66
[1235]
[1236] Example 3-67
[1237]
[1238] Example 3-68
[1239]
[1240] Example 3-69
[1241]
[1242] Examples of production methods are described below in detail. Basically, any known method commonly used in the production of ADCs or chemical modification of proteins (for example, those described in the following patent documents) can be appropriately selected and applied.
[1243] Japanese Patent No. 6186045
[1244] Synthetic Organic Chemistry Vol. 42 No. 4 (1984)
[1245] ·Drug Delivery System 34-1,2019
[1246] ·Nat.Commun.2018,9,2512
[1247] ·YAKUGAKU ZASSHI 139,No.2(2019)
[1248] ·Angew.Chem.Int.Ed.2019,58,11631 -11636
[1249] ·Chem.Rev.2015,115,2174-2195
[1250] ·Analytical Sciences January 2018,Vol.35,5-27
[1251] Manufacturing method-1
[1252] In the antibody-drug conjugate of the present invention (general formula (I)), the compound (general formula (I-1)) in which B is -S- (thioether bond) can be produced, for example, by the method shown below.
[1253] Method for producing an antibody-drug conjugate represented by general formula (I-1)
[1254] A-(SH) a + compound (III-1) → A-(SZ 1 -L 1 -D) a General formula (I-1)
[1255] [wherein, A-(SH)a is an antibody having one or more thiol groups (-SH), and compound (III-1) represents a reactive precursor in which Z in the above general formula (III) is a maleimide group (the above formula (ii)), a Hal-CH2-C(=O)- group (Hal is Cl, Br, or I), or an ethynylphosphonamide group (the above formula (iii), Angew. Chem. Int. Ed. 2019, 58, 11631-11636),
[1256] Z 1 represents a divalent residue (succinimidyl group, -CH2-C(=O)- group, or cis-vinylphosphonamide ester group) generated by the reaction of the reactive group Z defined above with the SH group of the antibody.
[1257] The succinimidyl group is represented by the following formula (iv),
[1258] Formula (iv)
[1259]
[1260] The cis-vinylphosphonamide group is represented by the following formula (v):
[1261] Formula (v)
[1262]
[1263] [In the above formula, R 16 is a methyl, ethyl, or -CH2CH2OCH2CH2OH group, * is the bonding point with "antibody AS-", ** is the bonding point with "L 1 "bonding point]
[1264] L 1 , D, and a have the same meanings as defined above.]
[1265] The above-mentioned production method can be specifically described as follows. [1]
[1267] A-(SH) a +Maleimido-L 1-1 -D→A-(S-succinimidyl-L 1-1 -D) a General formula (I-1-1)
[1268] or [2]
[1270] A-(SH) a +Hal-CH2-C(=O)-L 1-2 -D→A-(S-CH2-C(=O)-L1-2 -D) a General formula (I-1-2)
[1271] or [3]
[1273] A-(SH) a +Ethylenephosphonamide-L 1-3 -D→A-(S-cis-vinylphosphonamide ester-L 1-3 -D) a General formula (I-1-3)
[1274] [Where,
[1275] A-(SH)a is an "antibody" having one or more sulfhydryl groups (-SH).
[1276] L 1-1 、L 1-2 and L 1-3 represents a linker moiety formed by removing a succinimidyl group (the above formula (v)), a -CH2-C(=O)- group, or a cis-vinylphosphonamide ester group (the above formula (vi)) from the above-defined L, and these may be the same or different,
[1277] D and a have the same meanings as above.]
[1278] By reacting the antibody (A-(SH)a) having a thiol group with the compound (III-1) obtainable by the method described below, an antibody-drug conjugate (general formula (I-1)) can be produced.
[1279] Antibodies having thiol groups (A-(SH))a can be obtained by methods known in the art (Hermanson, GT, Bioconjugate Techniques, pp. 56-136, pp. 456-493, Academic Press (1996)).
[1280] For example, the following methods can be cited: allowing Traut's reagent to act on the amino groups of the antibody; allowing N-succinimidyl-S-acetylthioalkanoate to act on the amino groups of the antibody, and then allowing hydroxylamine to act; allowing N-succinimidyl-3-(pyridyldithio) propionate to act, and then allowing a reducing agent to act; allowing a reducing agent such as dithiothreitol, 2-mercaptoethanol, or tris(2-carboxyethyl)phosphine hydrochloride (TCEP) to act on the antibody to reduce the disulfide bonds in the hinge portion of the antibody to generate sulfhydryl groups; etc., but the present invention is not limited to these.
[1281] Specifically, by using 0.3 to 3 molar equivalents of TCEP as a reducing agent per disulfide bond within the antibody hinge region and reacting the antibody in a buffer containing a chelating agent, an antibody in which the disulfide bonds within the antibody hinge region are partially or completely reduced can be obtained. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). These can be used at concentrations of 1 mM to 20 mM. Buffers can be used such as sodium phosphate, sodium borate, sodium acetate solution, and phosphate-buffered saline. In a specific example, by reacting the antibody with TCEP at 4°C to 37°C for 1 to 4 hours, an antibody A-(SH)a having partially or completely reduced sulfhydryl groups can be obtained. Furthermore, by using 2 to 20 molar equivalents of compound (III-1) per antibody (A-(SH)a) having sulfhydryl groups, an antibody-drug conjugate (Formula (I-1)) having 1 to 10 linker-drug units (LDUs) bound to each antibody can be produced.
[1282] Specifically, a solution in which compound (III-1) is dissolved is added to a buffer containing an antibody (A-(SH)a) having a thiol group and the reaction is carried out. Here, as a buffer, sodium phosphate, sodium borate, sodium acetate solution, phosphate-buffered saline, etc. can be used. The pH during the reaction is 5 to 9, and the reaction is more preferably carried out at around pH 7. As a solvent for dissolving compound (III-1), organic solvents such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), N-methyl-2-pyridone (NMP) can be used. A 1 to 20% v / v organic solvent solution in which compound (III-1) is dissolved is added to a buffer containing an antibody (A-(SH)a) having a thiol group and the reaction is carried out. The reaction temperature is 0°C-37°C, more preferably 10°C-25°C, and the reaction time is 0.5 hours-2 hours. The reaction can be terminated by inactivating the reactive groups of unreacted compound (III-1) using a thiol-containing reagent. The thiol-containing reagent is, for example, cysteine or N-acetyl-L-cysteine (NAC). More specifically, the reaction can be terminated by adding 1 to 2 molar equivalents of NAC relative to the compound (III-1) used and incubating at room temperature for 10 to 30 minutes.
[1283] Manufacturing Method-2
[1284] In the antibody-drug conjugate of the present invention (general formula (I)), the compound (general formula (I-2)) in which B is -NH- can be produced, for example, by the method shown below.
[1285] Method for producing an antibody-drug conjugate represented by general formula (I-2)
[1286] A-(NH2) a+ Compound (III-2) → A-(NH-C(=O)-L 2 -D) a General formula (I-2)
[1287] [wherein, A-(NH2)a is an antibody having one or more amino groups (-NH2),
[1288] Compound (III-2) represents a reactive precursor wherein Z in the above general formula (III) is a carboxyl group (-COOH) or an active ester group thereof, such as an N-hydroxysuccinimide ester group (the above formula (iv)).
[1289] L 2 represents a linker moiety formed by removing the -C(=O)- group from the above-defined L,
[1290] D and a have the same meanings as defined above.]
[1291] The above-mentioned production method can be specifically described as follows. [1]
[1293] A-(NH2) a +HOOC-L 2-1 -D→
[1294] A-(NH-C(=O)-L 2-1 -D) a General formula (I-2-1)
[1295] or [2]
[1297] A-(NH2) a +N-Hydroxysuccinimidyl ester-L 2-2 -D→A-(NH-C(=O)-L 2-2 -D) a General formula (1-2-2)
[1298] [wherein, A-(NH2)a is an antibody having one or more amino groups (-NH2),
[1299] L 2-1 and L 2-2 represents a linker moiety formed by removing the -C(=O)- group from the above-defined L, which may be the same or different, and D and a have the same meanings as above.]
[1300] By reacting an antibody (A-(NH 2 )a) having an amino group (—NH 2 ) with a compound (III-2) obtainable by the method described below, an antibody-drug conjugate (general formula (I-2)) can be produced.
[1301] As the active ester group of compound (III-2), in addition to the N-hydroxysuccinimide ester (the above formula (v)) exemplified above, other active esters such as sulfosuccinimide ester, N-hydroxyphthalimide ester, N-hydroxysulfophthalimide ester, o-nitrophenyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, 3-sulfonyl-4-nitrophenyl ester, 3-carboxy-4-nitrophenyl ester, pentafluorophenyl ester, etc. can also be used.
[1302] Specifically, by using 2 to 20 molar equivalents of compound (III-2) per antibody having an amino group (A-(NH2)a), an antibody-drug conjugate (general formula (I-2)) can be produced in which 1 to 10 linker-drug units (LDU) are bound to each antibody.
[1303] Specifically, an antibody-drug conjugate (general formula (I-2)) can be produced by adding a solution in which compound (III-2) is dissolved to a buffer solution containing an antibody (A-(NH2)a) and reacting the solution. Here, as a buffer solution, sodium phosphate, sodium borate, sodium acetate solution, phosphate-buffered saline, etc. can be used. The pH during the reaction can be 5 to 9, and more preferably, the reaction can be carried out at around pH 7. As a solvent for dissolving compound (III-2), organic solvents such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), and N-methyl-2-pyridone (NMP) can be used. An organic solvent solution in which compound (III-2) is dissolved at 1 to 20% v / v is added to a buffer solution containing an antibody (A-(NH2)a) and reacted. The reaction temperature is 0°C to 37°C, more preferably 10°C to 25°C, and the reaction time is 0.5 hours to 20 hours.
[1304] Manufacturing Method-3
[1305] In the antibody-drug conjugate of the present invention (general formula (I)), the compound (general formula (I-3)) wherein B is -(1,2,3-triazolylene)- can be produced, for example, by the method shown below.
[1306] Method for producing antibody-drug conjugate represented by general formula (I-3)
[1307] A-(N3) a + Compound (III-3) → A-(1,2,3-triazolylene-LD) a General formula (I-3)
[1308] [wherein, A-(N3)a is an antibody having one or more azide groups (-N3),
[1309] Compound (III-3) represents a reactive precursor wherein Z in the above general formula (III) is an alkynyl group or a cycloalkynyl group, and D, L and a have the same meanings as defined above.]
[1310] The above-mentioned production method can be specifically described as follows (here, an example in which the reactive group in the general formula (III-3) is a dibenzazacyclooctynyl group is described).
[1311] A-(N3) a + dibenzazoline-KD→A-(1,2,3-triazole-LD) a General formula (I-3-1)
[1312] [wherein, A-(N3)a is an antibody having one or more azide groups (-N3),
[1313] The dibenzazetacyclooctynyl group is represented by the following formula (vi):
[1314] Formula (vi)
[1315]
[1316] The generated 1,2,3-triazolylene is represented by the following formula (vii):
[1317] Formula (vii)
[1318]
[1319] [In the above formula, * is the bonding point to "antibody residue A-", and ** is the bonding point to "-L"]
[1320] D, L and a have the same meanings as above.]
[1321] The above-mentioned production method 3 is widely known as a click reaction for synthesizing 1,2,3-triazoles from azide compounds and alkynes in aqueous solution under mild conditions, and is carried out according to the methods described in the following documents and the like.
[1322] Australian Journal of Chemistry 60(6):384-395.
[1323] Angew.Chem.Int.Ed.2001,40,2004-2021
[1324] J.Am.Chem.Soc.2004,126,12809-12818
[1325] Angew.Chem.Int.Ed.2004,43,3928-3932
[1326] Proc.Natl.Acad.Sci.USA2007,104,16793-16797
[1327] Manufacturing Method-4
[1328] The antibody-drug conjugate represented by the general formula (I) of the present invention can also be produced by the method represented by the following formula. [1]
[1330] A-(BQ 1 -W1) a +W 2 -Q 2 -D→A-(BL 1 -D) a
[1331] or [2]
[1333] A-(BQ 3 -W 2 ) a +W 1 -Q 4 -D→A-(BL 1 -D) a
[1334] [Where,
[1335] A, B, a, D and L 1 Same meaning as above,
[1336] Q 1 and Q 3 It is an auxiliary linker extending from the functional groups (-OH, -SH, -NH2, -COOH, etc.) present in the antibody.
[1337] Q 2 and Q 4 is an auxiliary linker extending from D,
[1338] During the coupling reaction, Q 1 and Q 2 Together, and Q 3 and Q 4 Together form L 1 part or all of
[1339] W 1 and W 2are independently a reactive group such as a mercapto group, an amino group, a maleimide group (the above formula (ii)), an α-halomethylcarbonyl group (the halogen is Cl, Br or I), an ethynylphosphonamide ester group (the above formula (iii)), a carboxyl group, an active ester of a carboxyl group, an azide group (-N3), an alkynyl group, a cycloalkynyl group or an azacycloalkynyl group, W 1 and W 2 Being in a relationship of "mutually reacting to each other",
[1340] W 1 When W is a thiol group, 2 is a maleimide group, an α-halomethylcarbonyl group, or an ethynylphosphonamide ester group,
[1341] W 1 When it is amino, W 2 is a carboxyl group or an active ester of a carboxyl group,
[1342] W 1 When W is a maleimide group, an α-halomethylcarbonyl group, or an ethynylphosphonic acid amide ester group, 2 For thiol,
[1343] W 1 When it is a carboxyl group or an active ester of a carboxyl group, W 2 For amino,
[1344] W 1 When it is an azido group, W 2 is an alkynyl group, a cycloalkynyl group or an azacycloalkynyl group,
[1345] W 1 When W is an alkynyl group, a cycloalkynyl group or an azacycloalkynyl group, 2 is an azido group]
[1346] This production method is carried out according to the methods described in the following known patents / documents.
[1347] WO2014 / 057687
[1348] Nat.Commun.2018,9,2512
[1349] YAKUGAKU ZASSHI 139,No.2(2019)
[1350] In the above formula, W 1 is an azido group, W 2 is an alkynyl group, a cycloalkynyl group or an azacycloalkynyl group, and W 1 is an alkynyl, cycloalkynyl or azacycloalkynyl group, W 2 In the case of an azido group, W 1 With W 2The reaction is called "click reaction" and is carried out in the same manner as the reaction described in the above-mentioned production method-3.
[1351] The antibody-drug conjugate produced according to the general production method described above can be concentrated, buffer exchanged, purified, and the antibody concentration and the average number of linker-drug units (LDUs) bound per antibody molecule can be measured according to the general conjugate treatment steps described below to identify the antibody-drug conjugate.
[1352] Conjugate Processing Step A: Concentration of Antibody or Antibody-Drug Conjugate Aqueous Solution
[1353] The antibody or antibody-drug conjugate solution was placed in an Amicon Ultra (50,000 MWCO, Millipore Corporation) container and concentrated by centrifugation (2000 to 3800 G for 5 to 20 minutes) using a centrifuge (Universal Refrigerated Centrifuge MODEL 5922, Kubota Corporation).
[1354] Conjugate Processing Step B: Antibody Concentration Determination
[1355] Antibody concentrations were measured using a microplate reader (Flex Station 3, Molecular Devices, LLC) according to the manufacturer's protocol, using different absorbances at 280 nm (1.3 mL mg cm-1 to 1.8 mL mg cm-1) for each antibody.
[1356] Conjugate Treatment Step C: Antibody Buffer Exchange
[1357] A NAP-25 column (Cat. No. 17-0854-02, GE Healthcare Japan Corporation) using a Sephadex G-10 support was equilibrated with phosphate buffer (pH 7.4) (referred to herein as PBS 6.0 / EDTA) according to the manufacturer's instructions. 1.0 mL of the antibody aqueous solution was loaded onto one NAP-10 column, and the fraction eluted with 1.5 mL of PBS (1.5 mL) was separated. This fraction was concentrated using Treatment A, and the antibody concentration was measured using Treatment B, after which the antibody concentration was adjusted using PBS.
[1358] Conjugate Processing Step D: Purification of Antibody-Drug Conjugates
[1359] A NAP-10 column was equilibrated with either a commercially available phosphate buffer (PBS 7.4, Cat. No. 10010-023, Invitrogen) containing sodium phosphate buffer (10 mM, pH 6.0; referred to herein as PBS 6.0) and sodium chloride (137 mM) or an acetate buffer (10 mM, pH 5.5; referred to herein as ABS) containing sorbitol (5%). The antibody-drug conjugate reaction aqueous solution (approximately 1.0 mL) was loaded onto the NAP-10 column and eluted with the manufacturer's specified amount of buffer to isolate the antibody fraction. This gel filtration purification procedure, in which the fraction was reloaded onto the NAP-10 column and eluted with buffer, was repeated 2-3 times to obtain an antibody-drug conjugate free of unbound drug linker and low-molecular-weight compounds (tris(2-carboxyethyl)phosphine hydrochloride (TCEP), N-acetyl-L-cysteine (NAC), and dimethyl sulfoxide).
[1360] Conjugate treatment step E: Calculate the antibody concentration in the antibody-drug conjugate and the average number of linker-drug units (LDUs) per antibody molecule (DAR) based on absorbance
[1361] The bound drug concentration in the antibody-drug conjugate can be calculated by measuring the UV absorbance of the antibody-drug conjugate aqueous solution at two wavelengths, 280 nm and 370 nm, and then performing the following calculation.
[1362] Since the total absorbance at a given wavelength is equal to the sum of the absorbances of all absorbing chemical species present in the system (additivity of absorbance), assuming that the molar absorptivity of the antibody and drug does not change before and after conjugation, the antibody and drug concentrations in the antibody-drug conjugate are expressed by the following relationship.
[1363] A280=AD, 280+AA, 280=εD, 280CD+εA, 280CA...Equation (1)
[1364] A370=AD, 370+AA, 370=εD, 370CD+εA, 370CA...Equation (2)
[1365] Wherein, A280 represents the absorbance of the antibody-drug conjugate aqueous solution at 280 nm, A370 represents the absorbance of the antibody-drug conjugate aqueous solution at 370 nm, AA,280 represents the absorbance of the antibody at 280 nm, AA,370 represents the absorbance of the antibody at 370 nm, AD,280 represents the absorbance of the conjugate precursor (the compound of the above-mentioned general formula (III); the same applies hereinafter) at 280 nm, AD,370 represents the absorbance of the conjugate precursor at 370 nm, εA,280 represents the molar absorptivity of the antibody at 280 nm, εA,370 represents the molar absorptivity of the antibody at 370 nm, εD,280 represents the molar absorptivity of the conjugate precursor at 280 nm, εD,370 represents the molar absorptivity of the conjugate precursor at 370 nm, CA represents the antibody concentration of the antibody-drug conjugate, and CD represents the drug concentration of the antibody-drug conjugate.
[1366] Here, εA,280, εA,370, εD,280, and εD,370 use previously prepared values (calculated estimated values or measured values obtained by UV measurement of the compound). For example, εA,280 can be estimated from the amino acid sequence of the antibody using a known calculation method (Protein Science, 1995, vol. 4, 2411-2423). εA,370 is usually zero. εD,280 and εD,370 can be obtained by measuring the absorbance of a solution in which the conjugate precursor used is dissolved to a certain molar concentration, according to the Lambert-Beer law (absorbance = molar concentration × molar absorption coefficient × cuvette optical path length). By measuring A280 and A370 of the antibody-drug conjugate aqueous solution, substituting these values into equations (1) and (2), and solving the simultaneous equations, CA and CD can be obtained. Furthermore, by dividing CD by CA, the average number of linker-drug units (LDU) bound per antibody can be determined.
[1367] Conjugate Processing Step F: Calculation of DAR in Antibody-Drug Conjugates by Cysteine Reactivity Evaluation
[1368] The DAR of the antibody-drug conjugate of the present invention (general formula: I-1) in which "-B-" in general formula (I) is "-S-" can be calculated and estimated by evaluating the reactivity of the reactive precursor (compound (III-1)) with L-cysteine. Specifically, the reactive precursor (compound (III-1)) is reacted with L-cysteine under the same conditions as the conjugation reaction. If L-cysteine is completely consumed, the DAR is estimated to be 8. The specific method is described below.
[1369] To 900 μL of 134 μM L-cysteine PBS / EDTA solution, 100 μL of a 1.51 mM reactive precursor (compound (III-1)) dimethyl sulfoxide solution for coupling was added. (Under these conditions, the reactive precursor was 10 equivalents relative to 8 equivalents of L-cysteine.) The reaction was then allowed to proceed on ice for 1 hour. 480 μL of the reacted solution was placed in a microtube and 20 μL of a 10 mM ethanol solution of 5,5'-dithiobis(2-nitrobenzoic acid) (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., 047-16401) was added. The reaction was allowed to proceed at room temperature for 15 minutes, and the reacted solution was added to a 96-well plate. The absorbance (412 nm) was measured using a microplate reader (FlexStation3, manufactured by Molecular Devices). The same operation was performed for an L-cysteine solution with a known concentration to prepare a standard curve, thereby determining the L-cysteine concentration in the sample.
[1370] The residual rate (%) of L-cysteine in the sample was determined by the following formula.
[1371] Residual rate of L-cysteine in the sample (%) = (a / 121) × 100
[1372] a: L-cysteine concentration in the sample (μM)
[1373] The DAR of the antibody-drug conjugate (general formula: I-1) obtained using the same batch of reactive precursor (Compound (III-1)) as that used in the above-mentioned cysteine reactivity evaluation was calculated / estimated by the following formula.
[1374] DAR = 8 × ((100-b) / 100)
[1375] b: L-cysteine residual rate in the sample (%)
[1376] It should be noted that, in order to ensure the amount of conjugates, conjugates prepared under the same conditions with the same average total drug count (e.g., approximately ±1) can be mixed to produce a new batch. In this case, the average total drug count is between the average total drug counts before mixing.
[1377] The antibody-drug conjugate precursor or salt thereof of the present invention may absorb water or form a hydrate by being left in the air or recrystallized. Such antibody-drug conjugates or salts thereof containing water are also included in the present invention.
[1378] When the "-LD" portion of the antibody-drug conjugate represented by the general formula (I) of the present invention contains a partial structure having an asymmetric center and optical isomers may occur, all optical isomers are encompassed by the present invention.
[1379] In addition, the present invention also includes compounds labeled with various radioactive or non-radioactive isotopes. One or more of the atoms constituting the antibody-drug conjugate of the present invention may also contain an unnatural ratio of atomic isotopes. Examples of atomic isotopes include deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) etc. In addition, the antibody-drug conjugates of the present invention can be treated with tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) radioactive isotopes. Radiolabeled compounds are useful as therapeutic or prophylactic agents, research reagents, such as detection reagents and diagnostic agents, such as in vivo imaging diagnostic agents. All isotopically modified forms of the antibody-drug conjugates of the present invention, whether or not radioactive, are encompassed within the scope of the present invention.
[1380] How to use
[1381] Treatment of tumors (including carcinomas, blood cancers, carcinomas, sarcomas, and brain tumors)
[1382] The antibody-drug conjugates of the present invention exhibit anti-tumor activity and can therefore be used as therapeutic and / or preventive drugs for tumors. Examples of tumors for which the antibody-drug conjugates of the present invention can be applied include hematopoietic tumors or cancers such as lymphoma (Hodgkin's lymphoma and non-Hodgkin's lymphoma) and leukemia, as well as solid tumors or solid cancers. Examples of hematopoietic tumors or cancers include follicular lymphoma, undifferentiated large cell lymphoma, mantle cell lymphoma, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, diffuse large cell B-cell lymphoma, and multiple myeloma. Examples of solid tumors or solid cancers include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, Kaposi's sarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, gastric cancer, oral cancer, nasal cancer, pharyngeal cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland cancer, sebaceous gland cancer, papillary carcinoma, papillary adenocarcinoma, and cystadenocarcinoma. , medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, small cell lung cancer, bladder cancer, lung cancer, epithelial cancer, thyroid cancer, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, skin cancer, melanoma, neuroblastoma, and retinoblastoma, etc., as long as the tumor cells to be treated are tumor cells that express an antigen that can be recognized by the antibody in the antibody-drug conjugate of the present invention, and are not limited to these.
[1383] The antibody-drug conjugates of the present invention can be administered to mammals, preferably humans.
[1384] The substances used in the pharmaceutical composition comprising the antibody-drug conjugate of the present invention can be arbitrarily selected from the formulation additives and other substances conventionally used in the art.
[1385] The antibody-drug conjugates of the present invention can be administered in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable components. For example, the pharmaceutical composition typically includes one or more pharmaceutically acceptable carriers. As such a carrier, for example, a sterilized liquid (e.g., water, mineral oil, animal oil, vegetable oil (e.g., peanut oil, soybean oil, sesame oil)) is included. Water is a representative carrier for intravenous administration of the pharmaceutical composition. Aqueous saline solutions, aqueous glucose solutions, and aqueous glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. As excipients, various pharmacologically acceptable substances known in the art can be used. The pharmaceutical composition may also contain trace amounts of wetting agents or emulsifiers, or pH buffers as needed. Examples of pharmaceutically acceptable carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin.
[1386] The antibody-drug conjugates of the present invention can be administered by various routes. A preferred route of administration is parenteral administration, which may include subcutaneous injection, intravenous injection, intramuscular injection, or intrasternal injection. Intravenous administration is more preferred, and may be administered by drip or bolus.
[1387] Pharmaceutical compositions suitable for intravenous administration to humans are formulated according to conventional methods. Representative pharmaceutical compositions for intravenous administration are solutions in sterilized isotonic aqueous buffers. The pharmaceutical compositions may contain, as needed, a local anesthetic (e.g., lidocaine) for relieving injection site pain.
[1388] The pharmaceutical composition may be a pharmaceutical composition comprising only the antibody-drug conjugate of the present invention, or a pharmaceutical composition comprising the antibody-drug conjugate and one or more other anti-tumor drugs.
[1389] The antibody-drug conjugates of the present invention can also be used in combination with other anti-tumor drugs to enhance the anti-tumor effect. Other anti-tumor drugs used for this purpose can be administered simultaneously, separately, or sequentially with the antibody-drug conjugates, and their respective dosing intervals can also be varied. Examples of such anti-tumor drugs include albumin-bound paclitaxel (abraxane), carboplatin, cisplatin, gemcitabine, irinotecan (CPT-11), paclitaxel, pemetrexed, sorafenib, vinblastine, or drugs described in International Publication No. WO2003 / 038043, as well as LH-RH analogs (leuprorelin, goserelin, etc.), estramustine phosphate, estrogen antagonists (tamoxifen, raloxifene, etc.), aromatase inhibitors (anastrozole, letrozole, exemestane, etc.), and the like. There is no limitation as long as the drug has anti-tumor activity. Such pharmaceutical compositions can be formulated in the form of freeze-dried preparations or liquid preparations. When formulated in the form of freeze-dried preparations, appropriate pharmaceutical additives used in the art can be added for formulation. The same applies to liquid preparations.
[1390] The composition and concentration of the pharmaceutical composition can vary depending on the route of administration and can be adjusted based on the affinity of the antibody-drug conjugate contained in the pharmaceutical composition for the target antigen and the anti-tumor activity of the conjugated anti-tumor drug. When administering the antibody-drug conjugate of the present invention to humans, for example, a single dose of about 0.001 to 100 mg / kg or multiple doses at intervals of 1 to 180 days can be used.
[1391] Example
[1392] The following describes in detail the methods for producing the antibody-drug conjugates of the present invention, along with methods for producing their raw materials and intermediates, as examples or reference examples. However, the present invention is not limited thereto. In addition, reagents, solvents, and starting materials not specifically described herein can be readily obtained from commercially available sources.
[1393] The correspondence between abbreviations and structures is as follows.
[1394]
[1395]
[1396]
[1397] 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
[1398] (Hereinafter referred to as HATU)
[1399]
[1400]
[1401] Preparation Example 1. Synthesis of U-001
[1402]
[1403] To a 5 mL dichloromethane solution of exitecan mesylate (284.1 mg, 0.534 mmol) and triethylamine (0.70 mL, 508.2 mg, 5.02 mmol) in a 30 mL cylindrical flask, 0.14 mL (151.2 mg, 1.481 mmol) of acetic anhydride was added while stirring at room temperature under an argon atmosphere. The mixture was stirred at room temperature for 2 hours. After completion of the reaction, the precipitate was filtered and washed with dichloromethane to obtain U-001 (239.9 mg, 94.0% yield) as a light brown solid.
[1404] MS (ESI) m / z 478 (M+H) +
[1405] Preparation Example 2. Synthesis of U-002
[1406]
[1407] In a 10mL cylindrical flask, a solution of exitecan mesylate (20.4mg, 0.038mmoL) in N,N-dimethylformamide 0.6mL was added while stirring under an argon stream at room temperature. 3-hydroxypropionic acid 0.015mL (4.86mg, 0.054mmoL), 1-hydroxybenzotriazole (15.6mg, 0.115mmoL), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (21.6mg, 0.113mmoL), and triethylamine 0.040mL (29.04mg, 0.287mmoL) were added and stirred at room temperature for 3 hours. After completion of the reaction, saturated sodium bicarbonate water was added to the reaction solution, and the mixed solution was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was subjected to Yamazen medium-pressure preparation (silica, M (16 g), ethyl acetate / methanol = 97 / 3 (V / V) → 60 / 40 (V / V)), and the fraction containing the target product (Rf value = 0.44 (ethyl acetate / methanol = 85 / 15 (V / V))) was concentrated under reduced pressure to obtain U-002 (9.8 mg, yield 50.31%) as a light yellow solid.
[1408] MS (ESI) m / z 508 (M+H) +
[1409] Preparation Example 3. Synthesis of U-003
[1410] 3-1. Synthesis of U-003-1
[1411]
[1412] To a solution of exitecan mesylate (22 mg, 0.041 mmol) in 0.8 mL of N,N-dimethylformamide in a 10 mL cylindrical flask, N-(tert-butoxycarbonyl)-N-methylglycine (11 mg, 0.058 mmol), 1-hydroxybenzotriazole (13 mg, 0.096 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (13 mg, 0.068 mmol), and 0.032 mL (23.23 mg, 0.230 mmol) of triethylamine were added while stirring at room temperature under an argon stream. The mixture was stirred at room temperature for 2 hours and then allowed to stand overnight. After completion of the reaction, saturated sodium bicarbonate solution (5 mL x 2) was added to the reaction solution, and the mixture was extracted with 15 mL of dichloromethane. The organic layer was washed with 5 mL of saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain U-003-1 (29 mg, quantitative yield).
[1413] MS (ESI) m / z 607 (M+H) +
[1414] 3-2. Synthesis of U-003
[1415]
[1416] To a 0.6 mL solution of U-003-1 (25 mg, 0.041 mmol) in dichloromethane in a 20 mL cylindrical flask, 0.050 mL of trifluoroacetic acid (74 mg, 0.649 mmol) was added while stirring under an argon stream at room temperature. After stirring at room temperature for 1.5 hours, the mixture was concentrated under reduced pressure. Methanol was added to the residue, and after concentration under reduced pressure, ethyl acetate was added and the resulting solid was filtered. The resulting solid was dried under reduced pressure to obtain the trifluoroacetic acid salt of U-003 (13 mg, 50.83% yield) as a brown solid.
[1417] MS (ESI) m / z 507 (M+H) +
[1418] Preparation Example 4. Synthesis of U-004
[1419] 4-1. Synthesis of U-004-1
[1420]
[1421] To a 10 mL cylindrical flask containing a solution of isotecan mesylate (20.6 mg, 0.039 mmol) and 0.020 mL (14.8 mg, 0.115 mmol) of N,N-diisopropylethylamine in 1 mL of dichloromethane, 3-nitrobenzoyl chloride (9.6 mg, 0.052 mmol) was added while stirring at room temperature. The mixture was stirred at room temperature for 1 hour. After the reaction, water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to obtain U-004-1 (22.6 mg, 99.76% yield).
[1422] 4-2. Synthesis of U-004
[1423]
[1424] A mixed solution of U-004-1 (22.6 mg, 0.039 mmol) and 10% palladium carbon NX type (20.6 mg, 0.0968 mmol) in 1 mL of ethanol and 1 mL of dichloromethane was added to a 30 mL eggplant flask and stirred at room temperature for 2 hours under a hydrogen atmosphere. After the reaction was completed, the catalyst was filtered and the solvent was concentrated under reduced pressure. The obtained residue was subjected to Yamazen medium pressure preparation (silica, M (16 g), dichloromethane / methanol = 100 / 0 (V / V) → 94 / 6 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain U-004 (9.4 mg, yield 43.84%) as a slightly yellow solid.
[1425] MS (DUIS) m / z 555 (M+H) +
[1426] Preparation Example 5. Synthesis of U-005
[1427] 5-1. Synthesis of U-005-1
[1428]
[1429] To a 10 mL cylindrical flask containing a solution of isotecan mesylate (21.2 mg, 0.040 mmol) and 0.020 mL (14.8 mg, 0.115 mmol) of N,N-diisopropylethylamine in 1 mL of dichloromethane, 4-nitrobenzoyl chloride (10.6 mg, 0.057 mmol) was added while stirring at room temperature, and the mixture was stirred at room temperature for 1 hour. Subsequently, 4-nitrobenzoyl chloride (10.6 mg, 0.057 mmol) was added while stirring at room temperature, and the mixture was stirred at room temperature for 1 hour. After the reaction, water and tert-butyl methyl ether were added to the reaction solution, and the mixture was stirred. The resulting solid was filtered and washed with water and tert-butyl methyl ether, respectively, to obtain U-005-1 (22.1 mg, 94.79% yield).
[1430] 5-2. Synthesis of U-005
[1431]
[1432] A mixed solution of U-005-1 (22.6 mg, 0.039 mmol) and 10% palladium carbon NX type (15.4 mg, 0.0724 mmol) in 1 mL of ethanol and 1 mL of dichloromethane was added to a 30 mL eggplant flask and stirred at room temperature for 2 hours under a hydrogen atmosphere. After the reaction was completed, the catalyst was filtered and the solvent was concentrated under reduced pressure. The residue was subjected to Yamazen medium pressure preparation (silica, M (16 g), dichloroethane / methanol = 100 / 0 (V / V) → 94 / 6 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain a crude product of U-005. The crude product was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was neutralized with saturated sodium bicarbonate water. After concentrated under reduced pressure, water was added to the precipitated solid, the insoluble matter was filtered, and washed with water to obtain U-005 (7.1 mg, yield 33.11%) as a slightly yellow solid.
[1433] MS (ESI) m / z 555 (M+H) +
[1434] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1435] Flow rate: 17 mL / min.
[1436] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1437] Gradient (Solution B): 30% (0.00 min.) → 95% (10.00 min.)
[1438] Preparation Example 6. Synthesis of U-006
[1439] 6-1. Synthesis of U-006-1
[1440]
[1441] In a 10mL cylindrical flask, a solution of isotecan mesylate (23.1mg, 0.043mmoL), 2-(3-nitrophenyl)acetic acid (15.7mg, 0.087mmoL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (16.7mg, 0.087mmoL), and 1-hydroxybenzotriazole (13.3mg, 0.087mmoL) in N,N-dimethylformamide was added, and triethylamine 0.012mL (8.71mg, 0.086mmoL) was added at room temperature while stirring under an argon atmosphere. The mixture was stirred at room temperature for 1 hour. After the reaction was completed, saturated sodium bicarbonate water was added to the reaction solution, and the mixed solution was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to obtain a crude product (38.4mg) of U-006-1.
[1442] MS (ESI) m / z 599 (M+H) +
[1443] 6-2. Synthesis of U-006
[1444]
[1445] A mixed solution of U-006-1 (38.4 mg, 0.044 mmol) and 10% palladium carbon NX type (21.3 mg, 0.200 mmol) in 1 mL of ethanol / 1 mL of dichloromethane was added to a 30 mL eggplant-shaped flask and stirred at room temperature under a hydrogen atmosphere for 2 hours. After the reaction was completed, the catalyst was filtered and the solvent was concentrated under reduced pressure. The obtained residue was subjected to Yamazen medium pressure preparation (silicon dioxide, M (16 g), dichloroethane / methanol = 100 / 0 (V / V) → 94 / 6 (V / V)), and the fraction containing the target was concentrated under reduced pressure. Ethanol was added to the residue, the precipitated solid was filtered, and washed with ethanol to obtain U-006 (16.6 mg, total yield of 6-1 and 6-2 66.92%) as a colorless solid.
[1446] MS (DUIS) m / z 569 (M+H) +
[1447] Preparation Example 7. Synthesis of U-007
[1448] 7-1. Synthesis of U-007-1
[1449]
[1450] To a 0.61 mL solution of exitecan mesylate (32.5 mg, 0.061 mmol), 2-(4-nitrophenyl)acetic acid (22.1 mg, 0.122 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (23.4 mg, 0.122 mmol), and 1-hydroxybenzotriazole (16.7 mg, 0.109 mmol) in N,N-dimethylformamide was added 0.017 mL (12.34 mg, 0.122 mmol) of triethylamine at room temperature while stirring. The mixture was stirred at room temperature for 1 hour. After completion of the reaction, saturated sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to obtain U-007-1 (26.8 mg, 73.23% yield).
[1451] MS (ESI) m / z 598 (M+H) +
[1452] 7-2. Synthesis of U-007
[1453]
[1454] A mixed solution of U-007-1 (26.8 mg, 0.045 mmol) and 10% palladium on carbon NX type (20.3 mg, 0.0954 mmol) in 1 mL of ethanol / 1 mL of dichloromethane was added to a 30 mL eggplant-shaped flask and stirred at room temperature for 2 hours under a hydrogen atmosphere. After the reaction was completed, the catalyst was filtered and the solvent was concentrated under reduced pressure. Ethanol was added to the resulting residue, and the precipitated solid was filtered and washed with ethanol to obtain U-007 (24.2 mg, 95.06% yield) as a light brown solid.
[1455] MS (DUIS) m / z 569 (M+H) +
[1456] Preparation Example 8. Synthesis of U-008
[1457] 8-1. Synthesis of U-008-1
[1458]
[1459] To a 5 mL dichloromethane solution of MMAE (0.36 g, 0.501 mmol) and 2-fluoro-5-nitrobenzaldehyde (0.25 g, 1.478 mmol) in a 30 mL cylindrical flask, sodium triacetoxyborohydride (0.32 g, 1.510 mmol) was added while stirring under an argon atmosphere at room temperature, and the mixture was stirred at room temperature for 1 hour. 2-Fluoro-5-nitrobenzaldehyde (0.25 g, 1.478 mmol) and sodium triacetoxyborohydride (0.32 g, 1.510 mmol) were additionally added, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, saturated sodium bicarbonate solution was added to the reaction solution, and the mixed solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was subjected to Yamazen medium-pressure preparation (silica, M (16 g), ethyl acetate:methanol = 100 / 0 (V / V) → 90 / 10 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain U-008-1 (406.6 mg, yield 93.09%) as a light yellow foamy substance.
[1460] MS (DUIS) m / z 873 (M+H) +
[1461] 8-2. Synthesis of U-008
[1462]
[1463] A 0.2 mL solution of U-008-1 (45.1 mg, 0.052 mmol) and zinc (89.3 mg, 1.366 mmol) in acetic acid was added to a 30 mL cylindrical flask and stirred at room temperature under an argon atmosphere for 2 hours. After the reaction was completed, saturated sodium bicarbonate solution was added to the reaction solution, and the mixed solution was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was subjected to Yamazen medium pressure preparation (silica, M (16 g), ethyl acetate / methanol = 100 / 0 (V / V) → 90 / 10 (V / V)), and the fraction containing the target product was concentrated under reduced pressure. The resulting residue was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target product was concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the formate salt of U-008 (13.3 mg, yield 28.96%) as a colorless foam.
[1464] MS (DUIS) m / z 841 (M+H) +
[1465] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1466] Flow rate: 17 mL / min.
[1467] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1468] Gradient (solution B): 30% (0.00 min.) → 95% (10.00 min.)
[1469] Preparation Example 9. Synthesis of U-009
[1470]
[1471] To a 0.1 mL solution of (tert-butoxycarbonyl)glycylglycine (8.4 mg, 0.036 mmol), 1-hydroxybenzotriazole (6.2 mg, 0.046 mmol), and MMAE (22.3 mg, 0.031 mmol) in N,N-dimethylformamide in a 10 mL cylindrical flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.8 mg, 0.046 mmol) was added while stirring at room temperature under an argon stream. The mixture was stirred at 60°C for 1 hour. The resulting reaction solution was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was concentrated under reduced pressure to obtain a colorless oil.
[1472] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1473] Flow rate: 17 mL / min.
[1474] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1475] Gradient (solution B): 30% (0.00 min.) → 95% (10.00 min.)
[1476] The obtained compound was dissolved in 1 mL of dichloromethane and 1 mL of trifluoroacetic acid, stirred at room temperature for 1 hour, and then concentrated under reduced pressure. The obtained reaction solution was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was concentrated under reduced pressure. Subsequently, DNH silica gel column chromatography was performed, eluted with dichloromethane / methanol = 9 / 1 (V / V), and the fraction containing the target product was concentrated under reduced pressure. Subsequently, it was dissolved in a water / acetonitrile mixed solvent and freeze-dried to obtain Preparation Example 9 (U-009) (2.2 mg, yield 8.51%) as a colorless solid.
[1477] MS (ESI) m / z 833 (M+H) +
[1478] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1479] Flow rate: 17 mL / min.
[1480] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1481] Gradient (solution B): 30% (0.00 min.) → 95% (10.00 min.)
[1482] Preparation Example 10. Synthesis of U-010
[1483]
[1484] To a 5 mL methanol solution of MMAE (0.37 g, 0.515 mmol) and 0.37 mL of 37% formaldehyde solution (0.4 g, 4.97 mmol) in a 30 mL cylindrical flask, sodium triacetoxyborohydride (0.32 g, 1.510 mmol) was added while stirring under an argon atmosphere at room temperature. The mixture was stirred at room temperature for 1 hour. After the reaction, saturated sodium bicarbonate solution was added to the reaction solution, and the mixed solution was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was subjected to Yamazen medium-pressure preparation (silica, M (16 g), dichloromethane / methanol = 100 / 0 (v / v) → 90 / 10 (v / v)), and the fraction containing the target compound was concentrated under reduced pressure to obtain U-010 (0.18 g, 47.72% yield) as a colorless foam.
[1485] MS (DUIS) m / z 732 (M+H) +
[1486] Preparation Example 11. Synthesis of U-011
[1487] 11-1. Synthesis of U-011-1
[1488]
[1489] To a 5 mL solution of MMAE (0.4996 g, 0.696 mmol) and sodium carbonate (0.1503 g, 1.418 mmol) in tetrahydrofuran in a 30 mL cylindrical flask was added 5 mL of water, and while stirring, 0.185 mL of di-tert-butyl dicarbonate (0.19 g, 0.848 mmol) was added at room temperature, and the mixture was stirred at room temperature for 18 hours. Thereafter, the mixture was stirred at 50°C for 1 hour. 0.015 mL of di-tert-butyl dicarbonate (0.02 g, 0.069 mmol) was added, and the mixture was stirred at 50°C for 1 hour. Furthermore, 0.015 mL of di-tert-butyl dicarbonate (0.02 g, 0.069 mmol) was added, and the mixture was stirred at 50°C for 2 hours. After the reaction was completed, ethyl acetate and saturated saline were added to the reaction solution, and the mixture was stirred at room temperature for a while. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain U-011-1 (570.5 mg, quantitative yield) as a white foamy substance.
[1490] MS (ESI) m / z 818 (M+H) +
[1491] 11-2. Synthesis of U-011-2
[1492]
[1493] To a 1 mL dichloromethane solution of U-011-1 (51.0 mg, 0.062 mmol) and bis(4-nitrophenyl) carbonate (38.8 mg, 0.128 mmol) was added to a 0.2-0.5 mL microwave reaction vessel. N,N-diisopropylethylamine (0.035 mL, 25.97 mg, 0.201 mmol) was added, the mixture was sealed with nitrogen, and stirred at room temperature for 3 hours. The mixture was then placed in a microwave reactor (Biotage) and reacted at 80°C for 1 hour. Bis(4-nitrophenyl) carbonate (100.0 mg, 0.329 mmol) and 0.5 mL of dichloromethane were then added, and the mixture was stirred at room temperature for 66 hours. The reaction solution was subjected to Yamazen medium-pressure preparation (general high-quality silica gel, S (7 g) (two phases connected), eluted with hexane / ethyl acetate = 33 / 67 (V / V) → 12 / 88 (V / V), and the fraction containing the target product was concentrated under reduced pressure to obtain U-011-2 (46.7 mg, yield 76.19%) as a slightly yellow foamy substance.
[1494] MS (ESI) m / z 983 (M+H) +
[1495] 11-3. Synthesis of U-011-3
[1496]
[1497] To a 20 mL dichloromethane solution of U-011-2 (46.7 mg, 0.047 mmol) and 3,6,9,12,15,18,21,24-octaoxopentacosan-1-amine (34.3 mg, 0.089 mmol) was added 0.030 mL of N,N-diisopropylethylamine (22.26 mg, 0.172 mmol) in a 20 mL eggplant-shaped flask. The mixture was stirred at room temperature under an argon atmosphere for 4 hours and then allowed to stand at room temperature for 16.75 hours. The reaction mixture was diluted with dichloromethane and charged to a Fuji SILYSIA Chromatorex Q-Pack DIOL 60 Size 20. Elution was performed with hexane / ethyl acetate (0→100). Fractions containing the target compound were concentrated under reduced pressure to obtain U-011-3 (49.2 mg, 84.38% yield) as a colorless oil.
[1498] MS (ESI) m / z 1227 (M+H) +
[1499] 11-4. Synthesis of U-011
[1500]
[1501] To a 2 mL dichloromethane solution of U-011-3 (47 mg, 0.038 mmol) in a 30 mL eggplant-shaped flask, 0.50 mL of trifluoroacetic acid (744.5 mg, 6.53 mmol) was added at room temperature, and the mixture was stirred at room temperature for 0.67 hours. The reaction solution was then concentrated under reduced pressure. 0.1% formic acid-acetonitrile / water (1 / 9 v / v) was added to the concentrated residue, followed by freeze-drying to obtain the trifluoroacetate salt of U-011 (47.3 mg, 99.51% yield) as a white solid.
[1502] MS (ESI) m / z 1127 (M+H) +
[1503] Preparation Example 12. Synthesis of U-012
[1504] 12-1. Synthesis of U-012-1
[1505]
[1506] To a 0.3 mL pyridine solution of U-011-1 (12.95 mg, 0.016 mmol) and 4-dimethylaminopyridine (1.46 mg, 0.012 mmol) was added to a 0.2 mL to 0.5 mL microwave reaction vessel. 0.010 mL (9.17 mg, 0.076 mmol) of 2,4,6-trimethylpyridine and 0.050 mL (59.6 mg, 0.43 mmol) of 2-methoxyethyl 2-chloroformate were added. The mixture was sealed with nitrogen and placed in a microwave reactor (Biotage) for 3 hours at 100°C. The reaction solution was diluted with ethyl acetate and washed sequentially with water (1 time), 5% potassium bisulfate aqueous solution (3 times), saturated sodium bicarbonate solution (1 time), and saturated brine (1 time). The mixture was then dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The concentrated residue was dissolved in hexane / ethyl acetate = 4 / 6 (V / V), loaded into Fuji SILYSIA Chromatorex Q-Pack DIOL60 Size 10, and eluted with hexane / ethyl acetate = 39 / 61 (V / V) → 18 / 82 (V / V). The obtained fractions containing the target product were concentrated under reduced pressure to obtain U-012-1 (9.4 mg, yield 64.53%) as a colorless oil.
[1507] MS (ESI) m / z 920 (M+H) +
[1508] 12-2. Synthesis of U-012
[1509]
[1510] To a 1 mL dichloromethane solution of U-012-1 (9.4 mg, 0.01022 mmol) in a 20 mL eggplant-shaped flask, 0.050 mL of trifluoroacetic acid (74.45 mg, 0.653 mmol) was added at room temperature, and the mixture was stirred at room temperature for 1 hour. Subsequently, 0.450 mL of trifluoroacetic acid (670.05 mg, 5.88 mmol) was added at room temperature, and the mixture was stirred at room temperature for 0.5 hour. The reaction solution was then concentrated under reduced pressure. The residue was separated by HPLC (column: Waters SunFire Prep C18 5μm ODB 19*150mm, 0.1% formic acid-acetonitrile / water (v / v) = 30 / 70 → 95 / 5), and the fraction containing the target product was concentrated under reduced pressure. A 0.1% formic acid aqueous solution was added to the concentrated residue, and the mixture was freeze-dried to obtain formate of U-012 as a white solid (3.8 mg, yield 42.95%).
[1511] MS (ESI) m / z 820 (M+H) +
[1512] Preparation Example 13. Synthesis of U-013
[1513] 13-1. Synthesis of U-013-1
[1514]
[1515] To a 50 mL solution of tert-butyl hydroxy(methyl)carbamate (7.40 g, 50.3 mmol) and potassium carbonate (13.84 g, 100 mmol) in acetonitrile in a 200 mL eggplant-shaped flask, ((2-bromoethoxy)methyl)benzene (11.36 g, 52.8 mmol) was added at room temperature while stirring under an argon atmosphere, and the mixture was stirred at 80°C for 5 hours. After completion of the reaction, the mixture was cooled at room temperature and concentrated under reduced pressure. Saturated sodium bicarbonate water was added to the residue, and the mixture was extracted twice with diisopropyl ether. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was subjected to Yamazen medium-pressure preparation (silica, L (40 g), hexane / ethyl acetate = 95 / 5 (V / V) → 80 / 20 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain U-013-1 (15.11 g, quantitative yield) as a colorless oil.
[1516] 13-2. Synthesis of U-013-2
[1517]
[1518] A 50 mL solution of U-013-1 (2.8 g, 9.95 mmol) and 10% palladium on carbon (1.4 g, 0.658 mmol) in ethanol was added to a 200 mL eggplant-shaped flask and stirred at room temperature under a hydrogen atmosphere for 4 hours. After the reaction, the catalyst was filtered and the reaction solution was concentrated under reduced pressure to obtain U-013-2 (1.90 g, 99.84% yield) as a pale yellow oil.
[1519] 13-3. Synthesis of U-013-3
[1520]
[1521] To a 5 mL solution of U-013-2 (0.19 g, 0.994 mmol) in dichloromethane in a 30 mL cylindrical flask, Dess-Martin periodinane (0.51 g, 1.202 mmol) was added while stirring at room temperature, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, saturated sodium bicarbonate solution was added to the reaction solution, followed by sodium thiosulfate aqueous solution. After stirring at room temperature for 20 minutes, the mixed solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain U-013-3 (162.7 mg, 86.54% yield) as a slightly yellow oil.
[1522] 13-4. Synthesis of U-013-4
[1523]
[1524] In the dichloromethane 5mL solution of MMAE (0.30g, 0.418mmoL) and U-013-3 (0.16g, 0.846mmoL) added to the cylindrical flask of 30mL, sodium triacetoxyborohydride (0.18g, 0.849mmoL) was added at room temperature while stirring under an argon atmosphere, and stirred at room temperature for 2 hours. After completion of the reaction, saturated sodium bicarbonate water was added to the reaction solution, and the mixed solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product of U-013-4 as a yellow solid. The crude product obtained was subjected to Yamazen medium-pressure preparation (silica, M (16 g), ethyl acetate / methanol = 100 / 0 (V / V) → 95 / 5 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain U-013-4 (206.5 mg, yield 55.46%) as a colorless foamy product.
[1525] MS (DUIS) m / z 893 (M+H) +
[1526] 13-5. Synthesis of U-013
[1527]
[1528] To a 0.2 mL solution of U-013-4 (45.3 mg, 0.051 mmol) in dichloromethane in a 30 mL cylindrical flask, 1 mL (4 mmol) of a 4 M hydrogen chloride solution in 1,4-dioxane was added while stirring under an argon atmosphere at room temperature. The mixture was stirred at room temperature for 2 hours. After the reaction, the reaction solution was concentrated under reduced pressure, dissolved in a mixed solvent of water and acetonitrile, and freeze-dried to obtain the hydrochloride salt of U-013 (44.3 mg, quantitative yield) as a slightly yellow foamy substance.
[1529] MS (DUIS) m / z 791 (M+H) +
[1530] Preparation Example 14. Synthesis of U-014
[1531] 14-1. Synthesis of U-014-1
[1532]
[1533] To a 1.8 mL solution of U-011-1 (102.1 mg, 0.125 mmol) and (2R,3R,4S,5R,6S)-2-bromo-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (463.2 mg, 1.17 mmol) in dichloromethane in a 10 mL cylindrical flask, 0.255 mL (233.8 mg, 1.93 mmol) of 2,4,6-trimethylpyridine was added at room temperature. Silver trifluoromethanesulfonate (387.2 mg, 1.93 mmol) was added under an argon atmosphere, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was diluted with ethyl acetate, filtered through Celite 545, and washed with ethyl acetate. The filtrate and washings were washed sequentially with 5% aqueous potassium bisulfate solution, saturated sodium bicarbonate solution, and saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a concentrated residue. Purification under the following conditions afforded U-014-1 (128 mg, 90.4% yield) as a white foam.
[1534] MS (DUIS) m / z 1134 (M+H) +
[1535] Recirculation separation device (YMC): LC Forte / R
[1536] Column (YMC Company): T-30000 ( 50nm) and T-4000( 10nm) and T-2000( 5nm) are connected for use.
[1537] Eluent: ethyl acetate
[1538] Temperature: Room temperature
[1539] 14-2. Synthesis of U-014
[1540]
[1541] In a 100mL eggplant-shaped flask, U-014-1 (166mg, 0.146mmoL) and 0.090mL (83.27mg, 0.777mmoL) of 2,6-lutidine in 5mL of dichloromethane were added, and 0.135mL (166.05mg, 0.747mmoL) of trimethylsilyl trifluoromethanesulfonate was added under ice-cold while stirring under an argon atmosphere. The mixture was stirred for 1 hour under ice-cold. After the reaction was completed, saturated sodium bicarbonate water was added to the reaction solution under ice-cold to separate the liquids. The aqueous layer was extracted with dichloromethane, and the organic layers were combined and dried over anhydrous sodium sulfate to obtain a concentrated residue. Purification was carried out under the conditions shown below, and the fraction containing the target product was concentrated under reduced pressure to obtain a colorless oil. After adding 2 mL of acetonitrile and 5 mL of distilled water, the mixture was freeze-dried to obtain U-014 (43.3 mg, yield 28.61%) as a white powder.
[1542] MS (DUIS) m / z 1034 (M+H) +
[1543] Recirculation separation device (YMC): LC Forte / R
[1544] Column (YMC Company): T-30000 ( 50nm) and T-4000( 10nm) and T-2000( 5nm) are connected for use.
[1545] Eluent: ethyl acetate
[1546] Temperature: Room temperature
[1547] Preparation Example 15. Synthesis of U-015
[1548] 15-1. Synthesis of U-015-1
[1549]
[1550] To a 30 mL solution of U-011-2 (101.3 mg, 0.103 mmol) and 2,5,8,11,14,17,20,23,26,29,32,35-dodeca-heptatriacontane-37-amine (98.1 mg, 0.175 mmol) in dichloromethane was added 0.060 mL of N,N-diisopropylethylamine (44.52 mg, 0.344 mmol) in a 30 mL cylindrical flask. The mixture was stirred at room temperature under an argon atmosphere for 7 hours. After completion of the reaction, the mixture was concentrated under reduced pressure. Isolation and purification were performed under the following conditions. The resulting ethyl acetate solution (150 mL) was washed twice with 50 mL of water and once with 50 mL of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain U-015-1 (91.8 mg, 63.47% yield) as a colorless oil.
[1551] MS (DUIS) m / z 702 (M+2H) 2+
[1552] Recirculation separation device (YMC): LC Forte / R
[1553] Column (YMC Company): T-30000 ( 50nm) and T-4000( 10nm) and T-2000( 5nm) are connected and used.
[1554] Eluent: ethyl acetate
[1555] Temperature: Room temperature
[1556] 15-2. Synthesis of U-015
[1557]
[1558] To a 5 mL dichloromethane solution of U-015-1 (88.2 mg, 0.063 mmol) added to a 50 mL eggplant flask, 0.48 mL of trifluoroacetic acid (714.72 mg, 6.27 mmol) was added under ice-cooling and stirred for 1.25 hours. Thereafter, the mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure. 5 mL of a 0.1% formic acid solution in acetonitrile / water = 1 / 9 (V / V) and 5 mL of a 0.1% formic acid solution in acetonitrile / water = 5 / 5 (V / V) were added to the concentrated residue and freeze-dried to obtain the trifluoroacetate of U-015 (96.1 mg, quantitative yield) as a colorless oil.
[1559] MS (ESI) m / z 1304 (M+H)+
[1560] Preparation Example 16. Synthesis of U-016
[1561] 16-1. Synthesis of U-016-1
[1562]
[1563] To a 2.5 mL solution of tert-butyl (3-fluoro-4-(2-oxoethyl)phenyl)carbamate (57.0 mg, 0.225 mmol) and MMAE (106.3 mg, 0.148 mmol) in dichloromethane in a 50 mL eggplant-shaped flask was added 0.015 mL (15.83 mg, 0.264 mmol), and then sodium triacetoxyborohydride (65.0 mg, 0.307 mmol) was added while stirring under an argon atmosphere under ice-cooling, and the mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the reaction solution was diluted with 5 mL of ethyl acetate, 3 mL of saturated sodium bicarbonate solution was added, and after stirring at room temperature for a while, the mixture was separated. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The concentrated residue was dissolved in hexane / ethyl acetate = 50 / 50 (V / V) and applied to Fuji SILYSIA Chromatorex Q-Pack DIOL60 Size 10. Elution was performed using hexane / ethyl acetate = 50 / 50 (V / V) → 19 / 81 (V / V). The fractions containing the target product were concentrated under reduced pressure to obtain U-016-1 (140.2 mg, 99.13% yield) as a white foamy product.
[1564] MS (ESI) m / z 955 (M+H) +
[1565] 16-2. Synthesis of U-016
[1566]
[1567] To a 3.6 mL solution of U-016-1 (136 mg, 0.142 mmol) in dichloromethane added to a 50 mL eggplant-shaped flask, 0.545 mL (811.51 mg, 7.12 mmol) of trifluoroacetic acid was added under ice-cold conditions while stirring under an argon atmosphere. The mixture was then stirred under ice-cold conditions for 0.5 hours. Thereafter, the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure, 5 mL of dichloromethane and 5 mL of saturated sodium bicarbonate water were added, the liquids were separated, the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a concentrated residue. Separation and purification were performed under the following conditions, and the obtained components were concentrated under reduced pressure to obtain U-016 (93.9 mg, yield 77.13%) as a white foam.
[1568] MS (ESI) m / z 855 (M+H) +
[1569] Recirculation separation device (YMC): LC Forte / R
[1570] Column (YMC Company): T-30000 ( 50nm) and T-4000( 10nm) and T-2000( 5nm) are connected and used.
[1571] Eluent: acetonitrile
[1572] Temperature: Room temperature
[1573] Preparation Example 17. Synthesis of U-017
[1574] 17-1. Synthesis of U-017-1
[1575]
[1576] In the methylene chloride 1mL solution of MMAE (71.8mg, 0.100mmoL) and 4-oxobutanoic acid methyl ester (34.8mg, 0.300mmoL) added in the cylindrical flask of 30mL, while stirring under argon atmosphere, sodium triacetoxyborohydride (63.6mg, 0.300mmoL) was added at room temperature, stirred at room temperature for 1 hour. After the reaction was completed, saturated sodium bicarbonate water was added in the reaction solution, and the mixed solutions were extracted with ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product of U-017-1 as a yellow solid. The obtained solid was subjected to Yamazen medium-pressure preparation (silica, M (16 g), dichloroethane / methanol = 100 / 0 (V / V) → 90 / 10 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain U-017-1 (20.2 mg, yield 24.69%) as a colorless foamy product.
[1577] 17-2. Synthesis of U-017
[1578]
[1579] To a 0.4 mL solution of U-017-1 (20.2 mg, 0.025 mmol) in ethanol placed in a 10 mL cylindrical flask, 0.050 mL (4 mg, 0.100 mmol) of a 2 N aqueous sodium hydroxide solution was added while stirring under an argon atmosphere at room temperature, and the mixture was stirred at room temperature for 2 hours. After neutralization with 0.2 mL of 2 N hydrochloric acid, the solvent was distilled off under reduced pressure. To the resulting residue was added 0.4 mL of N,N-dimethylformamide, followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (7.5 mg, 0.039 mmol), 1-hydroxybenzotriazole (6.5 mg, 0.042 mmol), exitecan mesylate (13.1 mg, 0.025 mmol), and 0.01 mL (7.26 mg, 0.072 mmol) of triethylamine, and the mixture was stirred at room temperature for 14 hours. After the reaction, water was added to the reaction solution, and ethyl acetate was added for separation. The insoluble matter was filtered, and the organic layer was subjected to Yamazen medium-pressure preparation (silica, S (7 g), dichloroethane / methanol = 90 / 10 (V / V) → 80 / 20 (V / V)). The fraction containing the target product (Rf value = 0.4 (dichloroethane / methanol = 90 / 10 (V / V))) was concentrated under reduced pressure. The resulting residue was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target product was neutralized with saturated sodium bicarbonate water and concentrated under reduced pressure. Water was added to the residue, and the residue was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and then dissolved in water / acetonitrile and freeze-dried to obtain U-017 (3.8 mg, yield 12.6%) as a colorless solid.
[1580] MS (DUIS) m / z 1222 (M+H) +
[1581] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1582] Flow rate: 17 mL / min.
[1583] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1584] Gradient (Solution B): 30% (0.00 min.) → 50% (10.00 min.)
[1585] Preparation Example 18. Synthesis of U-018
[1586] 18-1. Synthesis of U-018-1
[1587]
[1588] To a 0.4 mL solution of U-011-2 (61.5 mg, 0.063 mmol) in dichloromethane in a 20 mL cylindrical flask, 0.008 mL (6.88 mg, 0.125 mmol) of prop-2-yn-1-amine was added at room temperature while stirring under an argon stream, and the mixture was stirred at room temperature for 3 hours. The resulting residue was subjected to Yamazen medium-pressure preparation (Rf value = 0.25 (hexane / ethyl acetate = 20 / 80 (V / V)) (silica, M (16 g))), and the fraction containing the target product was concentrated under reduced pressure to obtain U-018-1 (57.6 mg, quantitative yield) as a white solid.
[1589] MS (ESI) m / z 900 (M+H) +
[1590] 18-2. Synthesis of U-018-2
[1591]
[1592] To a 0.2 mL solution of U-018-1 (67.6 mg, 0.075 mmol) in dichloromethane in a 20 mL cylindrical flask, 0.064 mL of trifluoroacetic acid (95.36 mg, 0.836 mmol) was added while stirring under an argon stream at room temperature. The mixture was stirred at room temperature for 3 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, and the resulting residue was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target compound was concentrated under reduced pressure to obtain U-018-2 (17.2 mg, 28.63% yield) as a white solid.
[1593] MS (ESI) m / z 799 (M+H) +
[1594] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1595] Flow rate: 17 mL / min.
[1596] Elution solvent: 0.1% formic acid in water (Solution A) → 0.1% formic acid in acetonitrile (Solution B)
[1597] Gradient (Solution B): 20% (0.00 min.) → 95% (10.00 min.)
[1598] 18-3. Synthesis of U-018
[1599]
[1600] To a 0.1 mL solution of U-018-2 (8.8 mg, 0.011 mmol) in water in a 20 mL cylindrical flask, (2R,3R,4S,5S,6R)-2-azido-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (3.8 mg, 3.09 μmol), copper (II) sulfate pentahydrate (3.5 mg, 0.022 mmol), and sodium ascorbate (7.1 mg, 0.033 mmol) were added while stirring at room temperature under an argon stream. The mixture was stirred at room temperature for 5 minutes. The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target compound was freeze-dried to obtain U-018 (3.1 mg, 28.03% yield) as a white solid.
[1601] MS (DUIS) m / z 1046 (M+HCOO) -
[1602] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1603] Flow rate: 17 mL / min.
[1604] Elution solvent: 0.1% formic acid aqueous solution (solution A) - 0.1% formic acid acetonitrile solution (solution B)
[1605] Gradient (Solution B): 20% (0.00 min.) → 61% (6.00 min.)
[1606] Preparation Example 19. Synthesis of U-019
[1607]
[1608] To a 0.2 mL solution of Production Example 18-1 (U-018-1) (8.2 mg, 10.26 μmoL) in water in a 10 mL cylindrical flask, (2R,3R,4S,5S,6R)-6-azido-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (2.8 mg, 0.013 mmol), copper (II) sulfate pentahydrate (2.0 mg, 0.013 mmol), and sodium ascorbate (3.5 mg, 0.016 mmol) were added while stirring at room temperature under an argon stream, and the mixture was stirred at room temperature for 5 minutes. The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was freeze-dried to obtain U-019 (5.4 mg, 51.68% yield) as a white solid.
[1609] MS (ESI) m / z 1016 (MH) -
[1610] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1611] Flow rate: 17 mL / min.
[1612] Elution solvent: 0.1% formic acid aqueous solution (solution A)-0.1% formic acid acetonitrile solution (solution B)
[1613] Gradient (Solution B): 20% (0.00 min.) → 61% (7.00 min.)
[1614] Preparation Example 20. Synthesis of U-020
[1615] 20-1. Synthesis of U-020-1
[1616]
[1617] To a 0.2 mL solution of U-011-2 (50.0 mg, 0.051 mmol) in dichloromethane in a 20 mL cylindrical flask, 0.00587 mL (5.71 mg, 0.102 mmol) of prop-2-yn-1-ol was added while stirring under an argon stream at room temperature, and the mixture was stirred at room temperature for 45 minutes. Subsequently, 4-dimethylaminopyridine (0.8 mg, 6.55 μmol) was added while stirring at room temperature, and the mixture was stirred at room temperature for 2.5 hours. Subsequently, 0.00587 mL (5.71 mg, 0.102 mmol) of prop-2-yn-1-ol was added, and the mixture was stirred for 14 hours. The obtained residue was subjected to Yamazen medium pressure preparation (Rf value = 0.3 (hexane / ethyl acetate = 20 / 80 (V / V) (silica, M (16 g))), and the fraction containing the target product was concentrated under reduced pressure to obtain U-020-1 (37.8 mg, yield 82.57%) as a white solid.
[1618] MS (ESI) m / z 900 (M+H) +
[1619] 20-2. Synthesis of U-020-2
[1620]
[1621] To a 0.2 mL solution of U-020-1 (36.8 mg, 0.041 mmol) in dichloromethane in a 20 mL cylindrical flask, 0.069 mL (102.81 mg, 0.902 mmol) of trifluoroacetic acid was added while stirring under an argon stream at room temperature, and the mixture was stirred at room temperature for 2.5 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, and the resulting residue was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target product was concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain U-020-2 (18.2 mg, 55.65% yield) as a white solid.
[1622] MS (ESI) m / z 800 (M+H) +
[1623] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1624] Flow rate: 17 mL / min.
[1625] Elution solvent: 0.1% formic acid aqueous solution (solution A)-0.1% formic acid acetonitrile solution (solution B)
[1626] Gradient (Solution B): 20% (0.00 min.) → 75% (6.50 min.)
[1627] 20-3. Synthesis of U-020
[1628]
[1629] To a 0.3 mL solution of U-020-2 (5.8 mg, 7.25 μmol) in water in a 20 mL cylindrical flask, (2R,3R,4S,5S,6R)-6-azido-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (2.3 mg, 10.49 μmol), copper (II) sulfate pentahydrate (0.6 mg, 2.403 μmol), and sodium ascorbate (0.8 mg, 3.77 μmol) were added while stirring at room temperature under an argon stream, and the mixture was stirred overnight at room temperature. The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was freeze-dried to obtain U-020 (6.3 mg, 85.26% yield) as a white solid.
[1630] MS (ESI) m / z 1020 (M+H) +
[1631] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1632] Flow rate: 17 mL / min.
[1633] Elution solvent: 0.1% formic acid aqueous solution (solution A)-0.1% formic acid acetonitrile solution (solution B)
[1634] Gradient (Solution B): 20% (0.00 min.) → 61% (6.00 min.)
[1635] Preparation Example 21. Synthesis of U-021
[1636] 21-1. Synthesis of U-021-1
[1637]
[1638] To a 20 mL solution of U-011-2 (25 mg, 0.025 mmol) in dichloromethane was added 2 mL, (1H-1,2,3-triazol-4-yl)methylamine hydrochloride (7.0 mg, 0.052 mmol) and 0.00354 mL (2.57 mg, 0.025 mmol) of triethylamine were added at room temperature while stirring under an argon stream, and the mixture was stirred at room temperature for 1 hour. Subsequently, 1 mL of N,N-dimethylformamide was added and stirred for 1 hour. After the reaction was completed, water was added to the reaction solution, and the mixed solution was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product of U-021-1. The product was not further purified and entered the next step.
[1639] MS (ESI) m / z 942 (M+H) +
[1640] 21-2. Synthesis of U-021
[1641]
[1642] To a 0.5 mL solution of crude U-021-1 (284 mg (8.5% content)) in dichloromethane in a 20 mL cylindrical flask, 0.10 mL (149 mg, 1.307 mmol) of trifluoroacetic acid was added while stirring under an argon stream at room temperature, and the mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting residue was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target product was concentrated under reduced pressure to remove acetonitrile, and then freeze-dried to obtain the trifluoroacetate salt of U-021 (8.8 mg) as a white solid.
[1643] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1644] Flow rate: 17 mL / min.
[1645] Elution solvent: 0.1% formic acid aqueous solution (solution A) - 0.1% formic acid acetonitrile solution (solution B)
[1646] Gradient (solution B): 5% (0.00 min.) → 95% (10.50 min.)
[1647] The obtained solid was dissolved in dichloromethane, washed with aqueous sodium bicarbonate solution and saturated brine, and dried over anhydrous sodium sulfate. The obtained residue was concentrated under reduced pressure to obtain U-021 (7.0 mg, total yield of 21-1 and 21-2: 32.63%) as a white solid.
[1648] MS (ESI) m / z 840 (MH) -
[1649] Preparation Example 22. Synthesis of U-022
[1650] 22-1. Synthesis of U-022-1
[1651]
[1652] To a 6 mL toluene solution of U-011-1 (400 mg, 0.489 mmol) in a 50 mL eggplant-shaped flask, 0.11 mL (173.8 mg, 1.461 mmol), tetrabutylammonium bromide (33.2 mg, 0.103 mmol), and 0.061 mL (19.52 mg, 0.488 mmol) of 8 equivalents of sodium hydroxide were added while stirring at room temperature under an argon stream. The mixture was stirred at room temperature for 6 hours. After completion of the reaction, saturated aqueous ammonium chloride was added to the reaction solution, and the mixed solution was extracted with dichloromethane. The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target compound was concentrated under reduced pressure to obtain U-022-1 (142.1 mg, 33.95% yield) as a white solid.
[1653] MS (ESI) m / z 857 (M+H) +
[1654] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1655] Flow rate: 17 mL / min.
[1656] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1657] Gradient (Solution B): 50% (0.00 min.) → 100% (10.00 min.)
[1658] 22-2. Synthesis of U-022-2
[1659]
[1660] To a 0.4 mL solution of U-022-1 (142.1 mg, 0.166 mmol) in dichloromethane in a 20 mL cylindrical flask, 0.254 mL (378 mg, 3.32 mmol) of trifluoroacetic acid was added while stirring under an argon stream at room temperature, and the mixture was stirred at room temperature for 20 hours. After completion of the reaction, the mixture was neutralized with triethylamine and concentrated under reduced pressure. The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was concentrated under reduced pressure. After distilling off the acetonitrile, the mixture was freeze-dried to obtain U-022-2 (69.6 mg, 55.47% yield) as a white solid.
[1661] MS (DUIS) m / z 757 (M+H) +
[1662] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1663] Flow rate: 17 mL / min.
[1664] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1665] Gradient (Solution B): 0% (0.00 min.) → 50% (10.00 min.)
[1666] 22-3. Synthesis of U-022
[1667]
[1668] To a 1 mL solution of U-022-2 (30 mg, 0.040 mmol) in water in a 30 mL cylindrical flask, (2S,3S,4S,5R,6R)-6-azido-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (11.2 mg, 0.051 mmol), copper sulfate pentahydrate (3.1 mg, 0.012 mmol), and sodium ascorbate (12.7 mg, 0.060 mmol) were added while stirring at room temperature under an argon stream, and the mixture was stirred at room temperature for 15 hours. The resulting residue was subjected to the following conditions, and the fraction containing the target product was concentrated under reduced pressure to obtain crude U-022 as a yellow solid.
[1669] Column: Waters XSelect HSS C18 SB OBD 5μm ODB 19*150mm
[1670] Flow rate: 17 mL / min.
[1671] Elution solvent:
[1672] 0.1% formic acid aqueous solution / acetonitrile with 0.1% formic acid added = 90 / 10 (Solution A)
[1673] 0.1% formic acid aqueous solution / acetonitrile with 0.1% formic acid added = 10 / 90 (Solution B)
[1674] Gradient (Solution B): 0% (0.00 min.) → 0% (5.00 min.) → 50% (5.10 min.) → 50% (20.00 min.)
[1675] The obtained crude product of U-022 was purified under the conditions shown below, and the obtained residue was freeze-dried to obtain U-022 (18.8 mg, yield 37.72%) as a white solid.
[1676] MS (ESI) m / z 976 (M+H) +
[1677] Column: Asahipak GS-510-20G, GS-310-20G, GS-310-20G (three connected) Shodex Co., Ltd. 20*500mm, 13μm
[1678] Flow rate: 7.5 mL / min.
[1679] Elution solvent: 0.1% formic acid / 0.1% formic acid in acetonitrile = 90 / 10
[1680] Detection wavelength: 254nm
[1681] Preparation Example 23. Synthesis of U-023
[1682] 23-1. Synthesis of U-023-1
[1683]
[1684] To a solution of (2S,3S,4S,5R,6S)-2-(methoxycarbonyl)-6-(4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-3,4,5-tolyl triacetate (0.7982 g, 1.318 mmol) in dichloromethane 8 mL in a 50 mL eggplant-shaped flask, 1.20 mL (0.86 g, 6.89 mmol) of N,N-diisopropylethylamine and 2-(methylsulfonyl)ethane-1-amine hydrochloride (0.2105 g, 1.319 mmol) were added sequentially at room temperature while stirring under an argon atmosphere, and the mixture was stirred at room temperature for 72 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the residue was diluted with 30 mL of ethyl acetate, washed five times with 10 mL of saturated sodium bicarbonate water, then washed with 20 mL of saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was subjected to Yamazen medium-pressure preparation (silica, L (40 g), hexane / ethyl acetate = 10 / 90 (V / V), (Rf = 0.51 (hexane / ethyl acetate = 10 / 90 (V / V)))), and the fraction containing the target compound was concentrated under reduced pressure to obtain U-023-1 (677.8 mg, yield 87.21%) as a white foam.
[1685] MS (ESI) m / z 635 (M+HCOOH) +
[1686] 23-2. Synthesis of U-023-2
[1687]
[1688] To a 1.5 mL solution of U-023-1 (100.3 mg, 0.170 mmol) in dichloromethane in a 20 mL cylindrical flask, paraformaldehyde (9.30 mg, 0.310 mmol) and 33 μL of trimethylsilyl chloride (28.25 mg, 0.260 mmol) were added sequentially at room temperature while stirring under an argon atmosphere. The mixture was stirred at room temperature for 5 hours. The reaction mixture was filtered, washed with dichloromethane, and the filtrate was concentrated under reduced pressure at room temperature to obtain U-023-2 (107.1 mg, 98.67% yield) as a white foam.
[1689] MS (ESI) m / z 651 (M+H2O) +
[1690] 23-3. Synthesis of U-023-3
[1691]
[1692] To a 0.5 mL dichloromethane solution of U-011-1 (100.8 mg, 0.123 mmol) placed in a 20 mL cylindrical flask, 150 μL (111.3 mg, 0.861 mmol) of N,N-diisopropylethylamine and a 1 mL dichloromethane solution of U-023-2 (108.55 mg, 0.170 mmol) were added sequentially at room temperature while stirring under an argon atmosphere. The mixture was stirred at room temperature for 22.5 hours. Subsequently, 110 μL (101.2 mg, 0.835 mmol) of 2,4,6-collidine was added at room temperature, followed by a 2 mL dichloromethane solution of U-023-2 (171.3 mg, 0.268 mmol). After stirring at room temperature for 21 hours, nitrogen was purged through the reaction mixture to distill off the solvent. After adding 0.75 mL of dichloromethane, 250 μL (185.5 mg, 1.435 mmol) of N,N-diisopropylethylamine was added, and the mixture was stirred at room temperature for 2 hours. The mixture was then ice-cooled, and a 3 mL solution of U-023-2 (446.7 mg, 0.700 mmol) in dichloromethane was added dropwise. After the addition was complete, the mixture was returned to room temperature and stirred for 18 hours. The reaction solution was concentrated, diluted with ethyl acetate, and washed sequentially with a 5% by weight aqueous potassium bisulfate solution, saturated sodium bicarbonate solution, and saturated brine. The mixture was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to Yamazen medium-pressure preparation (Fuji SILYSIA Chromatorex Q-Pack DIOL60 Size 60, hexane / ethyl acetate = 30 / 70 (V / V)) (Rf = 0.30 (hexane / ethyl acetate = 30 / 70 (V / V)))), and the fraction containing the target product was concentrated under reduced pressure to obtain a crude product of U-023-3 as a white foamy product.
[1693] The obtained white foamy product was purified under the following conditions to obtain U-023-3 (46.0 mg, yield 26.3%) as a white solid.
[1694] MS (ESI) m / z 1420 (M+H) +
[1695] Column: YMC-GPC T-30000, T-4000, T-2000 (three connected) 21.2*600mm, 10μm
[1696] Flow rate: 15 mL / min.
[1697] Elution solvent: ethyl acetate
[1698] Temperature: Room temperature
[1699] Detection wavelength: 254, 285nm
[1700] 23-4. Synthesis of U-023-4
[1701]
[1702] To a 20 mL dichloromethane solution of U-023-3 (43.2 mg, 0.030 mmol) and 160 μL of 2,6-lutidine (143 mg, 1.381 mmol) was added under ice-cold conditions while stirring under an argon atmosphere. The mixture was stirred under ice-cold conditions for 20 hours. Subsequently, 20 mL of saturated sodium bicarbonate solution was added to the reaction mixture under ice-cold conditions. After stirring at room temperature for a while, dichloromethane was added for extraction. The aqueous layer was extracted with dichloromethane, and the combined organic layers were dried over anhydrous sodium sulfate and concentrated. Purification was performed under the following conditions, and the fraction containing the target compound was concentrated under reduced pressure to yield a white foamy product. After adding 2 mL of acetonitrile and 4 mL of distilled water, the mixture was freeze-dried to obtain U-023-4 (18.3 mg, yield 45.58%) as a white powder.
[1703] MS (ESI) m / z 1320 (M+H) +
[1704] Column: Asahipak GS-510-20G, GS-310-20G, GS-310-20G (three connected) (Shodex) 20*500mm, 13μm
[1705] Flow rate: 17 mL / min.
[1706] Elution solvent: acetonitrile
[1707] Detection wavelength: 220nm
[1708] 23-5. Synthesis of U-023
[1709]
[1710] To a 4 mL methanol solution of U-023-4 (17.1 mg, 0.013 mmol) in a 20 mL eggplant flask, 52 μL (1.25 mg, 0.052 mmol) of 1 equivalent of lithium hydroxide was added while stirring at room temperature under ice-cooling in an air atmosphere. The mixture was returned to room temperature and stirred for 9.5 hours. Subsequently, 4 mL (12.61 mg, 0.200 mmol) of a 50 mM aqueous solution of ammonium formate was added. Purification was performed under the conditions shown below, and the fraction containing the target product was concentrated under reduced pressure. After adding 15 mL of acetonitrile to the concentrated residue, it was freeze-dried to obtain U-023 (13.10 mg, 85.71% yield) as a white solid.
[1711] MS (ESI) m / z 1180 (M+H) +
[1712] Column: Xselect CSH, Prep Fluoro-Phenyl (Waters)
[1713] 5μm 19*150mm
[1714] Flow rate: 17 mL / min.
[1715] Elution solvent: 10% methanol aqueous solution (solution A) - 90% methanol aqueous solution (solution B)
[1716] Gradient (Solution B): 50% (0.00 min.) → 50% (3.00 min.)
[1717] →62% (9.50 min.)
[1718] Detection wavelength: 220nm
[1719] Preparation Example 24. Synthesis of U-024
[1720]
[1721] To a 1 mL solution of MMAF (0.22 g, 0.301 mmol) in dichloromethane placed in a 30 mL cylindrical flask, 58 μL of methanesulfonic acid (0.09 g, 0.893 mmol) was added at room temperature while stirring under an argon stream, and the mixture was stirred at 60°C for 4 hours. After the reaction was completed, saturated sodium bicarbonate water was added to the reaction solution, and the mixed solution was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was subjected to Yamazen medium pressure preparation (silica, M (16 g), ethyl acetate / methanol = 100 / 0 (V / V) → 60 / 40 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain U-024 (183.9 mg, yield 74.61%) as a colorless foam.
[1722] MS (ESI) m / z 821 (M+H) +
[1723] Preparation Example 25. Synthesis of U-025
[1724] 25-1. Synthesis of U-025-1
[1725]
[1726] To a 1 mL solution of MMAE (43.5 mg, 0.061 mmol) in dichloromethane in a 5 mL sample vial, 10.3 μL (11.01 mg, 0.067 mmol), 5.2 μL (5.49 mg, 0.091 mmol), and sodium triacetoxyborohydride (25.1 mg, 0.118 mmol) were added sequentially while stirring at room temperature. The mixture was then stirred at room temperature for 1.5 hours. After the reaction was completed, 1.5 mL of saturated sodium bicarbonate solution was added dropwise while stirring at room temperature, and the mixture was stirred at room temperature for 30 minutes. The organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and subjected to Yamazen medium-pressure preparation (silica, S (7 g), dichloromethane / 2-propanol = 95 / 5 (V / V)) (Rf = 0.47 (dichloromethane / 2-propanol = 95 / 5 (V / V))), and the fraction containing the target product was concentrated under reduced pressure to obtain U-025-1 (43.8 mg, yield 84.84%) as a white foamy substance.
[1727] MS (ESI) m / z 853 (M+H) +
[1728] 25-2. Synthesis of U-025
[1729]
[1730] To a 2 mL ethanol solution of U-025-1 (43.8 mg, 0.051 mmol) placed in a 50 mL eggplant-shaped flask, 10.94 mg (0.273 mg, 2.57 μmol) of 5% palladium on carbon (ASCA-2 type, 50% water content) was added under a nitrogen atmosphere. After degassing under reduced pressure, the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. Subsequently, 0.2 mL of acetic acid was added, and the mixture was stirred at room temperature for 1 hour. The mixture was then heated and stirred at a bath temperature of 60°C for 4.5 hours. After the reaction was completed, the mixture was allowed to cool, filtered through Celite 545 (trade name), washed with ethanol, and the resulting filtrate was concentrated under reduced pressure. The concentrated residue was diluted with dichloromethane, washed with saturated sodium bicarbonate water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. To the concentrated residue were added 2 mL of acetonitrile and 3 mL of distilled water, followed by freeze-drying to obtain U-025 (34.6 mg, yield 88.34%) as a white solid.
[1731] MS (ESI) m / z 763 (M+H) +
[1732] Preparation Example 26. Synthesis of U-026
[1733]
[1734] To a 1.5 mL solution of MMAE (63.2 mg, 0.088 mmol) in dichloromethane in a 5 mL sample bottle, 8.00 μL (4.49 mg, 0.045 mmol) of a 5.6 M aqueous glutaraldehyde solution, 8.00 μL (8.44 mg, 0.141 mmol), and sodium triacetoxyborohydride (39.6 mg, 0.187 mmol) were added sequentially while stirring at room temperature, and the mixture was stirred at room temperature for 2.5 hours. After the reaction was completed, 2 mL of saturated sodium bicarbonate solution was added dropwise while stirring at room temperature. After the addition was completed, the mixture was stirred at room temperature for 30 minutes. After separating the organic layer, the aqueous layer was extracted with dichloromethane, the combined dichloromethane layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The concentrated residue was purified under the conditions shown below. The fraction containing the target product was concentrated under reduced pressure, dissolved in dichloromethane, added with diethyl ether, and subjected to ultrasonic treatment. The generated solid was filtered, washed with diethyl ether, and dried under reduced pressure to obtain U-026 (36.32 mg, yield 53.9%) as a white solid.
[1735] MS (ESI) m / z 753 (M+2H) 2+
[1736] Column: YMC-GPC T-30000, T-4000, T-2000 (three connected) 21.2*600mm, 10μm
[1737] Flow rate: 15 mL / min.
[1738] Elution solvent: ethyl acetate
[1739] Temperature: Room temperature
[1740] Detection wavelength: 260nm
[1741] Preparation Example 27. Synthesis of U-027
[1742] 27-1. Synthesis of U-027-1
[1743]
[1744] To a 1.3 mL toluene solution of U-011-1 (102.1 mg, 0.125 mmol) added to a 30 mL eggplant-shaped flask, tetrabutylammonium hydrogen sulfate (2.16 mg, 6.36 μmol) and 16 μL of 3-bromoprop-1-ene (22.37 mg, 0.185 mmol) were added at room temperature while stirring under an air atmosphere. Thereafter, 230 μL (345 mg, 4.31 mmol) of a 50 wt% aqueous sodium hydroxide solution was added at room temperature and stirred for 5 hours. After the reaction was completed, 2 mL of toluene and 3 mL of water were added to the reaction solution, stirred, and then separated. The organic layer was washed with 2 mL of water. The organic layer was diluted with ethyl acetate, washed in sequence with 5% potassium hydrogen sulfate aqueous solution, saturated sodium bicarbonate water, and saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a white foamy substance. Dichloromethane was added to the residue to dissolve it, and Yamazen medium-pressure preparation (Chromatorex_COOH_MB 100-40 / 75 (11.0 g), dichloromethane / 2-propanol = 100 / 0 (V / V) → 90 / 10 (V / V), (Rf = 0.90 (dichloromethane / 2-propanol = 80 / 20 (V / V))))) was performed. The fraction containing the target product was concentrated under reduced pressure to obtain a white foamy substance. 2 mL of acetonitrile and 2 mL of ultrapure water were added to the mixture, and the mixture was freeze-dried to obtain U-027-1 (58.3 mg, 54.44% yield) as a white solid.
[1745] MS (ESI) m / z 859 (M+H) +
[1746] 27-2. Synthesis of U-027-2
[1747]
[1748] To a 1 mL solution of U-027-1 (54.6 mg, 0.064 mmol) in tetrahydrofuran in a 20 mL eggplant-shaped flask, 640 μL (39.05 mg, 0.320 mmol) of a 0.5 M solution of 9-BBN in tetrahydrofuran was added while stirring under an argon atmosphere at room temperature, and the mixture was stirred at room temperature for 2.33 hours. Subsequently, 360 μL (21.96 mg, 0.180 mmol) of a 0.5 M solution of 9-BBN in tetrahydrofuran was added at room temperature, and the mixture was stirred at room temperature for 2.33 hours. The mixture was then ice-cooled, 1 mL of methanol was added, the mixture was returned to room temperature, stirred at room temperature for 1 hour, and concentrated under reduced pressure. To the concentrated residue were added 1 mL of tetrahydrofuran, 1 mL of tetrahydrofuran, and 1.0 mL (40 mg, 1.00 mmol) of 1 equivalent of sodium hydroxide, followed by ice cooling. 110 μL (122.1 mg, 1.077 mmol) of a 30% by weight aqueous hydrogen peroxide solution was added, followed by stirring under ice cooling and then stirring at room temperature for 1 hour. Subsequently, 5 mL of water and 5 mL of ethyl acetate were added for separation. The organic layer was washed sequentially with a 5% by weight aqueous potassium hydrogen sulfate solution, saturated sodium bicarbonate solution, and saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a colorless oil. The residue was dissolved in dichloromethane and subjected to Yamazen medium-pressure preparation (Chromatorex_COOH_MB 100-40 / 75 (11.0 g), dichloromethane / 2-propanol = 100 / 0 (V / V) → 90 / 10 (V / V)). Fractions containing the target product were concentrated under reduced pressure to obtain a colorless oil. 1 mL of acetonitrile and 1 mL of ultrapure water were added to the oil, followed by freeze-drying to obtain U-027-2 (39.2 mg, 70.32% yield) as a white solid.
[1749] MS (ESI) m / z 877 (M+H) +
[1750] 27-2. Synthesis of U-027
[1751]
[1752] To a 30 mL dichloromethane solution of U-027-2 (35.6 mg, 0.041 mmol) in a 30 mL eggplant-shaped flask, under an argon atmosphere, 99 μL (91.6 mg, 0.856 mmol) of 2,6-lutidine and 139 μL (171 mg, 0.771 mmol) of trimethylsilyl trifluoromethanesulfonate were added while stirring under ice-cold conditions. The mixture was stirred under ice-cold conditions for 6 hours. 4 mL of dichloromethane and 8 mL of saturated sodium bicarbonate water were added to the reaction mixture under ice-cold conditions to separate the liquids. The aqueous layer was extracted with dichloromethane, and the combined dichloromethane layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow oil. Purification was performed under the following conditions, and the fractions containing the target product were concentrated under reduced pressure. Acetonitrile and water were added to the concentrated residue, and the mixture was freeze-dried to obtain U-027 (21.69 mg, yield 68.79%) as a white solid.
[1753] MS (ESI) m / z 777 (M+H) +
[1754] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1755] Flow rate: 17 mL / min.
[1756] Elution solvent: acetonitrile
[1757] Detection wavelength: 220nm
[1758] Preparation Example 28. Synthesis of U-028
[1759]
[1760] To a 0.3 mL solution of U-022-2 (26.4 mg, 0.035 mmol), 0.095 mL (85.5 mg, 0.048 mmol) of an 11-15% toluene solution of 4-methylbenzenesulfonyl azide, and 2-aminophenol (4.0 mg, 0.037 mmol) in acetonitrile was added a solution of copper (II) acetate (3.2 mg, 0.018 mmol) in a 20 mL cylindrical flask while stirring under an argon stream. After stirring at room temperature for 5 hours, the mixture was allowed to stand for 15 hours. After completion of the reaction, acetonitrile was removed by nitrogen purging, 1 mL of methanol was added, and the mixture was heated to reflux for 2 hours. The obtained residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was concentrated under reduced pressure to remove acetonitrile, followed by freeze-drying to obtain a crude product of U-028 as a white solid.
[1761] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1762] Flow rate: 17 mL / min.
[1763] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1764] Gradient (Solution B): 20% (0.00 min.) → 100% (10.00 min.)
[1765] After purification under the following conditions, the product was freeze-dried to obtain U-028 (2.1 mg, yield 7.53%) as a white solid.
[1766] MS (DUIS) m / z 799 (M+H) +
[1767] Device: LC Forte / R (YMC)
[1768] Column: CHIRALPAK IB (20 x 250 mm, 5 μm) (Dacel Corporation)
[1769] Eluent: MeOH
[1770] Flow rate: 15 mL / min
[1771] Wavelength: 220, 254, 285nm
[1772] Preparation Example 29. Synthesis of U-029
[1773]
[1774] MMAF (49.7 mg, 0.068 mmol) and (S)-(-)-α-amino-γ-butyrolactone hydrochloride (i.e., L-homoserine lactone hydrochloride) (14.1 mg, 0.102 mmol) placed in a 30 mL cylindrical tube were dissolved in 1.0 mL of N,N-dimethylformamide, and 38 μL of triethylamine (27.59 mg, 0.273 mmol) was added. HATU (28.6 mg, 0.075 mmol) was then added at room temperature, and the mixture was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target product was concentrated under reduced pressure to remove the acetonitrile, and then freeze-dried to obtain the formate salt of U-029 (19.6 mg, 33.52% yield) as a colorless foam.
[1775] MS (ESI) m / z 816 (M+H) +
[1776] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1777] Flow rate: 17 mL / min.
[1778] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1779] Gradient (Solution B): 25% (0.00 min.) → 38% (6.00 min.)
[1780] Preparation Example 30. Synthesis of U-030
[1781] 30-1. Synthesis of U-030-1
[1782]
[1783] To a 15 mL solution of MMAE (0.7545 g, 1.051 mmol) in dichloromethane in a 50 mL eggplant-shaped flask, 0.73 mL (0.53 g, 5.24 mmol) of triethylamine and 0.73 mL (1.1 g, 5.25 mmol) of 2,2,2-trifluoroacetic anhydride were added sequentially under ice-cooling while stirring under an argon atmosphere. The mixture was stirred under ice-cooling for 1 hour. Subsequently, 3.8 mL (3.01 g, 94 mmol) of methanol and 0.38 mL (0.28 g, 2.73 mmol) of triethylamine were added sequentially under ice-cooling, and the mixture was stirred under ice-cooling for 1 hour. The mixture was then concentrated under reduced pressure, 30 mL of ethyl acetate was added, and the mixture was washed sequentially with 30 mL of a 5 wt% aqueous potassium bisulfate solution, 30 mL of saturated sodium bicarbonate solution, and 30 mL of saturated brine. The mixture was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. To the residue were added 10 mL of acetonitrile and 8 mL of ultrapure water, followed by freezing and freeze-drying to obtain U-030-1 (0.8320 g, yield 97.27%) as a white solid.
[1784] MS (ESI) m / z 815 (M+H) +
[1785] 30-2. Synthesis of U-030-2
[1786]
[1787] To a 30 mL dichloromethane solution of U-030-1 (0.8011 g, 0.984 mmol) and 1H-tetrazole (0.4840 g, 6.91 mmol) in a 50 mL eggplant-shaped flask, 1.28 mL (1.33 g, 3.85 mmol) of dibenzyl diisopropylphosphonoamidate was added while stirring at room temperature under an argon atmosphere. The mixture was stirred at room temperature for 2 hours. Subsequently, 0.60 mL (0.67 g, 5.87 mmol) of 30 wt% aqueous hydrogen peroxide was added under ice-cooling, and the mixture was stirred under ice-cooling for 1.5 hours.
[1788] Thereafter, 20 mL of a solution prepared by adding saturated sodium bicarbonate water to 100 mL of 12.75 g of sodium thiosulfate was added under ice cooling. The organic layer was separated, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
[1789] The obtained residue was subjected to Yamazen medium pressure preparation (Fuji SILYSIA Chromatorex Q-PACK, DIOL60), dichloromethane / isopropyl alcohol = 99 / 1 (V / V) → 95 / 5 (V / V), and the fraction containing the target product was decompressed to obtain crude U-030-2.
[1790] The obtained crude product was purified under the following conditions, and the fraction containing the target product was concentrated under reduced pressure. 10 mL of acetonitrile and 8 mL of ultrapure water were added to the residue, and the mixture was frozen and freeze-dried to obtain U-030-2 (0.6915 g, yield 65.41%) as a white solid.
[1791] MS (ESI) m / z 1075 (M+H) +
[1792] Device: LC Forte / R (YMC)
[1793] Column: YMC-GPC T-30000, T-4000, T-2000 (three connected) 21.2*600mm, 10μm
[1794] Temperature: Room temperature
[1795] Eluent: acetonitrile
[1796] Flow rate: 25 mL / min
[1797] Wavelength: 220nm
[1798] 30-3. Synthesis of U-030-3
[1799]
[1800] To a 5 mL methanol solution of U-030-2 (331 mg, 0.308 mmol) placed in a 50 mL eggplant-shaped flask, sodium borohydride (34.6 mg, 0.915 mmol) was added under ice-cooling while stirring under an argon atmosphere. The mixture was stirred under ice-cooling for 1.25 hours. Subsequently, sodium borohydride (107.4 mg, 2.838 mmol) was added in three portions under ice-cooling, and the mixture was stirred under ice-cooling for 3 hours.
[1801] After the reaction was completed, 20 mL of dichloromethane and 20 mL of saturated sodium bicarbonate solution were added under ice-cooling, and the organic layer was separated. The aqueous layer was extracted three times with 20 mL of dichloromethane. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain U-030-3 (325 mg, quantitative yield) as a colorless oil.
[1802] MS (ESI) m / z 979 (M+H) +
[1803] 30-4. Synthesis of U-030
[1804]
[1805] To a 30 mL solution of U-030-3 (301 mg, 0.308 mmol) in ethanol in a 100 mL eggplant-shaped flask, 5 wt% palladium carbon STD type (50 wt% water content, 82.3 mg, 0.019 mmol) was added at room temperature while stirring under a nitrogen atmosphere, and the mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere.
[1806] After the reaction, the mixture was filtered through Celite 545 (trade name), washed with ethanol, and concentrated under reduced pressure. Acetonitrile was added to the residue, and the resulting solid was filtered, washed with ice-cold acetonitrile, and dried under reduced pressure to obtain U-030 (220.3 mg, yield 89.72%) as a white solid.
[1807] MS (ESI) m / z 799 (M+H) +
[1808] Preparation Example 31. Synthesis of U-031
[1809]
[1810] To a 1 mL methanol solution of Preparation Example 30 (100.4 mg, 0.126 mmol) and 0.093 mL (101.37 mg, 1.249 mmol) of 37% formaldehyde aqueous solution placed in a 20 mL cylindrical flask, sodium triacetoxyborohydride (77.8 mg, 0.367 mmol) was added at room temperature while stirring under an argon atmosphere, and the mixture was stirred at room temperature for 1 hour.
[1811] After the reaction, the mixture was concentrated under reduced pressure and water was added. The resulting aqueous solution was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was concentrated under reduced pressure to obtain 41.0 mg of a crude purified product of U-031 as a white solid.
[1812] Column: Waters XBridge Prep C18 5μm ODB 19*150mm
[1813] Flow rate: 17 mL / min.
[1814] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1815] Gradient (Solution B): 10% (0.00 min.) → 30% (4.00 min.) → 30% (9.00 min.)
[1816] 41.0 mg of the crude purified product of U-031 obtained was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was freeze-dried to obtain U-031 (29.5 mg, yield 28.87%) as a white solid.
[1817] MS (ESI) m / z 810 (MH) -
[1818] Column: Waters XBridge Prep C18 5μm ODB 19*150mm
[1819] Flow rate: 17 mL / min.
[1820] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1821] Gradient (Solution B): 10% (0.00 min.) → 30% (5.00 min.) → 30% (10.00 min.)
[1822] Production Example 32. U-032
[1823]
[1824] To a 1 mL solution of exitecan mesylate (13.6 mg, 0.026 mmol) in dichloromethane in a 10 mL cylindrical flask, 35 μL of triethylamine (25.41 mg, 0.251 mmol) was added while stirring under an argon stream, and the mixture was ice-cooled. Under ice-cooling, 10 μL of 2,2-difluoroacetic anhydride (16 mg, 0.092 mmol) was added, and the mixture was stirred at 0°C for 2 hours. Subsequently, 17 μL of triethylamine (12.34 mg, 0.122 mmol) and 10 μL of 2,2-difluoroacetic anhydride (16 mg, 0.092 mmol) were added while stirring at room temperature, and the mixture was stirred at room temperature for 1 hour. Subsequently, 100 μL of methanol (79.2 mg, 2.472 mmol) was added while stirring at room temperature, and the mixture was stirred at room temperature for 0.5 hours. Next, 60 μL (43.56 mg, 0.430 mmol) of triethylamine was added at room temperature with stirring, and the mixture was stirred at room temperature for 0.5 hour.
[1825] After the reaction, 2 mL of diethyl ether was added, stirred for 5 minutes, and filtered with a membrane filter. The obtained solid was washed with ethyl acetate and water, and dried under reduced pressure to obtain U-032 (7.9 mg, yield 60.13%) as a pale yellow solid.
[1826] MS (ESI) m / z 514 (M+H) +
[1827] Production Example 33. U-033
[1828] 33-1.U-033-1
[1829]
[1830] To a 12 mL solution of U-032 (419 mg, 0.816 mmol) in dichloromethane in a 100 mL cylindrical flask, 820 μL (760.96 mg, 3.10 mmol) of diallyl N,N-diisopropylphosphoramidite) and 373 mg, 5.32 mmol) were added sequentially at room temperature while stirring under an argon atmosphere. The mixture was stirred at room temperature for 5 hours. Subsequently, 480 μL (532.8 mg, 4.70 mmol) of 30 wt% aqueous hydrogen peroxide was added under ice-cooling, and the mixture was stirred under ice-cooling for 1 hour. Subsequently, 6 mL of a solution prepared by adding 100 mL of water to 20.0 g (80.6 mmol) of sodium thiosulfate pentahydrate and 7.0 g (83.3 mmol) of sodium bicarbonate were added, followed by 6 mL of dichloromethane, and the mixture was separated. The aqueous layer was extracted with 6 mL of dichloromethane, combined with the organic layer, dried over 0.80 g of anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 967 mg of a concentrated residue. A 5% aqueous acetonitrile solution was added to the resulting residue, ultrasonicated, filtered under reduced pressure, and the resulting solid was dried to obtain U-033-1 (250 mg, 45.48% yield) as a brown solid.
[1831] MS (ESI) m / z 1348 (2M+H) +
[1832] 33-2.U-033
[1833]
[1834] To a 5 mL solution of U-033-1 (243 mg, 0.361 mmol) in tetrahydrofuran in a 50 mL eggplant-shaped flask, 84 μL (83.16 mg, 0.776 mmol) of N-methylaniline and tetrakis(triphenylphosphine)palladium (43 mg, 0.037 mmol) were added sequentially at room temperature while stirring under an argon atmosphere, and the mixture was stirred at room temperature for 1 hour.
[1835] After the reaction, 15 mL of tert-butyl methyl ether was added, and the mixture was stirred for 10 minutes. The precipitated solid was filtered, washed with tert-butyl methyl ether, and dried under reduced pressure to obtain 256 mg of crude U-033.
[1836] The resulting solid was dissolved in 15 mL of a 30% aqueous acetonitrile solution containing 2% by weight of ammonium acetate and subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target compound was freeze-dried to obtain U-033 (81 mg, 37.83% yield) as a pale yellow solid. (35905AL-028-2)
[1837] Column: Waters XBridge Prep C18 5μm ODB 19*150mm
[1838] Flow rate: 17 mL / min.
[1839] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1840] Gradient (Solution B): 30% (0.00 min.) → 60% (6.00 min.) → 90% (6.50 min.) → 90% (9.00 min.)
[1841] MS (ESI) m / z 592 (MH) -
[1842] Production Example 34. U-034
[1843]
[1844] To 1 mL of N,N-dimethylformamide containing isotecan mesylate (53.2 mg, 0.100 mmol), 2-(3-hydroxyphenyl)acetic acid (18.3 mg, 0.120 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (38.2 mg, 0.199 mmol), and 1-hydroxybenzotriazole (15.3 mg, 0.100 mmol) in a 10 mL cylindrical flask, 28 μL of triethylamine (20.33 mg, 0.201 mmol) was added at room temperature while stirring under an argon atmosphere, and the mixture was stirred at room temperature for 2 hours.
[1845] After the reaction, the reaction mixture was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target product was concentrated under reduced pressure, and the precipitated solid was collected by filtration and washed with water to obtain U-033 (25.4 mg, yield 44.56%) as a colorless solid.
[1846] MS (ESI) m / z 568 (MH) -
[1847] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1848] Flow rate: 17 mL / min.
[1849] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1850] Gradient (solution B): 50% (0.00 min.) → 95% (5.00 min.)
[1851] Production Example 35. U-035
[1852] 35-1.U-035-1
[1853]
[1854] To a 4 mL solution of DXd (162.6 mg, 0.329 mmol) in N,N-dimethylformamide in a 50 mL eggplant-shaped flask, 29.0 μL of trifluoromethanesulfonic acid (49.3 mg, 0.329 mmol) was added while stirring at room temperature under an argon atmosphere. The mixture was stirred at room temperature for 30 minutes. Subsequently, 350 μL of diallyl N,N-diisopropylphosphoramidite (324.8 mg, 1.324 mmol) and 1H-tetrazole (163.7 mg, 2.337 mmol) were added at room temperature, and the mixture was stirred at room temperature for 2 hours.
[1855] Then, 270 μL (253.8 mg, 1.971 mmol) of a 70% aqueous solution of tert-butyl peroxide was added at room temperature, and the mixture was stirred at room temperature for 1.5 hours.
[1856] Then, 40 mL of diethyl ether was added to the reaction solution, and the mixture was stirred for a while under ice-cooling. The generated solid was filtered, washed with diethyl ether, and dried under reduced pressure to obtain the trifluoromethanesulfonate of U-035-1 (249.6 mg, yield 94.26%) as a light brown solid.
[1857] MS (ESI) m / z 654 (M+H) +
[1858] 35-2.U-035
[1859]
[1860] In a 20 mL eggplant-shaped flask, to a 5 mL solution of the trifluoromethanesulfonate salt of U-035-1 (51.4 mg, 0.064 mmol) in tetrahydrofuran, 22 μL of N-methylaniline (21.78 mg, 0.203 mmol) and tetrakis(triphenylphosphine)palladium (10.4 mg, 9.00 μmol) were added sequentially while stirring at room temperature under an argon atmosphere. The mixture was stirred at room temperature for 1.25 hours. Subsequently, tetrakis(triphenylphosphine)palladium (27.9 mg, 0.024 mmol) was added, followed by 0.5 mL of N,N-dimethylformamide, and the mixture was stirred at room temperature for 0.75 hours.
[1861] The reaction mixture was concentrated under reduced pressure, diethyl ether was added to the concentrated residue, and the mixture was sonicated. The generated solid was collected by filtration, washed with diethyl ether, and dried under reduced pressure to obtain a gray-brown solid (55.2 mg).
[1862] The obtained gray-brown solid was subjected to the recycling separation shown below, and the fraction containing the target product was freeze-dried to obtain U-035 (6.4 mg, yield 17.45%) as a light yellow solid.
[1863] MS (ESI) m / z 574 (M+H) +
[1864] Device: LC Forte / R (YMC)
[1865] Column: Xbridege C18, 30x150mm, 5um
[1866] Eluent: 0.1% formic acid in water (solution A) - 0.1% formic acid in acetonitrile (solution B)
[1867] Solution composition (Solution B): 30%
[1868] Flow rate: 25 mL / min, 21 MPa
[1869] Wavelength: 254nm
[1870] Production Example 36. U-036
[1871]
[1872] To a solution of N-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-ethylglycine (15,06 mg, 0.046 mmol) in 0.6 mL of N,N-dimethylformamide in a 20 mL cylindrical flask, HATU (17,60 mg, 0.046 mmol) and 0.022 mL (16.32 mg, 0.126 mmol) of N,N-diisopropylethylamine were added at room temperature while stirring under an argon stream, and the mixture was stirred at room temperature for 15 minutes.
[1873] Next, exitecan mesylate (21.7 mg, 0.042 mmol) was added at room temperature with stirring, and the mixture was stirred at room temperature for 1 hour.
[1874] Next, 4,16 μL (3.58 mg, 0.042 mmol) of piperidine was added at room temperature with stirring, and the mixture was stirred at room temperature for 3 hours.
[1875] The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target compound (Rt around 7.5 min.) was freeze-dried to obtain U-036 formate (6.9 mg, yield 31.5%) as a white solid.
[1876] MS (ESI) m / z 521 (M+H)+
[1877] Column: Waters XBridge Prep C18 5μm ODB 19*150mm
[1878] Flow rate: 17 mL / min.
[1879] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1880] Gradient (Solution B): 15% (0.00 min.) → 55% (10.00 min.)
[1881] Synthesis of Reference Example 1
[1882]
[1883] Reference Example 1-1
[1884]
[1885] (S)-(-)-α-amino-γ-butyrolactone hydrochloride (i.e., L-homoserine lactone hydrochloride) (1.75 g, 12.72 mmol) was dissolved in 60 mL of N,N-dimethylformamide in a 200 mL eggplant-shaped flask. Fmoc-(L)-Asp-tert-butyl (5.23 g, 12.71 mmol) was then added, along with 3.65 mL (2.65 g, 26.2 mmol) of triethylamine. HATU (4.83 g, 12.70 mmol) was then added at room temperature, and the mixture was stirred at room temperature for 2 hours. After the reaction was completed, water was added to the reaction solution, and the mixed solution was extracted twice with ethyl acetate. The organic layer was concentrated under reduced pressure to obtain the title compound (6.16 g, 97.9% yield) as a colorless oil.
[1886] Reference Example 1-2
[1887]
[1888] Reference Example 1-1 (6.16 g, 12.46 mmol) placed in a 500 mL eggplant-shaped flask was dissolved in 60 mL of dichloromethane, followed by the addition of 60 mL of trifluoroacetic acid (1.421 g, 12.46 mmol). The mixture was stirred at room temperature for 2 hours. After completion of the reaction, the solvent was distilled off under reduced pressure. The resulting residue was dissolved in 50 mL of acetonitrile, and 50 mL of ethyl acetate was added. The precipitated solid was filtered and washed with ethyl acetate to obtain the title compound (3.86 g, 70.68% yield) as a colorless solid.
[1889] MS (ESI) m / z 439 (M+H)+
[1890] Reference Example 1-3
[1891]
[1892] To a solution of Reference Example 1-2 (298 mg, 0.680 mmol) in 4 mL of N,N-dimethylformamide in a 30 mL cylindrical flask, 0.270 mL (232.2 mg, 2.73 mmol) of piperidine was added at room temperature while stirring under an argon stream, and the mixture was stirred at room temperature for 1 hour.
[1893] After the reaction was completed, xylene was added and the solvent was removed under reduced pressure.
[1894] 4 mL of diethyl ether and 8 mL of ethyl acetate were added to the residue, and the mixture was sonicated. The solid was collected by filtration. A 20% aqueous acetonitrile solution was added to the collected solid, and the mixture was concentrated under reduced pressure.
[1895] Ethyl acetate was added to the obtained residue, followed by filtration. Diethyl ether was added to the obtained solid, followed by filtration and drying under reduced pressure to obtain the title compound (143 mg, yield 97.32%) as a white solid.
[1896] MS (ESI) m / z 215 (MH) -
[1897] Reference Example 1-4
[1898]
[1899] To a 30 mL solution of Fmoc-(L)-Val-(L)-Cit-PAB-PNP (Angene) (292.7 mg, 0.382 mmol), MMAE (MedChemExpress) (259.7 mg, 0.362 mmol), and 1-hydroxy-7-azabenzotriazole (56.3 mg, 0.414 mmol) in N,N-dimethylformamide was added 70 μL of N,N-diisopropylethylamine (51.94 mg, 0.402 mmol) while stirring under a nitrogen atmosphere. The mixture was stirred at room temperature for 19.5 hours. After completion of the reaction, the solvent was distilled off under reduced pressure. 20 mL of diethyl ether was added to the resulting residue, and the precipitated solid was filtered, washed with water, and then with diethyl ether to obtain the title compound (415.8 mg, 85.43% yield) as a beige solid.
[1900] MS (DUIS) m / z 673 (M+2H) 2+
[1901] Reference Example 1-5
[1902]
[1903] To a 5 mL solution of Reference Example 1-4 (414.7 mg, 0.308 mmol) in N,N-dimethylformamide in a 30 mL eggplant-shaped flask, 0.244 mL of piperidine (210 mg, 2.465 mmol) was added at room temperature, followed by stirring at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was dissolved by adding ethyl acetate, acetonitrile, and dichloromethane. Diethyl ether was then added and ultrasonicated. The resulting solid was filtered, washed with diethyl ether, and dried under reduced pressure to obtain the title compound (280.3 mg, 80.96% yield) as a pale yellow solid.
[1904] MS (ESI) m / z 1124 (M+H) +
[1905] Reference Example 1-6
[1906]
[1907] To a 5 mL solution of Reference Example 1-2 (130.1 mg, 0.297 mmol) and Reference Example 1-5 (309 mg, 0.275 mmol) in N,N-dimethylformamide in a 30 mL cylindrical flask, 41 μL (29.77 mg, 0.294 mmol) of triethylamine was added at room temperature, followed by HATU (112.9 mg, 0.297 mmol) and stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and dichloromethane and 2-propanol were added, followed by further concentration under reduced pressure. 10 mL of acetonitrile and 10 mL of water were added, and after ultrasonic treatment, the resulting solid was collected by filtration, washed with 10 mL of acetonitrile / water (1 / 1 (V / V)), and then washed with 20 mL of diethyl ether. The resulting solid was dried under reduced pressure to obtain the title compound (342.3 mg, 80.61% yield) as a white solid.
[1908] MS (ESI) m / z 773 (M+2H) 2+
[1909] Reference Example 1-7
[1910]
[1911] To a 450 μL solution of N,N-dimethylformamide of Reference Example 1-6 (49.7 mg, 0.032 mmol) added to a 10 mL eggplant-shaped flask, 10 μL of piperidine (8.62 mg, 0.101 mmol) was added at room temperature while stirring under an argon stream. After stirring at room temperature for 50 minutes, the solvent was removed under reduced pressure, and the mixture was washed with 10 mL of diethyl ether. The obtained solid was dried under reduced pressure to obtain the labeled compound (36.4 mg, yield 85.56%) as a white solid.
[1912] MS (ESI) m / z 1323 (M+H) +
[1913] Reference Example 1
[1914]
[1915] To a 0.4 mL solution of Reference Example 1-7 (10.0 mg, 7.57 μmoL) in N,N-dimethylformamide in a 5 mL cylindrical flask, a 400 μL solution of 1-maleimide-3-oxo-7,10,13,16-tetraoxa-4-azanonadecanoic acid N-succinimidyl ester (8.2 mg, 0.027 mmol) in acetonitrile was added while stirring under an argon atmosphere, and the mixture was stirred at room temperature for 1 hour.
[1916] The obtained reaction solution was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was freeze-dried to obtain Reference Example 1 (3.2 mg, yield 24.59%) as a white solid.
[1917] MS (ESI) m / z 861 (M+2H) 2 +
[1918] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1919] Flow rate: 17 mL / min.
[1920] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1921] Gradient (Solution B): 40% (0.00 min.) → 90% (10.00 min.)
[1922] Synthesis of Reference Example 2
[1923]
[1924] Reference Example 2-1
[1925]
[1926] (L)-Val-(L)-Cit-PAB (Angene) (1.90 g, 5.01 mmol) and Reference Example 1-2 (2.24 g, 5.11 mmol) were placed in a 200 mL eggplant flask and suspended in 50 mL of N,N-dimethylformamide. 0.71 mL (0.52 g, 5.09 mmol) of triethylamine was added, followed by HATU (1.94 g, 5.10 mmol), and the mixture was stirred at room temperature for 1 hour. To the resulting reaction mixture were added 30 mL of water and 20 mL of acetone, stirred for 30 minutes, filtered, and washed with water and then acetone to obtain the title compound (3.37 g, 84.13% yield) as a slightly yellow solid.
[1927] MS (ESI) m / z 800 (M+H) +
[1928] Reference Example 2-2
[1929]
[1930] To a 12 mL solution of Reference Example 2-1 (1.027 g, 1.284 mmol) in N,N-dimethylformamide in a 100 mL eggplant-shaped flask, bis(4-nitrophenyl) carbonate (760 mg, 2.498 mmol) and 440 μL (0.33 g, 2.52 mmol) of N,N-diisopropylethylamine were added at room temperature while stirring under an argon stream. The mixture was stirred at room temperature for 3 hours. Subsequently, 8 mL of N,N-dimethylformamide was added while stirring at room temperature. After stirring at room temperature for 0.5 hours, the insoluble matter was filtered and the filtrate was concentrated under reduced pressure. Diethyl ether and hexane were added to the residue, and the resulting solid was filtered, washed four times with water, then with diethyl ether, and dried under reduced pressure to obtain the title compound (760 mg, 61.34% yield) as a slightly yellow solid.
[1931] MS (ESI) m / z 965 (M+H) +
[1932] Reference Example 2-3
[1933]
[1934] To a 10 mL solution of Reference Example 2-2 (76.2 mg, 0.079 mmol), U-030 (55.1 mg, 0.069 mmol), and 1-hydroxy-7-azabenzotriazole (13.0 mg, 0.096 mmol) in N,N-dimethylformamide was added in a 10 mL eggplant-shaped flask. Then, 40 μL of N,N-diisopropylethylamine (29.68 mg, 0.230 mmol) was added at room temperature, and the mixture was stirred at room temperature for 18 hours. Subsequently, Reference Example 2-2 (22.3 mg, 0.023 mmol) was added, and the mixture was stirred at room temperature for 6.5 hours.
[1935] After the reaction, the mixture was concentrated under reduced pressure, diethyl ether was added to the residue, and the resulting solid was collected by filtration. 10 mL of acetonitrile / water (1 / 1 (V / V)) was added to the resulting solid, insoluble matter was removed by filtration, and the mixture was freeze-dried to obtain the title compound (57.4 mg, yield 51.19%) as a white solid.
[1936] MS (ESI) m / z 812 (M+2H) 2+
[1937] Reference Example 2-4
[1938]
[1939] To a 2 mL solution of N,N-dimethylformamide of Reference Example 2-3 (57.4 mg, 0.035 mmol) in a 100 mL eggplant-shaped flask, 11 μL of piperidine (9.48 mg, 0.111 mmol) was added at room temperature while stirring under an argon stream. After stirring at room temperature for 1 hour, the solvent was removed under reduced pressure, and the solid was washed with 10 mL of diethyl ether. The obtained solid was dried under reduced pressure to obtain the labeled compound (51.8 mg, yield 93.23%) as a light yellow solid.
[1940] MS (ESI) m / z 1402 (M+H) +
[1941] Reference Example 2
[1942]
[1943] Using Reference Example 2-4 (18 mg, 13 μmoL), the reaction was carried out in the same manner as in Reference Example 1 to obtain the title compound (5.2 mg, yield 22.49%) as a white solid.
[1944] MS (ESI) m / z 901 (M+2H) 2+
[1945] Synthesis of Reference Example 3
[1946]
[1947] Reference Example 3-1
[1948]
[1949] To a 10 mL solution of di-tert-butyl phosphite (1.94 g, 9.99 mmol) in acetonitrile in a 100 mL eggplant flask, 1.68 mL (1.78 g, 10.98 mmol) of benzyl acrylate was added at room temperature while stirring under a nitrogen stream, and the mixture was stirred at 80°C for 6 hours.
[1950] After the reaction, the reaction was concentrated under reduced pressure, and the residue was subjected to Yamazen medium-pressure preparation (silica, L (40 g), hexane / ethyl acetate = 70 / 30 (V / V) → 50 / 50 (V / V)), and the fraction containing the target product was concentrated under reduced pressure to obtain the labeled compound (2.23 g, yield 62.64%) as a colorless oil.
[1951] MS (ESI) m / z 357 (M+H) +
[1952] Reference Example 3-2
[1953]
[1954] To a 22 mL ethanol solution of Reference Example 3-1 (2.23 g, 6.26 mmol) added to a 200 mL eggplant-shaped flask, 10 wt% palladium carbon NX type (50 wt% water content, 1.30 g, 0.611 mmol) was added while stirring under a nitrogen atmosphere, and the mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere.
[1955] After completion of the reaction, the mixture was filtered through Celite 545 (trade name), washed with ethanol, and concentrated under reduced pressure to obtain the title compound (1.68 g, quantitative yield) as a colorless oil.
[1956] MS (ESI) m / z 267 (M+H) +
[1957] Reference Example 3-3
[1958]
[1959] To a 4 mL dichloromethane solution of (S)-3-((tert-butoxycarbonyl)amino)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid (i.e., (L)-3-((tert-butoxycarbonyl)amino)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid) (1.21 g, 4.26 mmol) (described in WO2019 / 195665) added to a 100 mL eggplant-shaped flask, 21.3 mL (3.11 g, 85 mmol) of a 4 M hydrogen chloride solution in 1,4-dioxane was added at room temperature while stirring under an argon stream, and the mixture was stirred at room temperature for 1 hour.
[1960] After the reaction, the solvent was removed under reduced pressure, ethyl acetate was added to the residue, and the generated solid was filtered. The resulting solid was dissolved in methanol and concentrated under reduced pressure to obtain the title compound (1.17 g, quantitative yield) as a pale yellow foam.
[1961] Reference Example 3-4
[1962]
[1963] To a 3 mL solution of Reference Example 3-2 (0.26 g, 0.976 mmol) in N,N-dimethylformamide placed in a 30 mL cylindrical flask, 0.13 mL (0.09 g, 0.933 mmol) of triethylamine and HATU (0.37 g, 0.973 mmol) were added while stirring at room temperature under an argon stream. The mixture was stirred at room temperature for 1 hour. This was designated Solution A.
[1964] To a 3 mL solution of N,N-dimethylformamide of Reference Example 3-3 (0.21 g, 0.952 mmol) placed in a 20 mL cylindrical flask, 0.065 mL (0.045 g, 0.466 mmol) of triethylamine was added at room temperature while stirring under an argon stream, and the mixture was stirred at room temperature for 10 minutes.
[1965] Solution A was added to the above-mentioned 20 mL cylindrical flask at room temperature, and the mixture was stirred at room temperature for 6 hours.
[1966] After the reaction, water was added to the reaction solution, and the mixture was filtered through a membrane filter. The resulting solution was subjected to preparative HPLC chromatography under the following conditions. The fraction containing the target compound was freeze-dried to obtain the title compound (143.9 mg, yield 34.96%) as a colorless solid.
[1967] MS (ESI) m / z 433 (M+H) +
[1968] Column: Waters XBridge Prep C18 5μm ODB 19*150mm
[1969] Flow rate: 17 mL / min.
[1970] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1971] Gradient (Solution B): 30% (0.00 min.) → 36% (5.00 min.)
[1972] Reference Example 3-5
[1973]
[1974] To a 3 mL solution of Reference Example 3-4 (143.8 mg, 0.333 mmol) in N,N-dimethylformamide in a 30 mL eggplant-shaped flask, 56 μL of triethylamine (40.66 mg, 0.402 mmol) and HATU (152.5 mg, 0.401 mmol) were added while stirring at room temperature under an argon stream. The mixture was stirred at room temperature for 2 minutes. Subsequently, a 0.5 mL solution of tert-butyl 1-amino-3,6,9,12-tetraoxopentadecane-15-ate (112.5 mg, 0.350 mmol) in N,N-dimethylformamide was added at room temperature, and the mixture was stirred at room temperature for 1 hour.
[1975] After the reaction, the reaction solution was subjected to preparative HPLC chromatography under the following conditions, and the fraction containing the target product was freeze-dried to obtain the title compound (143.5 mg, yield 58.64%) as a colorless solid.
[1976] MS (ESI) m / z 734 (MH) -
[1977] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[1978] Flow rate: 17 mL / min.
[1979] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[1980] Gradient (Solution B): 20% (0.00 min.) → 60% (8.00 min.)
[1981] Reference Example 3-6
[1982]
[1983] To a 1.5 mL solution of Reference Example 3-5 (63.3 mg, 0.086 mmol) in dichloromethane placed in a 30 mL eggplant-shaped flask, 150 μL of trifluoroacetic acid (223.35 mg, 1.959 mmol) was added at room temperature while stirring under a nitrogen stream, and the mixture was stirred at room temperature for 2.5 hours. Subsequently, 0.5 mL of trifluoroacetic acid (744.5 mg, 6.530 mmol) was added at room temperature, and the mixture was stirred at room temperature for 2 hours.
[1984] After completion of the reaction, the reaction solution was concentrated under reduced pressure, 2 mL of acetonitrile / water (1 / 1 (V / V)) was added to the residue, and the mixture was freeze-dried to obtain the title compound (56.6 mg, quantitative yield) as a white solid.
[1985] MS (ESI) m / z 568 (M+H) +
[1986] Reference Example 3-7
[1987]
[1988] To a 6 mL solution of Reference Example 2-1 (340.9 mg, 0.426 mmol) in N,N-dimethylformamide in a 100 mL eggplant-shaped flask, 255 μL (242.25 mg, 0.804 mmol) of 3-((bis(diisopropylamino)phosphino)oxy)propionitrile) and 1H-tetrazole (56.6 mg, 0.808 mmol) were added at room temperature while stirring under an argon atmosphere. The mixture was stirred at room temperature for 15 minutes. Subsequently, 215 μL (245.1 mg, 0.800 mmol) of triisopropylsilyl trifluoromethanesulfonate was added at room temperature, and the mixture was stirred at room temperature for 30 minutes.
[1989] Then, U-010 (146 mg, 0.199 mmol) and 5-(ethylthio)-1H-tetrazole (109.4 mg, 0.840 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Then, 330 μL (310.2 mg, 2.409 mmol) of tert-butyl hydroperoxide was added under ice cooling, and the mixture was stirred at room temperature for 2 hours.
[1990] Then, 600 μL (612 mg, 4.02 mmol) of diazabicycloundecene was added under ice-cooling, and the mixture was stirred at room temperature for 1 hour.
[1991] After the reaction was completed, 50 mL of diethyl ether was added and the supernatant was removed. 25 mL of diethyl ether was then added and the supernatant was removed. 25 mL of diethyl ether was then added and the supernatant was removed, followed by drying under reduced pressure. The residue was purified under the following recirculation separation conditions, and the fraction containing the target product was decompressed to obtain the title compound (185.6 mg, 67.8% yield) as a colorless oil.
[1992] MS (ESI) m / z 1372 (M+H) +
[1993] Device: LC Forte / R (YMC)
[1994] Column: Xserect HSS C18 19*150mm, 5μm
[1995] Flow rate: 17 mL / min.
[1996] Elution solvent: 0.1% formic acid aqueous solution (solution A) - 0.1% formic acid in acetonitrile (solution B)
[1997] Solution composition (Solution B): 50%
[1998] Reference Example 3
[1999]
[2000] To a 600 μL solution of Reference Example 3-6 (11.9 mg, 0.021 mmol) in N,N-dimethylformamide placed in a 10 mL cylindrical flask, 9 μL of triethylamine (6.53 mg, 0.065 mmol) was added while stirring under an argon stream. HATU (8.7 mg, 0.023 mmol) was then added, and the mixture was stirred at room temperature for 5 minutes. Subsequently, 400 μL of a solution of Reference Example 3-7 (12.5 mg, 9.11 μmol) in N,N-dimethylformamide was added at room temperature, and the mixture was stirred at room temperature for 3 hours.
[2001] After completion of the reaction, the reaction solution was concentrated under reduced pressure. The resulting residue was subjected to preparative HPLC chromatography under the following conditions, and the fractions containing the target compound were freeze-dried to obtain the title compound (1.29 mg, yield 7.37%) as a white solid.
[2002] MS (ESI) m / z 961 (M+2H) 2+
[2003] Column: Waters XSELECT HSS T3 Prep 5μm ODB 19*150mm Flow rate: 17mL / min.
[2004] Elution solvent: 0.1% formic acid aqueous solution (solution A) - acetonitrile (solution B)
[2005] Gradient (Solution B): 20% (0.00 min.) → 35% (6.00 min.) → 80% (6.50 min.) → 80% (9.00 min.)
[2006] Synthesis of Reference Example 4
[2007]
[2008] Reference Example 4-1
[2009]
[2010] Instead of Fmoc-(L)-Val-(L)-Cit-PAB-PNP (manufactured by Angene) (263.5 mg, 0.344 mmol) and MMAE, the formate salt of the free form of U-003 (167.8 mg, 0.304 mmol) was used and reacted in the same manner as in Reference Example 1-4 to obtain a crude product of the labeled compound (390 mg, quantitative yield) as a light brown solid.
[2011] MS (ESI) m / z 1134 (M+H) +
[2012] Reference Example 4-2
[2013]
[2014] To a 2 mL solution of Reference Example 4-1 (103.3 mg, 0.091 mmol) in N,N-dimethylformamide in a 30 mL cylindrical flask, 87 μL of piperidine (74.99 mg, 0.881 mmol) was added at room temperature while stirring under a nitrogen stream. After stirring at room temperature for 0.5 hour, the solvent was removed under reduced pressure.
[2015] To the resulting residue were added Reference Example 1-2 (115.5 mg, 0.263 mmol), 72 μL (53.42 mg, 0.528 mmol), 2 mL of N,N-dimethylformamide, and HATU (106.4 mg, 0.280 mmol) at room temperature, and the mixture was stirred at room temperature for 10 minutes. Subsequently, Reference Example 1-2 (115.5 mg, 0.263 mmol), 72 μL (53.42 mg, 0.528 mmol), and HATU (106.4 mg, 0.280 mmol) were added at room temperature, and the mixture was stirred at room temperature for 2 minutes.
[2016] The reaction mixture was subjected to preparative HPLC chromatography under the following conditions, and the fractions containing the target product were freeze-dried to obtain the title compound (57.1 mg, yield 47.05%) as a white solid.
[2017] MS (ESI) m / z 1333 (M+H) +
[2018] Column: Waters SunFire Prep C18 5μm ODB 19*150mm
[2019] Flow rate:...
Claims
1. An antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof, which is represented by the following general formula (I): A-(B-L-D) a (I) A-(B-L-D) a (I) In the formula, A is an antibody residue obtained by removing functional groups in the antibody that are involved in binding to a linker from an antibody that is capable of targeting tumor cells, B is a divalent group derived from a functional group in the antibody, a is an integer from 1 to 10, D is an antitumor drug residue obtained by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug molecule, an analog thereof, or a derivative thereof, L is a linker connecting B and D, At least one of D and L has one or more lactone groups as substituents or protecting groups at any positions.
2. The antibody-drug conjugate according to claim 1, its pharmacologically acceptable salt, or hydrate thereof, wherein: A is an antibody residue obtained by removing a functional group in the antibody that participates in binding to a linker from an antibody having any one or more of the properties of being able to recognize target cells, being able to bind to target cells, being able to be internalized into target cells, and being able to damage target cells.
3. The antibody-drug conjugate according to claim 1 or 2, its pharmacologically acceptable salt, or hydrate thereof, wherein: A is an antibody residue obtained by removing a thiol group, a hydroxyl group, an amino group, an azide group, an alkynyl group, a cycloalkynyl group, or an azacycloalkynyl group which is a functional group in the antibody from an antibody capable of targeting tumor cells.
4. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 3, wherein: A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-EPHA3 antibody, anti-c-KIT antibody, Anti-PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-GloboH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF-1R Antibodies, anti-KDR antibody, anti-CEACAM8 antibody, anti-IL5R antibody, anti-CD205 (Ly75) antibody, anti-MSR1 antibody, anti-KREMEN2 antibody, anti-SSEA-4 antibody, anti-CD228 antibody, anti-CD5 antibody, anti-DLL4 antibody, anti-FAP antibody, anti-Notch3 antibody, anti-AG7 antibody, anti-guanylate cyclase antibody, anti-adhesion protein-4 antibody, anti-CD226 (DNAM-1) antibody, anti-FcRL5 antibody, anti-HLA-DR antibody, anti-ITGB3 antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-MICA (MHC Class I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin Antibodies to αvβ3, anti-AGS-5, anti-CA19-9, anti-PSA, anti-MAGE3, anti-transferrin receptor 1 (CD71), anti-CEACAM1, anti-SLC3A2 (CD98), anti-ACVR1, anti-AG-7, anti-AMHR2, anti-ABCB1, anti-C16orf54, anti-cathepsin D, anti-CCR7, anti-SLC44A4, anti-CD300LF, anti-DPEP3, anti-FucGM1, anti-GPR20, anti-ITGB6, anti-Lewis-A carbohydrate-like antibody, anti-prolactin receptor antibody, anti-SialylAntibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-proteinase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody.
5. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 4, wherein: A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti- TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-mucin-16 (CA125) antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-EGFR variant III antibody, anti-PTK7 antibody, anti-GPC1 antibody, anti-CD38 antibody, anti-DDL3 antibody, anti-SEZ6 antibody, anti-CD166 (ALCAM) antibody, anti-CDH3 antibody, anti-FGFR3 antibody, anti-Globo H antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CD46 antibody, anti-FLT3 antibody, CD138 antibody, anti-TM4SF1 antibody, anti-IGF-1R antibody, anti-CEACAM8 antibody, anti-CD205 (Ly75) antibody, anti-CD228 antibody, anti-FAP antibody, anti-AG7 antibody, anti-adhesion protein-4 antibody, anti-CD226 (DNAM-1) antibody, anti-HLA-DR antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-CCR5 antibody, anti-ROR2 antibody, anti-LIV -1 antibody, anti-TIM-1 antibody, anti-CA19-9 antibody, anti-CEACAM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-cathepsin D antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carbohydrate antibody, anti-prolactin receptor antibody, anti-SialylAntibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-proteinase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody.
6. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 5, wherein: A is selected from anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD123 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-mucin-16 (CA125) antibody, anti-sodium-dependent phosphate transporter Antibody residues obtained by removing functional groups within the antibody that participate in binding to a linker from 2B (SLC34A2) antibody, anti-CD25 antibody, anti-CEACAM5 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-PTK7 antibody, anti-CD38 antibody, anti-CDH3 antibody, anti-CD37 antibody, anti-FLT3 antibody, anti-IGF-1R antibody, anti-FAP antibody, anti-fibronectin-4 antibody, anti-CD56 (NCAM1) antibody, anti-AG-7 antibody, anti-CCR7 antibody, anti-DPEP3 antibody, anti-ITGB6 antibody, anti-proteinase antibody, anti-Cripto antibody, anti-ALPP antibody, or anti-GPRC5D antibody.
7. The antibody-drug conjugate according to claim 1, its pharmacologically acceptable salt, or hydrate thereof, wherein: A represents an antibody residue obtained by removing functional groups in the anti-HER2 antibody that participate in the binding to the linker.
8. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 7, wherein: B is a -S- group, a -O- group, a -NH- group, or a 1,2,3-triazolylene group.
9. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 8, wherein: B is a -S- group or a -NH- group.
10. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 9, wherein: B is a -S- group.
11. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 10, wherein: a is an integer from 1 to 8.
12. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 11, wherein: a is an integer from 2 to 8.
13. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 12, wherein: a is an integer from 4 to 8.
14. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 13, wherein: D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of: camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; duocarmycin; Aplysia 10; superdox; ciprofloxacin; caderfloxacin (CS-940); or analogs of these anti-tumor drugs; or the anti-tumor drug molecules or their analogs and derivatives; 15. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 14, wherein: D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of: camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; duocarmycin; Aplysia 10; superdox; or analogs of these antitumor drugs; or the above-mentioned antitumor drug molecules or their analogs and derivatives; 16. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 15, wherein: D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of: camptothecin; auristatin E (AE) or monomethyl auristatin E (MMAE); maytansine; PBD (pyrrolobenzodiazepine) dimer; eribulin; or analogs of these anti-tumor drugs; or the anti-tumor drug molecules or their analogs and derivatives.
17. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 16, wherein: D is a residue formed by removing one hydrogen atom or one hydroxyl group from any position of: an antitumor drug or an analogue of these antitumor drugs in which at least one hydroxyl group present in the molecule is phosphated; or the antitumor drug molecule or an analogue or derivative thereof.
18. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 17, wherein: L is an optionally substituted alkylene group; One or more methylene groups in the alkylene chain are optionally independently selected from -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-OP(=S)(OR 13 )-O-;-OP(=O)(OR 13 )-S-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -; optionally substituted alkenylene; optionally substituted alkynylene; optionally substituted cycloalkylene; optionally substituted cycloalkenylene; optionally substituted cycloalkynylene; optionally substituted azacycloalkynylene; optionally substituted arylene; optionally substituted heteroarylene; and optionally substituted heterocyclylene are replaced by one or more divalent groups, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 each independently represents a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted cycloalkynyl group; an optionally substituted azacycloalkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclic group, R 3 When it is an alkyl group, the alkyl group may form a ring structure together with the alkyl group in the adjacent methylene group. m and n are each independently an integer of 0-2.
19. The antibody-drug conjugate according to claim 18, its pharmacologically acceptable salt, or hydrate thereof, wherein: L is an optionally substituted alkylene group; One or more methylene groups in the chain of the alkylene group are replaced with one or more divalent groups independently selected from the following chemical formula group: Chemical formula group: -OC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-; -SC(H or C1-C4 alkyl)(H or C1-C4 alkyl)-; -N(H or C1-C4 alkyl)-; -N(H or C1-C4 alkyl)-OC(H or C1-C4 alkyl)(C(H or C1-C4 alkyl)-; -C(H or C1-C4 alkyl)-SO 0-2 -C(H or C1-C4 alkyl)-; -C(H or C1-C4 alkyl)-SSC(H or C1-C4 alkyl)-; -C(H or C1-C4 alkyl)=C(H or C1-C4 alkyl)-; -C(H or C1-C4 alkyl)=N-; -C(H or C1-C4 alkyl)=NO-; -C(H or C1-C4 alkyl)=NN(H or C1-C4 alkyl)-; -C(=C(H or C1-C4 alkyl)(H or C1-C4 alkyl))-; -C(=NO(H or C1-C4 alkyl))-; -C(=NN(H or C1-C4 alkyl)(H or C1-C4 alkyl))-; -O-Si(C1-C4 alkylCH3)(C1-C4 alkyl)-O-; -C(H or C1-C4 alkyl)-N(C1-C4 alkyl)-CH2-; -C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-C(═O)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(H or C1-C4 alkyl)-; -OC(=O)-O-; -N(H or C1-C4 alkyl)-C(=O)-N(H or C1-C4 alkyl)-; -C(=O)-N(H or C1-C4 alkyl)-C(H or C1-C4 alkyl)(H or C1-C4 alkyl)-; -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -C(=O)-; -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-; -NH-CH2-(CH2) 1-10 (O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-; -C(=O)-N(C1-C4 alkyl)-CH2CH2-N(C1-C4 alkyl)-C(=O)-; In the formula, * is the bonding point with the adjacent group; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=S)(OH)-O-; -OP(=O)(OH)-S-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH2-NH2)-; -CH(CH2-NH(C1-C4 alkyl))-; -CH(CH2-N(C1-C4alkyl)2)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 0-20 -C1-C4 alkyl)-; -CH(CH2-NH-C(=O)-(CH2) 0-20 -lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-C(=O)-lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-lactone)-; -CH(CH2-NH-(CH2) 1-20 -(O) 0-1 -(P(=O)(OH)2)-; -CH(CH2-NH-C(=O)-(CH2) 1-20 -(P(=O)(OH)2))-; -CH(CH2-NH-C(=O)-(CH2) 1-20 -C(=O)-NH-(CH2) 1-10 -(P(=O)(OH)2)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-(P(=O)(OH)2)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -(P(=O)(OH)2)-; -CH(CH2-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-; -CH(CH2-NH-C(=O)-(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2, or C1-C4 alkyl)(P(=O)(OH)2)2)-; -(cis)-CH=CH-P(=O)(O-CH2CH3)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Ser-; -Cys-; -Ama-: -Asp-; -Glu-; -Orn-; -Lys-; -ValLys-; -ValCit-; -ValAla-; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysAspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GlyGlyPheGly-C(=O)-NH-CH2-; -AspGlyGlyPheGly-C(=O)-NH-CH2-; and a 1,2,3-triazolylene group of the following formula, Among the above-mentioned amino acid residues, and amino acid residues in peptides, The carboxyl groups of the side chains of Ama, Asp, and Glu may form (alkyl)esters, (aminoalkyl)esters, ((N-alkylamino)alkyl)esters, ((N,N-dialkylamino)alkyl)esters, ((trialkylammonium)alkyl)esters, (lactonyl)esters, ((lactonyl)alkyl)esters, ((phosphoryl)alkyl)esters, or ((bisphosphoryl)alkyl)esters, and may also form unsubstituted amides, alkylamides, dialkylamides, ((N-alkylamino)alkyl)amides, ((N,N-dialkylamino)alkyl)amides, ((trialkylammonium)alkyl)amides, (lactonyl)amides, ((lactonyl)alkyl)amides, (phosphoryl)amides, ((phosphoryl)alkyl)amides, or ((bisphosphoryl)alkyl)amides. The amino group in the side chain of Lys and Orn may have one or two alkyl groups, alkylcarbonyl groups, (aminoalkyl)carbonyl groups, ((N-alkylamino)alkyl)carbonyl groups, ((N,N-dialkylamino)alkyl)carbonyl groups, ((trialkylammonium)alkyl)carbonyl groups, lactone groups, (lactonyl)alkyl groups, (lactonyl)carbonyl groups, ((lactonyl)alkyl)carbonyl groups, phosphoryl groups, (phosphoryl)alkyl groups, ((phosphoryl)alkyl)carbonyl groups, (bisphosphoryl)alkyl groups, or ((bisphosphoryl)alkyl)carbonyl groups as substituents, The hydroxyl group of the side chain of Ser and the thiol group of the side chain of Cys optionally have an alkyl group, an alkylcarbonyl group, an aminoalkyl group, an (aminoalkyl)carbonyl group, a (N-alkylamino)alkyl group, a ((N-alkylamino)alkyl)carbonyl group, a (N,N-dialkylamino)alkyl group, a ((N,N-dialkylamino)alkyl)carbonyl group, a (trialkylammonium)alkyl group, a ((trialkylammonium)alkyl)carbonyl group, a lactone group, a (lactonyl)alkyl group, a (lactonyl)carbonyl group, a ((lactonyl)alkyl)carbonyl group, a phosphoryl group, a (phosphoryl)alkyl group, a ((phosphoryl)alkyl)carbonyl group, a (bisphosphoryl)alkyl group, or a ((bisphosphoryl)alkyl)carbonyl group as a substituent, In the formula, * is the bonding point with the adjacent group.
20. The antibody-drug conjugate according to claim 18, its pharmacologically acceptable salt, or hydrate thereof, wherein: L is any one divalent group selected from the following chemical formula group, Chemical formula group In the formula, * 1 is the bonding point with antibody residue AS-, * 2 is the bonding point with the antibody residue A-NH-, and # is the bonding point with the anti-tumor drug residue D-.
21. The antibody-drug conjugate, a pharmacologically acceptable salt thereof, or a hydrate thereof according to any one of claims 1 to 20, wherein: At least one of D and L has one or more lactone groups as substituents or protecting groups at any position, and, independently of this, At least one of D or L has as a substituent or protecting group at any position a group selected from phosphoryl (-P(=O)(OH)2); phosphorylalkylcarbonyl (-C(=O)-alkylene-P(=O)(OH)2); bisphosphorylmethyl (-C(H, OH, NH2, Cl, or alkyl)(P(=O)(OH)2)2); amino; monoalkylamino; dialkylamino; a cyclic amino group in which the two alkyl groups of the dialkylamino group form a ring together with the nitrogen atom to which they are bonded; and one or more groups from trialkylammonium groups, and when the total number of such groups is plural, they may be the same or different.
22. The antibody-drug conjugate according to any one of claims 1 to 21, a pharmacologically acceptable salt thereof, or a hydrate thereof, which is selected from the group consisting of the following chemical formulas: In the formula, A HER2 It is an antibody residue obtained by removing a thiol group present in the anti-HER2 antibody, and a has the same meaning as above.
23. A pharmaceutical composition comprising the antibody-drug conjugate according to any one of claims 1 to 22, a pharmacologically acceptable salt thereof, or a hydrate thereof.
24. An antitumor drug comprising the antibody-drug conjugate according to any one of claims 1 to 22, a pharmacologically acceptable salt thereof, or a hydrate thereof.
25. A pharmaceutical composition comprising the antibody-drug conjugate according to any one of claims 1 to 22, a pharmacologically acceptable salt thereof, or a hydrate thereof as an active ingredient, and further comprising a pharmacologically acceptable formulation ingredient.
26. A method for treating a tumor, characterized in that: Administration of the antibody-drug conjugate according to any one of claims 1 to 22, a pharmacologically acceptable salt thereof, or a hydrate thereof.
Citation Information
Patent Citations
Antibody-drug conjugate
JP2016196484A
Combinations of dr5 antibody and other therapeutic agents
WO2003038043A2
Treatment of immunological disorders using Anti-CD30 antibodies
WO2003043583A2
Antibody-drug conjugate
WO2014057687A1
Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016001485A1
Cited By
Exatecan derivative and application thereof
CN117024438A
Epothilone derivatives and their use
CN117024438B
